{"info":{"_postman_id":"28fbfb1c-afd1-4d55-b7b7-30c55990f302","name":"PV/Safety API Documentation Archived Labels","description":"<html><head></head><body><h1 id=\"authentication\">Authentication:</h1>\n<ul>\n<li>Basic (Bearer token with base64-encoded string username:password)</li>\n</ul>\n</body></html>","schema":"https://schema.getpostman.com/json/collection/v2.0.0/collection.json","toc":[{"content":"Authentication:","slug":"authentication"}],"owner":"9081486","collectionId":"28fbfb1c-afd1-4d55-b7b7-30c55990f302","publishedId":"2s93eYVsdJ","public":true,"customColor":{"top-bar":"FFFFFF","right-sidebar":"303030","highlight":"FF6C37"},"publishDate":"2024-06-14T16:06:00.000Z"},"item":[{"name":"Bulk import label metadata","id":"123a24e2-fdda-4c88-9c36-8899d4b369af","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]},"isInherited":false},"method":"POST","header":[],"body":{"mode":"raw","raw":"{\n  \"skip\": 0,\n  \"limit\": 100,\n  \"country\": \"all\"\n}\n","options":{"raw":{"language":"json"}}},"url":"https://labelae.doctorevidence.com/discontinued/annotation/label","description":"<ul>\n<li>Bulk import of all archived labels in database having annotation data, this will return only label metadata.</li>\n<li>To be used with <em>skip</em> and <em>limit</em> params.</li>\n</ul>\n<p>e.g. To fetch all records, start with skip=0 and limit=100 (100 is max)<br />and then every subsequent query will skip in multiples of 100<br />(value of limit)</p>\n<h6 id=\"note-do-not-use-this-for-daily-monitoring-this-is-only-to-fetch-data-for-initial-data-set\"><em>NOTE: DO NOT USE THIS FOR DAILY MONITORING. THIS IS ONLY TO FETCH DATA FOR INITIAL DATA SET.</em></h6>\n<h6 id=\"all-the-params-should-be-passed-as-raw-data-in-json-format--eg--skip0-limit10--\"><strong>All the Params should be passed as raw data in JSON format (</strong> eg. { \"skip\":0, \"limit\":10 } <strong>)</strong></h6>\n<h1 id=\"response-data\">Response Data:</h1>\n<ul>\n<li><code>totalcount</code> is the total number of archived labels retrieved for the given filter criteria.</li>\n<li><code>skip</code> is used to skip the given number of labels from the result, default 0.</li>\n<li><code>limit</code> is the number of labels retrieved in the result, default 100.</li>\n<li><code>BaseURL</code> is the base url of the API, that gets the annotation details.</li>\n<li><code>MeddraVersion</code> shows the current MedDRA version.</li>\n<li><code>data</code> contains generic name wise list of label details and current MedDRA version.</li>\n<li><code>GenericName</code> is the generic name of the label.</li>\n<li><code>Labels</code> contains the list of label details including id(s), ndccode, updated date, country, version and label's annotation details.</li>\n<li>The <code>Id</code> property uniquely identifies the label.<ul>\n<li>For <code>US/AU</code> it is the combination of <code>Country</code> and <code>FileId</code><br />  (<code>FileId</code> uniquely identifies the label version).</li>\n<li>For <code>UK</code>, <code>CA</code>, and <code>EU</code> <code>Id</code> is the combination of <code>Country</code>, <code>ProductId</code>, and <code>Version</code>.</li>\n<li>e.g. UK19887-2: UK label with productid 19887 and version 2.</li>\n</ul>\n</li>\n<li><code>NDCCode</code> is the label NDC Code, available for US only.</li>\n<li><code>UpdatedDate</code> is the date on which the label is imported.</li>\n<li><code>LabelSource</code> contains the label id, label version and country of label.</li>\n<li><code>LabelTitle</code> displays the title of the label.</li>\n<li><code>TradeName</code> shows the BrandName of the label.</li>\n<li><code>Manufacturer</code> displays the Manufacturer Name of the label.</li>\n<li><code>Country</code> displays the region of the label.</li>\n<li><code>ProductId</code> is populated by the <code>SetId</code> for US/AU labels and the <code>ProductId</code> for UK/CA/EU labels.</li>\n<li><code>FileId</code> is a unique value for <code>US/AU</code> for each version of the label, while other regions only have <code>ProductId</code> for all the versions of the label. So <code>FileId</code> will be the actual value of the <code>FileId</code> field for the <code>US</code> region, for other regions it will be the combination of <code>ProductId</code> and <code>Version</code>.<ul>\n<li>e.g. EUEMEA_H_C_000088-31: productid is EUEMEA_H_C_000088 and version is 31<br />  (EU label)</li>\n</ul>\n</li>\n<li><code>Version</code> shows the latest version of the label.</li>\n<li><code>LabelURL</code> shows the label url on parent site.</li>\n<li><code>genericNames</code> If the label's generic name is changed, this will show the list of current as well as previous generic names(the label belongs to) or else it will show the current generic name.</li>\n<li>The response data is sorted by <code>UpdatedDate</code> in ascending order and then sorted by <code>SetId</code> for <code>US/AU</code> labels and by <code>ProductId</code> for <code>UK/CA/EU</code> labels.</li>\n</ul>\n<h6 id=\"note-append-_id_-value-at-the-end-of-the-_baseurl_-to-get-the-annotation-details-for-the-given-label\"><em>NOTE: APPEND</em> <code>_Id_</code> <em>VALUE AT THE END OF THE</em> <code>_BaseURL_</code> <em>TO GET THE ANNOTATION DETAILS FOR THE GIVEN LABEL.</em></h6>\n","urlObject":{"protocol":"https","path":["discontinued","annotation","label"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"38276c3b-374d-4b35-936d-31077c91d28c","name":"Bulk import label metadata","originalRequest":{"method":"POST","header":[],"body":{"mode":"raw","raw":"{\n    \"skip\": 0,\n    \"limit\": 10,\n    \"country\": \"all\"\n}"},"url":"https://labelae.doctorevidence.com/discontinued/annotation/label"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Encoding","value":"gzip"},{"key":"Content-Type","value":"text/plain; charset=utf-8"},{"key":"Date","value":"Mon, 29 Apr 2024 08:07:44 GMT"},{"key":"Server","value":"Kestrel"},{"key":"Vary","value":"Accept-Encoding"},{"key":"Transfer-Encoding","value":"chunked"}],"cookie":[],"responseTime":null,"body":"{\n    \"totalcount\": 5018,\n    \"skip\": 0,\n    \"limit\": 100,\n    \"BaseURL\": \"https://labelae.doctorevidence.com/discontinued/annotation/label/\",\n    \"MeddraVersion\": \"26.1\",\n    \"data\": [\n        {\n            \"GenericName\": \"sodium iodide i 131\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USed6202f9-42ac-4736-b014-545f9c5c2be6\",\n                    \"NDCCode\": \"0019-9452\",\n                    \"UpdatedDate\": \"Nov 18, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"SODIUM IODIDE I 131 -  sodium iodide i - 131 capsule, gelatin coated Mallinckrodt Inc.\",\n                        \"TradeName\": \"SODIUM IODIDE I 131\",\n                        \"Manufacturer\": \"Mallinckrodt Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"000e2ca1-9a11-46f2-860c-4de0ca5be369\",\n                        \"FileId\": \"ed6202f9-42ac-4736-b014-545f9c5c2be6\",\n                        \"Version\": \"18\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000e2ca1-9a11-46f2-860c-4de0ca5be369\",\n                        \"genericNames\": \"sodium iodide i 131\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sulfacetamide sodium and sulfur\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US9b4ff6b6-2976-4054-9aae-234aa726e925\",\n                    \"NDCCode\": \"58980-330\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CERISA -  sulfacetamide sodium and sulfur lotion Stratus Pharamceuticals, Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Cerisa\",\n                        \"Manufacturer\": \"STRATUS PHARMACEUTICALS INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00278dd5-328f-4f4c-992c-a02ecde24e51\",\n                        \"FileId\": \"9b4ff6b6-2976-4054-9aae-234aa726e925\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00278dd5-328f-4f4c-992c-a02ecde24e51\",\n                        \"genericNames\": \"sulfacetamide sodium and sulfur\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US626ed157-f5a1-57e0-e053-2991aa0a500a\",\n                    \"NDCCode\": \"75854-310\",\n                    \"UpdatedDate\": \"Jan 11, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FERIVAFA -  ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium capsule, gelatin coated Avion Pharmaceuticals, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FeRivaFA\",\n                        \"Manufacturer\": \"Avion Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"002df203-be22-41aa-a52c-d14ecbc00dbe\",\n                        \"FileId\": \"626ed157-f5a1-57e0-e053-2991aa0a500a\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002df203-be22-41aa-a52c-d14ecbc00dbe\",\n                        \"genericNames\": \"ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tropicamide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6c37858c-d1d5-4cb0-af32-b63eb6d09178\",\n                    \"NDCCode\": \"0404-7192\",\n                    \"UpdatedDate\": \"Feb 09, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TROPICAMIDE -  tropicamide solution/ drops Henry Schein Inc.\",\n                        \"TradeName\": \"Tropicamide\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"002e4f96-7a74-4501-8b81-dc6f092c807a\",\n                        \"FileId\": \"6c37858c-d1d5-4cb0-af32-b63eb6d09178\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002e4f96-7a74-4501-8b81-dc6f092c807a\",\n                        \"genericNames\": \"tropicamide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"metronidazole\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n                    \"NDCCode\": \"0781-7077\",\n                    \"UpdatedDate\": \"Feb 14, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METRONIDAZOLE -  metronidazole gel Sandoz Inc.\",\n                        \"TradeName\": \"Metronidazole\",\n                        \"Manufacturer\": \"Sandoz Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0030514f-879d-416d-b422-24b67e334b36\",\n                        \"FileId\": \"5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0030514f-879d-416d-b422-24b67e334b36\",\n                        \"genericNames\": \"metronidazole\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US81779794-0dbf-454b-8179-3a985d6ba813\",\n                    \"NDCCode\": \"99207-140\",\n                    \"UpdatedDate\": \"May 29, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METRONIDAZOLE -  metronidazole gel Medicis Pharmaceutical Corp\",\n                        \"TradeName\": \"METRONIDAZOLE\",\n                        \"Manufacturer\": \"Medicis Pharmaceutical Corp\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01f0f7b8-0586-4b8e-890d-4ecf3488c617\",\n                        \"FileId\": \"81779794-0dbf-454b-8179-3a985d6ba813\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f0f7b8-0586-4b8e-890d-4ecf3488c617\",\n                        \"genericNames\": \"metronidazole\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydroquinone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd2083da3-67bd-4f36-a105-a088a50dd5e0\",\n                    \"NDCCode\": \"42851-032\",\n                    \"UpdatedDate\": \"Oct 11, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MELAMIN SKIN BLEACHING AND CORRECTING HYDROQUINONE -  hydroquinone cream ZO Skin Health, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"MELAMIN Skin Bleaching and Correcting Hydroquinone\",\n                        \"Manufacturer\": \"ZO Skin Health, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0036ad62-e92a-42cb-b0ae-61bb87049ff2\",\n                        \"FileId\": \"d2083da3-67bd-4f36-a105-a088a50dd5e0\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0036ad62-e92a-42cb-b0ae-61bb87049ff2\",\n                        \"genericNames\": \"hydroquinone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"dextrose monohydrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0038c31a-5b2d-4271-9141-04b67695996c\",\n                    \"NDCCode\": \"0338-0023\",\n                    \"UpdatedDate\": \"Sep 27, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DEXTROSE -  dextrose hydrous injection, solution Baxter Healthcare Corporation\",\n                        \"TradeName\": \"DEXTROSE\",\n                        \"Manufacturer\": \"Baxter Healthcare Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"FileId\": \"0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"genericNames\": \"dextrose monohydrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"iodoquinol 1% - hydrocortisone acetate 2% - aloe polysaccharides 1%\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScce6a8e9-53c5-4298-9a3b-3dacc7add9be\",\n                    \"NDCCode\": \"13925-174\",\n                    \"UpdatedDate\": \"May 05, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"IODOQUINOL 1%  -  HYDROCORTISONE ACETATE 2%  -  ALOE POLYSACCHARIDES 1% -  iodoquinol, hydrocortisone acetate and aloe vera leaf polysaccharides gel Seton Pharmaceuticals      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Iodoquinol 1% - Hydrocortisone Acetate 2% - Aloe Polysaccharides 1%\",\n                        \"Manufacturer\": \"Seton Pharmaceuticals\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"005c57c2-a323-4ab6-b994-0a63bf9b915f\",\n                        \"FileId\": \"cce6a8e9-53c5-4298-9a3b-3dacc7add9be\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=005c57c2-a323-4ab6-b994-0a63bf9b915f\",\n                        \"genericNames\": \"iodoquinol 1% - hydrocortisone acetate 2% - aloe polysaccharides 1%\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"chlorzoxazone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US31777bf1-9074-4232-b32f-3e675a68f51d\",\n                    \"NDCCode\": \"68462-724\",\n                    \"UpdatedDate\": \"Jun 28, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CHLORZOXAZONE -  chlorzoxazone tablet Glenmark Pharmaceuticals Inc., USA\",\n                        \"TradeName\": \"chlorzoxazone\",\n                        \"Manufacturer\": \"Glenmark Pharmaceuticals Inc., USA\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00663cd9-5405-4a1d-8038-23ec0874dc28\",\n                        \"FileId\": \"31777bf1-9074-4232-b32f-3e675a68f51d\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00663cd9-5405-4a1d-8038-23ec0874dc28\",\n                        \"genericNames\": \"chlorzoxazone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ketorolac tromethamine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US1c79d44d-8f10-4a8f-a0b5-21c2ba258777\",\n                    \"NDCCode\": \"65862-770\",\n                    \"UpdatedDate\": \"Dec 29, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"KETOROLAC TROMETHAMINE  -  ketorolac tromethamine solution/ drops Aurobindo Pharma Limited\",\n                        \"TradeName\": \"Ketorolac Tromethamine\",\n                        \"Manufacturer\": \"Aurobindo Pharma Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"007a4da5-d794-416c-94b3-6ee9e7842c52\",\n                        \"FileId\": \"1c79d44d-8f10-4a8f-a0b5-21c2ba258777\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a4da5-d794-416c-94b3-6ee9e7842c52\",\n                        \"genericNames\": \"ketorolac tromethamine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tapentadol hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US926544cc-122c-4f9f-9434-a886827b0871\",\n                    \"NDCCode\": \"50458-830\",\n                    \"UpdatedDate\": \"Nov 01, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NUCYNTA -  tapentadol hydrochloride tablet, film coated Janssen Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"NUCYNTA\",\n                        \"Manufacturer\": \"Janssen Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00a8921e-46a6-4df1-a744-9e532b6fb06f\",\n                        \"FileId\": \"926544cc-122c-4f9f-9434-a886827b0871\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a8921e-46a6-4df1-a744-9e532b6fb06f\",\n                        \"genericNames\": \"tapentadol hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"donepezil hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8c8f4e5f-acf1-443f-a890-6665c7cc9aa4\",\n                    \"NDCCode\": \"68382-347\",\n                    \"UpdatedDate\": \"Nov 12, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DONEPEZIL HYDROCHLORIDE  -  donepezil hydrochloride tablet, orally disintegrating Zydus Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"donepezil hydrochloride\",\n                        \"Manufacturer\": \"Zydus Pharmaceuticals (USA) Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00a9d965-4c27-419b-a23a-b109864e47fa\",\n                        \"FileId\": \"8c8f4e5f-acf1-443f-a890-6665c7cc9aa4\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a9d965-4c27-419b-a23a-b109864e47fa\",\n                        \"genericNames\": \"donepezil hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"amoxicillin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe8bb6e15-4912-4ab8-a5d5-4ccede21853d\",\n                    \"NDCCode\": \"0143-9820\",\n                    \"UpdatedDate\": \"Aug 03, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"AMOXICILLIN -  amoxicillin tablet, chewable Hikma Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"Amoxicillin\",\n                        \"Manufacturer\": \"Hikma Pharmaceuticals USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00c35e29-0b05-4232-a4d6-38a230102ef5\",\n                        \"FileId\": \"e8bb6e15-4912-4ab8-a5d5-4ccede21853d\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c35e29-0b05-4232-a4d6-38a230102ef5\",\n                        \"genericNames\": \"amoxicillin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sodium fluoride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0a04a9d3-c869-4a4a-b96f-4f56c91553e6\",\n                    \"NDCCode\": \"48878-3160\",\n                    \"UpdatedDate\": \"Jun 03, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUORIDE TREATMENT -  sodium fluoride solution 3M ESPE Dental Products      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Fluoride Treatment\",\n                        \"Manufacturer\": \"3M ESPE Dental Products\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00c68fa6-ae49-4b73-bb71-5e960dc98368\",\n                        \"FileId\": \"0a04a9d3-c869-4a4a-b96f-4f56c91553e6\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c68fa6-ae49-4b73-bb71-5e960dc98368\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US61eee3de-2569-40e0-bab8-33e9e1994dcd\",\n                    \"NDCCode\": \"69962-014\",\n                    \"UpdatedDate\": \"Jul 17, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FIDELIS APF -  sodium fluoride gel Webco Dental &amp; Medical Supplies, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FIDELIS APF\",\n                        \"Manufacturer\": \"Webco Dental & Medical Supplies, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"011ba0c9-7b31-4cac-8c2a-9bcd4d5b8ef9\",\n                        \"FileId\": \"61eee3de-2569-40e0-bab8-33e9e1994dcd\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=011ba0c9-7b31-4cac-8c2a-9bcd4d5b8ef9\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"USa530e5e7-f391-4af7-9137-f673fc454378\",\n                    \"NDCCode\": \"69509-076\",\n                    \"UpdatedDate\": \"Feb 21, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PRIMO APF -  sodium fluoride aerosol, foam Tri State Dental Supply      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Primo APF\",\n                        \"Manufacturer\": \"Tri State Dental Supply\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0202ab96-5f39-4fd5-8d5f-b828e81c1ab4\",\n                        \"FileId\": \"a530e5e7-f391-4af7-9137-f673fc454378\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0202ab96-5f39-4fd5-8d5f-b828e81c1ab4\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US7e9203d2-c833-76f0-e053-2a91aa0a305a\",\n                    \"NDCCode\": \"64778-0378\",\n                    \"UpdatedDate\": \"Jan 05, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DENTI - CARE DENTI - FOAM TOPICAL SODIUM FLUORIDE RASPBERRY -  sodium fluoride aerosol, foam AMD Medicom Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Denti-Care Denti-Foam\",\n                        \"Manufacturer\": \"AMD Medicom Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02486b16-b1a4-4a1d-b7ca-ed77d97e97e4\",\n                        \"FileId\": \"7e9203d2-c833-76f0-e053-2a91aa0a305a\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02486b16-b1a4-4a1d-b7ca-ed77d97e97e4\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US30c61365-3693-4c64-9eec-a38bba83bdaa\",\n                    \"NDCCode\": \"69962-020\",\n                    \"UpdatedDate\": \"Jul 17, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FIDELIS APF -  sodium fluoride aerosol, foam Webco Dental &amp; Medical Supplies, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FIDELIS APF\",\n                        \"Manufacturer\": \"Webco Dental & Medical Supplies, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02a9ae8d-2910-4986-8493-d378d09ab4b1\",\n                        \"FileId\": \"30c61365-3693-4c64-9eec-a38bba83bdaa\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a9ae8d-2910-4986-8493-d378d09ab4b1\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US7e40fae9-b3eb-49c9-e053-2991aa0a21b3\",\n                    \"NDCCode\": \"64778-0214\",\n                    \"UpdatedDate\": \"Jan 01, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DENTI - CARE DENTI - PRO TOPICAL SODIUM FLUORIDE 60 SECOND -  sodium fluoride gel AMD Medicom Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Denti-Care Denti-Pro\",\n                        \"Manufacturer\": \"AR Medicom Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05af0929-6a37-4b76-b3f9-94ccd8a3a17b\",\n                        \"FileId\": \"7e40fae9-b3eb-49c9-e053-2991aa0a21b3\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05af0929-6a37-4b76-b3f9-94ccd8a3a17b\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"USb60be188-1df3-c64e-e053-2a95a90a2cdc\",\n                    \"NDCCode\": \"66467-3790\",\n                    \"UpdatedDate\": \"Dec 11, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DARBY TOPICAL SODIUM FLUORIDE STRAWBERRY -  sodium fluoride aerosol, foam Darby Dental Supply, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Darby\",\n                        \"Manufacturer\": \"Darby Dental Supply, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05daaae5-57c5-47e9-834a-e453c7526782\",\n                        \"FileId\": \"b60be188-1df3-c64e-e053-2a95a90a2cdc\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05daaae5-57c5-47e9-834a-e453c7526782\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fluoride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US28d952e7-7caa-492f-a1f5-7a39098da55e\",\n                    \"NDCCode\": \"51862-172\",\n                    \"UpdatedDate\": \"Aug 02, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUORIDE  -  sodium fluoride tablet, chewable Mayne Pharma Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Fluoride\",\n                        \"Manufacturer\": \"Mayne Pharma Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00e1f644-1538-4054-b112-227e7254317e\",\n                        \"FileId\": \"28d952e7-7caa-492f-a1f5-7a39098da55e\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00e1f644-1538-4054-b112-227e7254317e\",\n                        \"genericNames\": \"fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mirtazapine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US325197a6-1a5f-4c6f-bb05-c8b3f64ce3ad\",\n                    \"NDCCode\": \"0052-0110\",\n                    \"UpdatedDate\": \"Oct 15, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REMERON -  mirtazapine tablet, film coated REMERONSOLTAB -  mirtazapine tablet, orally disintegrating Organon USA Inc.\",\n                        \"TradeName\": \"REMERONSOLTAB\",\n                        \"Manufacturer\": \"Organon USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"010f9162-9f7f-4b6d-a6e4-4f832f26f38e\",\n                        \"FileId\": \"325197a6-1a5f-4c6f-bb05-c8b3f64ce3ad\",\n                        \"Version\": \"32\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010f9162-9f7f-4b6d-a6e4-4f832f26f38e\",\n                        \"genericNames\": \"mirtazapine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"zileuton\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USf1429302-86df-1568-e053-2995a90a9b93\",\n                    \"NDCCode\": \"69339-130\",\n                    \"UpdatedDate\": \"Jan 04, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ZILEUTON -  zileuton tablet, multilayer, extended release DASH Pharmaceutical LLC\",\n                        \"TradeName\": \"Zileuton\",\n                        \"Manufacturer\": \"DASH Pharmaceutical LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01249483-f82f-4b09-b116-b50f1c7ebdf3\",\n                        \"FileId\": \"f1429302-86df-1568-e053-2995a90a9b93\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01249483-f82f-4b09-b116-b50f1c7ebdf3\",\n                        \"genericNames\": \"zileuton\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"dextrose monohydrate, sodium chloride and potassium chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa5043890-7a8f-4718-bfc3-d20792d4bd61\",\n                    \"NDCCode\": \"0338-6335\",\n                    \"UpdatedDate\": \"Jul 28, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE -  dextrose monohydrate, sodium chloride and potassium chloride injection, solution Baxter Healthcare Corporation\",\n                        \"TradeName\": \"Potassium Chloride in Dextrose and Sodium Chloride\",\n                        \"Manufacturer\": \"Baxter Healthcare Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01321de3-bf0b-4460-9aee-511406ee101e\",\n                        \"FileId\": \"a5043890-7a8f-4718-bfc3-d20792d4bd61\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01321de3-bf0b-4460-9aee-511406ee101e\",\n                        \"genericNames\": \"dextrose monohydrate, sodium chloride and potassium chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fenofibrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                    \"NDCCode\": \"70199-027\",\n                    \"UpdatedDate\": \"Nov 15, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FENOFIBRATE  -  fenofibrate tablet Casper Pharma LLC\",\n                        \"TradeName\": \"FENOFIBRATE\",\n                        \"Manufacturer\": \"Casper Pharma LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"FileId\": \"0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"genericNames\": \"fenofibrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"etonogestrel and ethinyl estradiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USeb39f2fd-0ee1-4cee-ad04-e5371706310a\",\n                    \"NDCCode\": \"0052-0273\",\n                    \"UpdatedDate\": \"Feb 05, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NUVARING -  etonogestrel and ethinyl estradiol insert, extended release Organon USA Inc.\",\n                        \"TradeName\": \"NuvaRing\",\n                        \"Manufacturer\": \"Organon USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"017343fb-86c4-45ab-9c47-52cc5b9f3a02\",\n                        \"FileId\": \"eb39f2fd-0ee1-4cee-ad04-e5371706310a\",\n                        \"Version\": \"27\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017343fb-86c4-45ab-9c47-52cc5b9f3a02\",\n                        \"genericNames\": \"etonogestrel and ethinyl estradiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"trimipramine maleate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USff72526a-1529-4354-a265-c23f5704a65e\",\n                    \"NDCCode\": \"51285-554\",\n                    \"UpdatedDate\": \"Aug 06, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"SURMONTIL -  trimipramine maleate capsule Teva Women's Health, Inc.\",\n                        \"TradeName\": \"Surmontil\",\n                        \"Manufacturer\": \"Teva Women's Health, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0177d783-773c-41bf-9db9-eb7e5c64474a\",\n                        \"FileId\": \"ff72526a-1529-4354-a265-c23f5704a65e\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0177d783-773c-41bf-9db9-eb7e5c64474a\",\n                        \"genericNames\": \"trimipramine maleate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydroxypropyl cellulose\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US587d995e-963a-4990-9077-747490bfface\",\n                    \"NDCCode\": \"25010-805\",\n                    \"UpdatedDate\": \"Oct 08, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LACRISERT -  hydroxypropyl cellulose (type h) pellet Aton Pharma, Inc.\",\n                        \"TradeName\": \"Lacrisert\",\n                        \"Manufacturer\": \"ATON PHARMA INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"017980de-48b6-4b28-aec0-315411149a7e\",\n                        \"FileId\": \"587d995e-963a-4990-9077-747490bfface\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017980de-48b6-4b28-aec0-315411149a7e\",\n                        \"genericNames\": \"hydroxypropyl cellulose\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tobramycin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe59394a3-3474-4186-9986-5c589cd851ed\",\n                    \"NDCCode\": \"0404-7196\",\n                    \"UpdatedDate\": \"Feb 09, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TOBRAMYCIN -  tobramycin solution/ drops Henry Schein Inc.\",\n                        \"TradeName\": \"Tobramycin\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"019172e3-bf24-4b76-9253-f58765d7b4f3\",\n                        \"FileId\": \"e59394a3-3474-4186-9986-5c589cd851ed\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=019172e3-bf24-4b76-9253-f58765d7b4f3\",\n                        \"genericNames\": \"tobramycin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cimetidine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0337689b-c5d5-d881-e063-6394a90aaec9\",\n                    \"NDCCode\": \"62135-631\",\n                    \"UpdatedDate\": \"Aug 22, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CIMETIDINE -  cimetidine tablet, film coated Chartwell RX, LLC\",\n                        \"TradeName\": \"CIMETIDINE\",\n                        \"Manufacturer\": \"Chartwell RX, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01997826-7ca1-473e-bfc9-075b14b58a35\",\n                        \"FileId\": \"0337689b-c5d5-d881-e063-6394a90aaec9\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01997826-7ca1-473e-bfc9-075b14b58a35\",\n                        \"genericNames\": \"cimetidine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cat pelt, standardized\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc7ac1890-9d51-4036-9022-d4f406b9dc88\",\n                    \"NDCCode\": \"0268-2002\",\n                    \"UpdatedDate\": \"May 23, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CAT PELT, STANDARDIZED -  felis catus skin injection, solution CAT PELT, STANDARDIZED -  felis catus skin solution ALK - Abello, Inc.\",\n                        \"TradeName\": \"Cat Pelt, Standardized\",\n                        \"Manufacturer\": \"ALK-Abello, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01a914b7-51b5-4aab-952f-2eae56d25e9c\",\n                        \"FileId\": \"c7ac1890-9d51-4036-9022-d4f406b9dc88\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a914b7-51b5-4aab-952f-2eae56d25e9c\",\n                        \"genericNames\": \"cat pelt, standardized\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"clopidogrel bisulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USfdbc18a6-b364-4f85-9fd1-71d04b3a7ab1\",\n                    \"NDCCode\": \"63653-1171\",\n                    \"UpdatedDate\": \"Mar 11, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PLAVIX -  clopidogrel bisulfate tablet, film coated Bristol - Myers Squibb/Sanofi Pharmaceuticals Partnership\",\n                        \"TradeName\": \"Plavix\",\n                        \"Manufacturer\": \"Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01b14603-8f29-4fa3-8d7e-9d523f802e0b\",\n                        \"FileId\": \"fdbc18a6-b364-4f85-9fd1-71d04b3a7ab1\",\n                        \"Version\": \"34\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b\",\n                        \"genericNames\": \"clopidogrel||clopidogrel bisulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"torsemide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US5da4dfd2-88e9-4270-a408-c0bbd566acf4\",\n                    \"NDCCode\": \"0037-5010\",\n                    \"UpdatedDate\": \"Jan 13, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DEMADEX -  torsemide tablet Meda Pharmaceuticals\",\n                        \"TradeName\": \"Demadex\",\n                        \"Manufacturer\": \"Meda Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01b388a0-7dfb-11de-bc4e-0002a5d5c51b\",\n                        \"FileId\": \"5da4dfd2-88e9-4270-a408-c0bbd566acf4\",\n                        \"Version\": \"13\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b388a0-7dfb-11de-bc4e-0002a5d5c51b\",\n                        \"genericNames\": \"torsemide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"vincristine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USaaacd521-3f4e-450d-a8cc-f5229e7fb65c\",\n                    \"NDCCode\": \"0703-4412\",\n                    \"UpdatedDate\": \"Jun 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VINCASAR PFS -  vincristine sulfate injection, solution Teva Parenteral Medicines, Inc.\",\n                        \"TradeName\": \"Vincasar PFS\",\n                        \"Manufacturer\": \"Teva Parenteral Medicines, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01cee93f-3ab9-44fa-8c9a-dd5958fd2db9\",\n                        \"FileId\": \"aaacd521-3f4e-450d-a8cc-f5229e7fb65c\",\n                        \"Version\": \"18\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cee93f-3ab9-44fa-8c9a-dd5958fd2db9\",\n                        \"genericNames\": \"vincristine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"thyroid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US7c47ad19-42de-592f-e053-2991aa0a3c35\",\n                    \"NDCCode\": \"43063-819\",\n                    \"UpdatedDate\": \"Dec 06, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NATURE - THROID -  thyroid, porcine tablet PD - Rx Pharmaceuticals, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Nature-Throid\",\n                        \"Manufacturer\": \"PD-Rx Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01cf8d6f-5ec1-4bd4-94f0-e9edf116cf2f\",\n                        \"FileId\": \"7c47ad19-42de-592f-e053-2991aa0a3c35\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cf8d6f-5ec1-4bd4-94f0-e9edf116cf2f\",\n                        \"genericNames\": \"thyroid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ondansetron hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USffbc2301-05e0-5f75-e053-6394a90ab415\",\n                    \"NDCCode\": \"82449-200\",\n                    \"UpdatedDate\": \"Oct 03, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ONDANSETRON HYDROCHLORIDE -  ondansetron hydrochloride injection Steriscience Specialties Private Limited\",\n                        \"TradeName\": \"ondansetron hydrochloride\",\n                        \"Manufacturer\": \"Steriscience Specialties Private Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01d69f4d-eddf-4fc8-820b-832f11f2e3c0\",\n                        \"FileId\": \"ffbc2301-05e0-5f75-e053-6394a90ab415\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01d69f4d-eddf-4fc8-820b-832f11f2e3c0\",\n                        \"genericNames\": \"ondansetron hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"albumin (human)\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USeddd4478-99a9-4827-ba0b-17e04ba67454\",\n                    \"NDCCode\": \"76125-785\",\n                    \"UpdatedDate\": \"Dec 22, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ALBUKED  -  albumin human solution KEDRION BIOPHARMA, INC.\",\n                        \"TradeName\": \"Albuked\",\n                        \"Manufacturer\": \"KEDRION BIOPHARMA INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01d78cc3-765c-89a9-7a60-b578e5723cbb\",\n                        \"FileId\": \"eddd4478-99a9-4827-ba0b-17e04ba67454\",\n                        \"Version\": \"12\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01d78cc3-765c-89a9-7a60-b578e5723cbb\",\n                        \"genericNames\": \"albumin (human)\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cholera vaccine, live, oral\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USaa67e293-7e9e-4b1d-9637-17ce3a0161a4\",\n                    \"NDCCode\": \"70460-001\",\n                    \"UpdatedDate\": \"Oct 26, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VAXCHORA -  cholera vaccine, live, oral \\t\\t\\t Paxvax, Inc.\",\n                        \"TradeName\": \"Vaxchora\",\n                        \"Manufacturer\": \"Paxvax, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01dae2ac-8332-4e23-b971-67dc36c3ee16\",\n                        \"FileId\": \"aa67e293-7e9e-4b1d-9637-17ce3a0161a4\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01dae2ac-8332-4e23-b971-67dc36c3ee16\",\n                        \"genericNames\": \"cholera vaccine, live, oral\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"medroxyprogesterone acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US10fdc3f5-de88-4bbb-9f3f-c0a0630d0222\",\n                    \"NDCCode\": \"62756-091\",\n                    \"UpdatedDate\": \"Dec 20, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEDROXYPROGESTERONE ACETATE  -  medroxyprogesterone acetate injection, suspension Sun Pharmaceutical Industries, Inc.\",\n                        \"TradeName\": \"MEDROXYPROGESTERONE ACETATE\",\n                        \"Manufacturer\": \"Sun Pharmaceutical Industries, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01e28bef-9758-40cf-a4ff-86ae9f4f5105\",\n                        \"FileId\": \"10fdc3f5-de88-4bbb-9f3f-c0a0630d0222\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e28bef-9758-40cf-a4ff-86ae9f4f5105\",\n                        \"genericNames\": \"medroxyprogesterone acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US4e917729-3eac-400c-bbaf-8b30a04a380c\",\n                    \"NDCCode\": \"24201-150\",\n                    \"UpdatedDate\": \"May 04, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION -  medroxyprogesterone acetate injection, suspension Hikma Pharmaceuticals USA inc.\",\n                        \"TradeName\": \"Medroxyprogesterone Acetate Injectable Suspension\",\n                        \"Manufacturer\": \"Hikma Pharmaceuticals USA inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0476eac5-d96c-4910-aa86-1ddeeefefe50\",\n                        \"FileId\": \"4e917729-3eac-400c-bbaf-8b30a04a380c\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0476eac5-d96c-4910-aa86-1ddeeefefe50\",\n                        \"genericNames\": \"medroxyprogesterone acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"benzoyl peroxide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US19004b02-2e4b-4d66-aa84-7a19ad8c3c69\",\n                    \"NDCCode\": \"45802-910\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PERRIGO BENZOYL PEROXIDE AQUEOUS BASE -  benzoyl peroxide gel Perrigo New York Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Perrigo Benzoyl Peroxide\",\n                        \"Manufacturer\": \"PERRIGO NEW YORK INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01e8bf1e-db02-4dd0-a448-645f0f367401\",\n                        \"FileId\": \"19004b02-2e4b-4d66-aa84-7a19ad8c3c69\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e8bf1e-db02-4dd0-a448-645f0f367401\",\n                        \"genericNames\": \"benzoyl peroxide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"progesterone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6339e30d-a5d3-09b0-852a-84ef2e8c2a83\",\n                    \"NDCCode\": \"0032-1708\",\n                    \"UpdatedDate\": \"Aug 26, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PROMETRIUM -  progesterone capsule AbbVie Inc.\",\n                        \"TradeName\": \"Prometrium\",\n                        \"Manufacturer\": \"AbbVie Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0224b5a6-25a3-44c9-b94f-90e2e064c164\",\n                        \"FileId\": \"6339e30d-a5d3-09b0-852a-84ef2e8c2a83\",\n                        \"Version\": \"23\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224b5a6-25a3-44c9-b94f-90e2e064c164\",\n                        \"genericNames\": \"progesterone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"desvenlafaxine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USbf7c38d6-3cba-42dd-a439-ed28c34789c3\",\n                    \"NDCCode\": \"49884-375\",\n                    \"UpdatedDate\": \"Dec 20, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"KHEDEZLA EXTENDED - RELEASE -  desvenlafaxine tablet, extended release Par Pharmaceutical Inc.\",\n                        \"TradeName\": \"KHEDEZLA\",\n                        \"Manufacturer\": \"Par Pharmaceutical Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0224e77b-7f6f-4191-ad3b-06847d5930e2\",\n                        \"FileId\": \"bf7c38d6-3cba-42dd-a439-ed28c34789c3\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224e77b-7f6f-4191-ad3b-06847d5930e2\",\n                        \"genericNames\": \"desvenlafaxine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"luvira\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99d7525d-b62e-7f8e-e053-2a95a90a2080\",\n                    \"NDCCode\": \"69336-351\",\n                    \"UpdatedDate\": \"Dec 18, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LUVIRA -  omega - 3 - acid ethyl esters, 12 - hydroxyeicosapentaenoic acid, (12r) -  and 4,7,10,13,16,19 - docosahexaenoic acid, (4e,7e,10e,13e,16e,19e) -  capsule Sterling - Knight Pharmaceuticals, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Luvira\",\n                        \"Manufacturer\": \"Sterling-Knight Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"025679cf-dfb2-4988-9e18-2f55ef9b306f\",\n                        \"FileId\": \"99d7525d-b62e-7f8e-e053-2a95a90a2080\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=025679cf-dfb2-4988-9e18-2f55ef9b306f\",\n                        \"genericNames\": \"luvira\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine, and glycine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USdad76e26-0274-4501-abaf-216a4165a2ae\",\n                    \"NDCCode\": \"0409-4191\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"AMINOSYN -  isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine and glycine injection, solution Hospira, Inc.\",\n                        \"TradeName\": \"Aminosyn\",\n                        \"Manufacturer\": \"Hospira, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02597da7-70bc-44f5-50a5-d67934125b7f\",\n                        \"FileId\": \"dad76e26-0274-4501-abaf-216a4165a2ae\",\n                        \"Version\": \"13\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02597da7-70bc-44f5-50a5-d67934125b7f\",\n                        \"genericNames\": \"isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine, and glycine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fenortho\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US91b0ac5b-994c-468f-9331-542b8f92f9a8\",\n                    \"NDCCode\": \"54288-130\",\n                    \"UpdatedDate\": \"Jun 16, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FENORTHO -  fenoprofen calcium capsule BPI Labs LLC\",\n                        \"TradeName\": \"FENORTHO\",\n                        \"Manufacturer\": \"BPI Labs LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02a23e48-f371-448b-92b2-e2d010be1886\",\n                        \"FileId\": \"91b0ac5b-994c-468f-9331-542b8f92f9a8\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a23e48-f371-448b-92b2-e2d010be1886\",\n                        \"genericNames\": \"fenortho\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"neomycin sulfate, polymyxin b sulfate and bacitracin zinc\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd6ca470d-dd66-45d4-b2b5-23090c9223b6\",\n                    \"NDCCode\": \"0404-7194\",\n                    \"UpdatedDate\": \"Feb 05, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NEOMYCIN AND POLYMYXIN B SULFATES, AND BACITRACIN ZINC -  neomycin sulfate, polymyxin b sulfate and bacitracin zinc ointment Henry Schein Inc.\",\n                        \"TradeName\": \"Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02af2a5f-32fb-460b-b29f-7b18cb95204c\",\n                        \"FileId\": \"d6ca470d-dd66-45d4-b2b5-23090c9223b6\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c\",\n                        \"genericNames\": \"neomycin sulfate, polymyxin b sulfate and bacitracin zinc\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"betamethasone valerate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6094e3c6-ba85-4774-a61d-233f92b92c6c\",\n                    \"NDCCode\": \"0145-0021\",\n                    \"UpdatedDate\": \"Jul 01, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LUXIQ -  betamethasone valerate aerosol, foam Stiefel Laboratories Inc\",\n                        \"TradeName\": \"LUXIQ\",\n                        \"Manufacturer\": \"Stiefel Laboratories Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55\",\n                        \"FileId\": \"6094e3c6-ba85-4774-a61d-233f92b92c6c\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55\",\n                        \"genericNames\": \"betamethasone valerate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methenamine hippurate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6b264a9e-f32b-4d56-8738-70b8d36c95b2\",\n                    \"NDCCode\": \"30698-277\",\n                    \"UpdatedDate\": \"Jan 26, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HIPREX -  methenamine hippurate tablet Validus Pharmaceuticals LLC\",\n                        \"TradeName\": \"HIPREX\",\n                        \"Manufacturer\": \"Validus Pharmaceuticals LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02c70c23-b644-430c-b524-29af3360436d\",\n                        \"FileId\": \"6b264a9e-f32b-4d56-8738-70b8d36c95b2\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c70c23-b644-430c-b524-29af3360436d\",\n                        \"genericNames\": \"methenamine hippurate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tranexamic acid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa2b02c92-a449-4624-9936-423a9c0993e2\",\n                    \"NDCCode\": \"66993-121\",\n                    \"UpdatedDate\": \"Dec 07, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TRANEXAMIC ACID -  tranexamic acid tablet Prasco Laboratories\",\n                        \"TradeName\": \"Tranexamic Acid\",\n                        \"Manufacturer\": \"Prasco Laboratories\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03003067-1bbc-4f5b-85ec-c21a955fbc06\",\n                        \"FileId\": \"a2b02c92-a449-4624-9936-423a9c0993e2\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03003067-1bbc-4f5b-85ec-c21a955fbc06\",\n                        \"genericNames\": \"tranexamic acid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (mdck cell derived, propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated)\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe2f91bc2-f0dc-462c-87bf-847d95aad516\",\n                    \"NDCCode\": \"63851-612\",\n                    \"UpdatedDate\": \"Aug 21, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUCELVAX -  influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated),  influenza a virus a/texas/50/2012 x - 223a (h3n2) antigen (mdck cell derived, propiolactone inactivated) and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated) injection, suspension Novartis Vaccines and Diagnostics GmbH\",\n                        \"TradeName\": \"Flucelvax\",\n                        \"Manufacturer\": \"Novartis Vaccines and Diagnostics GmbH\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"030dfb30-589d-4335-85fe-d609644088e0\",\n                        \"FileId\": \"e2f91bc2-f0dc-462c-87bf-847d95aad516\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=030dfb30-589d-4335-85fe-d609644088e0\",\n                        \"genericNames\": \"influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (mdck cell derived, propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated)\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"doxepin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8989ba3a-9624-40f6-92d4-7ec21d75e54d\",\n                    \"NDCCode\": \"40085-716\",\n                    \"UpdatedDate\": \"Jan 26, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DOXEPIN HYDROCHLORIDE -  doxepin hydrochloride cream Renaissance Pharma, Inc.\",\n                        \"TradeName\": \"Doxepin Hydrochloride\",\n                        \"Manufacturer\": \"Renaissance Pharma, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03107529-561a-4408-b319-94b245b3117b\",\n                        \"FileId\": \"8989ba3a-9624-40f6-92d4-7ec21d75e54d\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03107529-561a-4408-b319-94b245b3117b\",\n                        \"genericNames\": \"doxepin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"halobetasol propionate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScd9a3fc1-f9e4-4ab7-9c75-50ab9c65e270\",\n                    \"NDCCode\": \"10631-102\",\n                    \"UpdatedDate\": \"Jan 30, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ULTRAVATE -  halobetasol propionate cream ULTRAVATE -  halobetasol propionate ointment Ranbaxy Laboratories Inc.\",\n                        \"TradeName\": \"Ultravate\",\n                        \"Manufacturer\": \"Ranbaxy Laboratories Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"031f1120-7da1-4ea6-a0be-d368018e2c1f\",\n                        \"FileId\": \"cd9a3fc1-f9e4-4ab7-9c75-50ab9c65e270\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=031f1120-7da1-4ea6-a0be-d368018e2c1f\",\n                        \"genericNames\": \"halobetasol propionate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"abciximab\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US36b7d963-49cb-4192-ab24-ea8f6e81d2d6\",\n                    \"NDCCode\": \"0002-7140\",\n                    \"UpdatedDate\": \"Sep 27, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REOPRO -  abciximab injection, solution Eli Lilly and Company\",\n                        \"TradeName\": \"REOPRO\",\n                        \"Manufacturer\": \"Eli Lilly and Company\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"033d4c3b-4630-4256-b8f7-9ed5f15de9a3\",\n                        \"FileId\": \"36b7d963-49cb-4192-ab24-ea8f6e81d2d6\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3\",\n                        \"genericNames\": \"abciximab\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"leuprolide acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US24a44295-5073-434e-af06-a405a6f3ba55\",\n                    \"NDCCode\": \"62935-302\",\n                    \"UpdatedDate\": \"Apr 26, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ELIGARD  -  leuprolide acetate \\t\\t\\t TOLMAR Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"ELIGARD\",\n                        \"Manufacturer\": \"TOLMAR PHARMACEUTICALS INC.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0342f4a9-1037-4d41-b791-e5b0dbaeffeb\",\n                        \"FileId\": \"24a44295-5073-434e-af06-a405a6f3ba55\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0342f4a9-1037-4d41-b791-e5b0dbaeffeb\",\n                        \"genericNames\": \"leuprolide acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cyanocobalamin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USed0ce38e-b59a-9e8f-e053-2995a90a2341\",\n                    \"NDCCode\": \"68001-509\",\n                    \"UpdatedDate\": \"Nov 11, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CYANOCOBALAMIN -  cyanocobalamin injection, solution BluePoint Laboratories\",\n                        \"TradeName\": \"Cyanocobalamin\",\n                        \"Manufacturer\": \"BluePoint Laboratories\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"034615bb-9f98-4034-b3a2-b1cc22a00a46\",\n                        \"FileId\": \"ed0ce38e-b59a-9e8f-e053-2995a90a2341\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=034615bb-9f98-4034-b3a2-b1cc22a00a46\",\n                        \"genericNames\": \"cyanocobalamin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methylphenidate hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US663ba889-95b5-45c2-af06-c90459d30d6d\",\n                    \"NDCCode\": \"0093-5346\",\n                    \"UpdatedDate\": \"Nov 20, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METHYLPHENIDATE HYDROCHLORIDE (LA) -  methylphenidate hydrochloride capsule, extended release Teva Pharmaceuticals USA, Inc.\",\n                        \"TradeName\": \"Methylphenidate Hydrochloride\",\n                        \"Manufacturer\": \"Teva Pharmaceuticals USA, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"034fb7cd-e183-475e-8beb-64fd88facc8f\",\n                        \"FileId\": \"663ba889-95b5-45c2-af06-c90459d30d6d\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=034fb7cd-e183-475e-8beb-64fd88facc8f\",\n                        \"genericNames\": \"methylphenidate hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US6b2dcacd-6280-421e-8ac2-ac00db79a5d5\",\n                    \"NDCCode\": \"0591-2716\",\n                    \"UpdatedDate\": \"Jul 16, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METHYLPHENIDATE HYDROCHLORIDE -  methylphenidate hydrochloride tablet Actavis Pharma, Inc.\",\n                        \"TradeName\": \"methylphenidate hydrochloride\",\n                        \"Manufacturer\": \"Actavis Pharma, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"038ae416-4bd5-411b-bd28-d4f0af5c2ab7\",\n                        \"FileId\": \"6b2dcacd-6280-421e-8ac2-ac00db79a5d5\",\n                        \"Version\": \"14\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038ae416-4bd5-411b-bd28-d4f0af5c2ab7\",\n                        \"genericNames\": \"methylphenidate hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"bicalutamide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USdbfb2d98-13ad-4815-83d6-b0e10e184881\",\n                    \"NDCCode\": \"0310-0705\",\n                    \"UpdatedDate\": \"Nov 15, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CASODEX -  bicalutamide tablet AstraZeneca Pharmaceuticals LP\",\n                        \"TradeName\": \"CASODEX\",\n                        \"Manufacturer\": \"AstraZeneca Pharmaceuticals LP\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03607c0d-b772-435f-c985-ecce8ea8cafd\",\n                        \"FileId\": \"dbfb2d98-13ad-4815-83d6-b0e10e184881\",\n                        \"Version\": \"20\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03607c0d-b772-435f-c985-ecce8ea8cafd\",\n                        \"genericNames\": \"bicalutamide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"trypan blue\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd0d5872f-d428-189b-e053-2995a90a7f32\",\n                    \"NDCCode\": \"68803-672\",\n                    \"UpdatedDate\": \"Nov 17, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEMBRANEBLUE -  trypan blue injection, solution Dutch Ophthalmic Research Center (International) B.V.\",\n                        \"TradeName\": \"MEMBRANEBLUE\",\n                        \"Manufacturer\": \"Dutch Ophthalmic Research Center (International) B.V.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0364aceb-dd3f-4bac-b468-25379a07ccfc\",\n                        \"FileId\": \"d0d5872f-d428-189b-e053-2995a90a7f32\",\n                        \"Version\": \"16\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0364aceb-dd3f-4bac-b468-25379a07ccfc\",\n                        \"genericNames\": \"trypan blue\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"diclofenac sodium, capsaicin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US039c9724-fa4e-1b84-e063-6394a90ac491\",\n                    \"NDCCode\": \"59088-798\",\n                    \"UpdatedDate\": \"Aug 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEXTOL -  diclofenac sodium, capsaicin \\t\\t\\t PureTek Corporation      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Lextol\",\n                        \"Manufacturer\": \"PureTek Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"039ca738-c2c4-41c8-e063-6394a90ab4c4\",\n                        \"FileId\": \"039c9724-fa4e-1b84-e063-6394a90ac491\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=039ca738-c2c4-41c8-e063-6394a90ab4c4\",\n                        \"genericNames\": \"diclofenac sodium, capsaicin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tramadol hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US96bec1b6-7ff2-4e89-be58-d5c359fb51f4\",\n                    \"NDCCode\": \"50458-655\",\n                    \"UpdatedDate\": \"Sep 12, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ULTRAM ER -  tramadol hydrochloride tablet, extended release Janssen Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"Ultram ER\",\n                        \"Manufacturer\": \"Janssen Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"039f9e7c-97f5-4062-8656-6f355c82008e\",\n                        \"FileId\": \"96bec1b6-7ff2-4e89-be58-d5c359fb51f4\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=039f9e7c-97f5-4062-8656-6f355c82008e\",\n                        \"genericNames\": \"tramadol hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mesalamine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3712f360-d3ac-407d-85bf-48e0d7f298cf\",\n                    \"NDCCode\": \"0430-0783\",\n                    \"UpdatedDate\": \"Dec 01, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ASACOL HD -  mesalamine tablet, delayed release Allergan, Inc.\",\n                        \"TradeName\": \"ASACOL HD\",\n                        \"Manufacturer\": \"Warner Chilcott (US), LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03a3bff5-e652-4771-9bf7-3b6850423cc5\",\n                        \"FileId\": \"3712f360-d3ac-407d-85bf-48e0d7f298cf\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5\",\n                        \"genericNames\": \"mesalamine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"diclofenac sodium and benzalkonium chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US12dd097b-f199-4a63-bbba-3d52ac54fa3c\",\n                    \"NDCCode\": \"15455-9565\",\n                    \"UpdatedDate\": \"Apr 21, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DST PLUS PAK -  diclofenac sodium and benzalkonium chloride \\t\\t\\t Alvix Laboratories, LLC\",\n                        \"TradeName\": \"DST Plus Pak\",\n                        \"Manufacturer\": \"Alvix Laboratories, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03ac5de0-68da-40a9-8f2d-feba05c799c1\",\n                        \"FileId\": \"12dd097b-f199-4a63-bbba-3d52ac54fa3c\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ac5de0-68da-40a9-8f2d-feba05c799c1\",\n                        \"genericNames\": \"diclofenac sodium and benzalkonium chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"folic acid, cholecalciferol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US52531723-606a-1dda-e054-00144ff88e88\",\n                    \"NDCCode\": \"70033-113\",\n                    \"UpdatedDate\": \"Jun 20, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ZOLATE -  folic acid and cholecalciferol capsule Axiom Pharma      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Zolate\",\n                        \"Manufacturer\": \"Axiom Pharma\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03b4af81-152e-40d4-84d7-e213b0ee31fc\",\n                        \"FileId\": \"52531723-606a-1dda-e054-00144ff88e88\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b4af81-152e-40d4-84d7-e213b0ee31fc\",\n                        \"genericNames\": \"folic acid, cholecalciferol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"capecitabine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa38e2215-77d1-4671-8093-746efa1c5344\",\n                    \"NDCCode\": \"0378-2511\",\n                    \"UpdatedDate\": \"Dec 07, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CAPECITABINE -  capecitabine tablet, film coated Mylan Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Capecitabine\",\n                        \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03dd3301-e9ce-40af-84e1-7b70fc6557b0\",\n                        \"FileId\": \"a38e2215-77d1-4671-8093-746efa1c5344\",\n                        \"Version\": \"14\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dd3301-e9ce-40af-84e1-7b70fc6557b0\",\n                        \"genericNames\": \"capecitabine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"esomeprazole magnesium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US26990f16-e3d3-4491-a99d-1cc5411f2e86\",\n                    \"NDCCode\": \"16714-736\",\n                    \"UpdatedDate\": \"Nov 30, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ESOMEPRAZOLE MAGNESIUM  -  esomeprazole magnesium dihydrate capsule, delayed release NorthStar Rx LLC\",\n                        \"TradeName\": \"Esomeprazole Magnesium\",\n                        \"Manufacturer\": \"NorthStar Rx LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03ddda6d-2ac0-42d3-a329-7e8f05ee9b22\",\n                        \"FileId\": \"26990f16-e3d3-4491-a99d-1cc5411f2e86\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ddda6d-2ac0-42d3-a329-7e8f05ee9b22\",\n                        \"genericNames\": \"esomeprazole magnesium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"bortezomib\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US81e8728c-5928-4029-8aa0-0e7f761af75a\",\n                    \"NDCCode\": \"63323-721\",\n                    \"UpdatedDate\": \"Apr 29, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"BORTEZOMIB -  bortezomib injection, powder, lyophilized, for solution Fresenius Kabi USA, LLC\",\n                        \"TradeName\": \"Bortezomib\",\n                        \"Manufacturer\": \"Fresenius Kabi USA, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"042329d6-8077-4af2-816f-cd0a2bbcbbd3\",\n                        \"FileId\": \"81e8728c-5928-4029-8aa0-0e7f761af75a\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=042329d6-8077-4af2-816f-cd0a2bbcbbd3\",\n                        \"genericNames\": \"bortezomib\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sargramostim\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USac281296-b49b-4f33-a16c-a83e60964713\",\n                    \"NDCCode\": \"0024-5844\",\n                    \"UpdatedDate\": \"Jun 14, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEUKINE -  sargramostim liquid LEUKINE -  sargramostim injection, powder, for solution sanofi - aventis U.S. LLC\",\n                        \"TradeName\": \"Leukine\",\n                        \"Manufacturer\": \"sanofi-aventis U.S. LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04765fbf-f005-43aa-a628-5cc3d80f91e7\",\n                        \"FileId\": \"ac281296-b49b-4f33-a16c-a83e60964713\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04765fbf-f005-43aa-a628-5cc3d80f91e7\",\n                        \"genericNames\": \"sargramostim\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"moderna covid-19 vaccine, bivalent\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc1811012-39af-4116-a873-4a5b93bf6468\",\n                    \"NDCCode\": \"80777-283\",\n                    \"UpdatedDate\": \"Dec 20, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MODERNA COVID - 19 VACCINE, BIVALENT -  elasomeran and cx - 034476 omicron (ba.4/ba.5) injection, suspension Moderna US, Inc.\",\n                        \"TradeName\": \"Moderna COVID-19 Vaccine, Bivalent\",\n                        \"Manufacturer\": \"Moderna US, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04c2d0f3-6209-4ae8-823c-842d0881b61b\",\n                        \"FileId\": \"c1811012-39af-4116-a873-4a5b93bf6468\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04c2d0f3-6209-4ae8-823c-842d0881b61b\",\n                        \"genericNames\": \"moderna covid-19 vaccine, bivalent\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"indomethacin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8a792cbe-8874-4655-a1e7-ca9007eee950\",\n                    \"NDCCode\": \"42211-202\",\n                    \"UpdatedDate\": \"Feb 22, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TIVORBEX -  indomethacin capsule Iroko Pharmaceuticals, LLC\",\n                        \"TradeName\": \"Tivorbex\",\n                        \"Manufacturer\": \"Iroko Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04ca474c-798e-43dd-be7a-1b36720e6a3d\",\n                        \"FileId\": \"8a792cbe-8874-4655-a1e7-ca9007eee950\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d\",\n                        \"genericNames\": \"indomethacin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ribavirin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3380c831-db90-4ac0-9c2f-398a00137e58\",\n                    \"NDCCode\": \"0085-1385\",\n                    \"UpdatedDate\": \"Apr 01, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REBETOL -  ribavirin capsule REBETOL -  ribavirin liquid Merck Sharp &amp; Dohme Corp.\",\n                        \"TradeName\": \"REBETOL\",\n                        \"Manufacturer\": \"Merck Sharp & Dohme Corp.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04d2b6f4-bd9b-4871-9527-92c81aa2d4d0\",\n                        \"FileId\": \"3380c831-db90-4ac0-9c2f-398a00137e58\",\n                        \"Version\": \"33\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0\",\n                        \"genericNames\": \"ribavirin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"risedronate sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3cbf30c0-30dd-4022-88b6-86a84697379c\",\n                    \"NDCCode\": \"68382-075\",\n                    \"UpdatedDate\": \"Nov 16, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"RISEDRONATE SODIUM  -  risedronate sodium anhydrous tablet, delayed release Zydus Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"Risedronate Sodium\",\n                        \"Manufacturer\": \"Zydus Pharmaceuticals USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04e4baa7-62a5-45d0-8f8d-a4daea68c5aa\",\n                        \"FileId\": \"3cbf30c0-30dd-4022-88b6-86a84697379c\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04e4baa7-62a5-45d0-8f8d-a4daea68c5aa\",\n                        \"genericNames\": \"risedronate sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"levonorgestrel\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US054f9706-94d2-4ea3-8e32-7185457f5c63\",\n                    \"NDCCode\": \"73302-911\",\n                    \"UpdatedDate\": \"Dec 02, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEVONORGESTREL -  levonorgestrel tablet HRA Pharma America, Inc.\",\n                        \"TradeName\": \"Levonorgestrel\",\n                        \"Manufacturer\": \"HRA Pharma America, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0518a86b-af59-455e-b834-04fa8b20a637\",\n                        \"FileId\": \"054f9706-94d2-4ea3-8e32-7185457f5c63\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0518a86b-af59-455e-b834-04fa8b20a637\",\n                        \"genericNames\": \"levonorgestrel\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ursodiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd126d870-95f5-bb75-e053-2995a90ad67d\",\n                    \"NDCCode\": \"51079-383\",\n                    \"UpdatedDate\": \"Nov 23, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"URSODIOL -  ursodiol capsule Mylan Institutional Inc.\",\n                        \"TradeName\": \"Ursodiol\",\n                        \"Manufacturer\": \"Mylan Institutional Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05243d8f-9057-46a9-ae50-6e16ba6cd7dc\",\n                        \"FileId\": \"d126d870-95f5-bb75-e053-2995a90ad67d\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05243d8f-9057-46a9-ae50-6e16ba6cd7dc\",\n                        \"genericNames\": \"ursodiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"moxifloxacin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USba96c083-00b4-4b6f-8aa0-327e9e918461\",\n                    \"NDCCode\": \"0065-0006\",\n                    \"UpdatedDate\": \"Aug 21, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MOXEZA  -  moxifloxacin hydrochloride solution Alcon Laboratories, Inc.\",\n                        \"TradeName\": \"MOXEZA\",\n                        \"Manufacturer\": \"Alcon Laboratories, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05248b68-16a9-488d-a39f-5137d2410471\",\n                        \"FileId\": \"ba96c083-00b4-4b6f-8aa0-327e9e918461\",\n                        \"Version\": \"20\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05248b68-16a9-488d-a39f-5137d2410471\",\n                        \"genericNames\": \"moxifloxacin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ulipristal acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd6ca82aa-9488-4aa7-a5f1-69873ecb8d0e\",\n                    \"NDCCode\": \"50102-911\",\n                    \"UpdatedDate\": \"Jan 30, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ELLA -  ulipristal acetate tablet Afaxys Pharma LLC\",\n                        \"TradeName\": \"Ella\",\n                        \"Manufacturer\": \"Afaxys Pharma LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"052bfe45-c485-49e5-8fc4-51990b2efba4\",\n                        \"FileId\": \"d6ca82aa-9488-4aa7-a5f1-69873ecb8d0e\",\n                        \"Version\": \"12\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4\",\n                        \"genericNames\": \"ulipristal acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha-tocopherol succinate, d-, riboflavin, niacinamide,\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc697dfae-210c-43a6-b893-f3054e74901c\",\n                    \"NDCCode\": \"68220-089\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PREFERA OB PLUS DHA -  folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha - tocopherol succinate, d - , riboflavin, niacinamide, pyridoxine hydrochloride, cyanocobalamin, biotin and calcium pantothenate tablet Alaven Pharmaceutical LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Prefera OB plus DHA\",\n                        \"Manufacturer\": \"ALAVEN PHARMACEUTICAL LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0539ec9c-b625-4c4e-a321-e7073041c8e0\",\n                        \"FileId\": \"c697dfae-210c-43a6-b893-f3054e74901c\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0539ec9c-b625-4c4e-a321-e7073041c8e0\",\n                        \"genericNames\": \"folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha-tocopherol succinate, d-, riboflavin, niacinamide,\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydromorphone hcl\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScc127289-395c-46bc-b705-d08529e9fce5\",\n                    \"NDCCode\": \"52533-002\",\n                    \"UpdatedDate\": \"Mar 26, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HYDROMORPHONE HCL  -  hydromorphone hydrochloride injection, solution Cantrell Drug Company      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Hydromorphone HCl\",\n                        \"Manufacturer\": \"Cantrell Drug Company\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"053a62b8-92c2-47e8-bbdd-ff2ec4d75dc7\",\n                        \"FileId\": \"cc127289-395c-46bc-b705-d08529e9fce5\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053a62b8-92c2-47e8-bbdd-ff2ec4d75dc7\",\n                        \"genericNames\": \"hydromorphone hcl\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"morphine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USffd2a1bb-d072-8af8-e053-6394a90a48ed\",\n                    \"NDCCode\": \"51862-188\",\n                    \"UpdatedDate\": \"Jul 08, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MORPHINE SULFATE -  morphine sulfate tablet, film coated, extended release Mayne Pharma Commercial LLC\",\n                        \"TradeName\": \"Morphine Sulfate\",\n                        \"Manufacturer\": \"Mayne Pharma Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"053e3fd9-25fc-4b55-b683-63fb9d190dae\",\n                        \"FileId\": \"ffd2a1bb-d072-8af8-e053-6394a90a48ed\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053e3fd9-25fc-4b55-b683-63fb9d190dae\",\n                        \"genericNames\": \"morphine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"gabapentin enacarbil\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6330994e-5391-42ac-ac85-7eda5c6c875f\",\n                    \"NDCCode\": \"0173-0832\",\n                    \"UpdatedDate\": \"Apr 01, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HORIZANT- gabapentin enacarbil tablet, extended release GlaxoSmithKline LLC\",\n                        \"TradeName\": \"HORIZANT\",\n                        \"Manufacturer\": \"GlaxoSmithKline LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05506250-1641-4b64-ac0c-69f96c46a773\",\n                        \"FileId\": \"6330994e-5391-42ac-ac85-7eda5c6c875f\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05506250-1641-4b64-ac0c-69f96c46a773\",\n                        \"genericNames\": \"gabapentin enacarbil\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"oxycodone hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US056f088d-cff1-4b46-8539-ff85880586bf\",\n                    \"NDCCode\": \"63304-684\",\n                    \"UpdatedDate\": \"Jan 14, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OXYCODONE HCL -  oxycodone hydrochloride tablet, film coated, extended release Ranbaxy Pharmaceuticals Inc.\",\n                        \"TradeName\": \"OXYCODONE HCl\",\n                        \"Manufacturer\": \"Ranbaxy Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"FileId\": \"056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"genericNames\": \"oxycodone hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"benzhydrocodone and acetaminophen\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US4e76bae1-6ed1-4624-af64-2151218705b4\",\n                    \"NDCCode\": \"70040-0189\",\n                    \"UpdatedDate\": \"Jul 02, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"APADAZ -  benzhydrocodone hydrochloride and acetaminophen tablet KemPharm, Inc.\",\n                        \"TradeName\": \"APADAZ\",\n                        \"Manufacturer\": \"KemPharm, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0590d4e5-7107-4015-a6a8-deac14265aa2\",\n                        \"FileId\": \"4e76bae1-6ed1-4624-af64-2151218705b4\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0590d4e5-7107-4015-a6a8-deac14265aa2\",\n                        \"genericNames\": \"benzhydrocodone and acetaminophen\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"erythromycin and benzoyl peroxide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                    \"NDCCode\": \"45802-083\",\n                    \"UpdatedDate\": \"Jul 23, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ERYTHROMYCIN - BENZOYL PEROXIDE -  erythromycin and benzoyl peroxide \\t\\t\\t Perrigo New York Inc\",\n                        \"TradeName\": \"Erythromycin-Benzoyl Peroxide\",\n                        \"Manufacturer\": \"PERRIGO NEW YORK INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"FileId\": \"059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"genericNames\": \"erythromycin and benzoyl peroxide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"olmesartan medoxomil\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USf29310d1-7b00-4057-9dd1-d9a69f542d5e\",\n                    \"NDCCode\": \"49252-066\",\n                    \"UpdatedDate\": \"Sep 20, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OLMESARTAN MEDOXOMIL -  olmesartan medoxomil tablet, coated Inventia Healthcare Limited\",\n                        \"TradeName\": \"OLMESARTAN MEDOXOMIL\",\n                        \"Manufacturer\": \"Inventia Healthcare Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05a807bf-5175-43a2-a676-215bba2645a8\",\n                        \"FileId\": \"f29310d1-7b00-4057-9dd1-d9a69f542d5e\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05a807bf-5175-43a2-a676-215bba2645a8\",\n                        \"genericNames\": \"olmesartan medoxomil\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"drospirenone and estradiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USC8074480-B1ED-4468-78AE-C2BCAC4D8079\",\n                    \"NDCCode\": \"50419-483\",\n                    \"UpdatedDate\": \"Sep 27, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ANGELIQ -  estradiol and drospirenone tablet, film coated Berlex\",\n                        \"TradeName\": \"Angeliq\",\n                        \"Manufacturer\": \"BAYER HEALTHCARE PHARMACEUTICA\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05B46F6A-9C52-4246-B500-D359B25A45DC\",\n                        \"FileId\": \"C8074480-B1ED-4468-78AE-C2BCAC4D8079\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05B46F6A-9C52-4246-B500-D359B25A45DC\",\n                        \"genericNames\": \"drospirenone and estradiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fulvestrant\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US45b2245b-9f11-4b58-a275-b664b5b89e7d\",\n                    \"NDCCode\": \"0310-7720\",\n                    \"UpdatedDate\": \"Jun 08, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FULVESTRANT -  fulvestrant injection AstraZeneca Pharmaceuticals LP\",\n                        \"TradeName\": \"Fulvestrant\",\n                        \"Manufacturer\": \"AstraZeneca Pharmaceuticals LP\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05b6bd57-36aa-47c3-bcf6-2470ba42feb5\",\n                        \"FileId\": \"45b2245b-9f11-4b58-a275-b664b5b89e7d\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05b6bd57-36aa-47c3-bcf6-2470ba42feb5\",\n                        \"genericNames\": \"fulvestrant\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fondaparinux sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US26db3097-342b-48cb-a91d-8f39d64c46ca\",\n                    \"NDCCode\": \"0007-3232\",\n                    \"UpdatedDate\": \"Sep 17, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ARIXTRA -  fondaparinux sodium injection, solution GlaxoSmithKline LLC\",\n                        \"TradeName\": \"ARIXTRA\",\n                        \"Manufacturer\": \"GlaxoSmithKline LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f\",\n                        \"FileId\": \"26db3097-342b-48cb-a91d-8f39d64c46ca\",\n                        \"Version\": \"16\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f\",\n                        \"genericNames\": \"fondaparinux sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USee12ad5a-2004-4a59-8173-20bb9eefa655\",\n                    \"NDCCode\": \"35573-300\",\n                    \"UpdatedDate\": \"Apr 30, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"URAMIT MB -  methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule Burel Pharmaceuticals, Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"URAMIT MB\",\n                        \"Manufacturer\": \"Burel Pharmaceuticals, Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05bc6057-7dec-4e35-b8ec-3dffa655520c\",\n                        \"FileId\": \"ee12ad5a-2004-4a59-8173-20bb9eefa655\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05bc6057-7dec-4e35-b8ec-3dffa655520c\",\n                        \"genericNames\": \"methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"influenza vaccine, adjuvanted\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US97c3669d-ac04-4c97-b2ab-2ce4d0bf6e12\",\n                    \"NDCCode\": \"70461-019\",\n                    \"UpdatedDate\": \"Jul 16, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUAD -  influenza a virus a/brisbane/02/2018 ivr - 190 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/kansas/14/2017 x - 327 (h3n2) antigen (formaldehyde inactivated) and influenza b virus b/maryland/15/2016 antigen (formaldehyde inactivated) injection, suspension Seqirus, Inc.\",\n                        \"TradeName\": \"FLUAD\",\n                        \"Manufacturer\": \"Seqirus, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05be1932-bb7a-4e3a-9200-4ccdc5565edc\",\n                        \"FileId\": \"97c3669d-ac04-4c97-b2ab-2ce4d0bf6e12\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05be1932-bb7a-4e3a-9200-4ccdc5565edc\",\n                        \"genericNames\": \"influenza vaccine, adjuvanted\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"clobetasol propionate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99d8672a-7e92-4a25-9a7b-849efaafb525\",\n                    \"NDCCode\": \"0378-8055\",\n                    \"UpdatedDate\": \"Apr 22, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CLOBETASOL PROPIONATE -  clobetasol propionate aerosol, foam Mylan Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Clobetasol Propionate\",\n                        \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05cff296-2daf-408c-8e63-883737cbfb22\",\n                        \"FileId\": \"99d8672a-7e92-4a25-9a7b-849efaafb525\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05cff296-2daf-408c-8e63-883737cbfb22\",\n                        \"genericNames\": \"clobetasol propionate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"metformin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8ed86d67-8a49-4334-82c4-1dbf6a489d3b\",\n                    \"NDCCode\": \"10631-206\",\n                    \"UpdatedDate\": \"Dec 12, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"RIOMET -  metformin hydrochloride solution Sun Pharmaceutical Industries, Inc.\",\n                        \"TradeName\": \"Riomet\",\n                        \"Manufacturer\": \"Ranbaxy Laboratories Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05d4df4b-dfe8-4828-b423-a3d4f2c4114a\",\n                        \"FileId\": \"8ed86d67-8a49-4334-82c4-1dbf6a489d3b\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05d4df4b-dfe8-4828-b423-a3d4f2c4114a\",\n                        \"genericNames\": \"metformin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"valproic acid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USfb8bf963-9299-45f0-926a-18da554412ff\",\n                    \"NDCCode\": \"68094-193\",\n                    \"UpdatedDate\": \"Dec 03, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VALPROIC ACID -  valproic acid solution Precision Dose Inc.\",\n                        \"TradeName\": \"Valproic Acid\",\n                        \"Manufacturer\": \"Precision Dose Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05e16c10-ff0a-4238-8181-f3e84379ed6a\",\n                        \"FileId\": \"fb8bf963-9299-45f0-926a-18da554412ff\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e16c10-ff0a-4238-8181-f3e84379ed6a\",\n                        \"genericNames\": \"valproic acid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"desmopressin acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US517c673f-db39-4b91-bd86-eb35db5bea7f\",\n                    \"NDCCode\": \"0075-2452\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DDAVP -  desmopressin acetate solution sanofi - aventis U.S. LLC\",\n                        \"TradeName\": \"DDAVP\",\n                        \"Manufacturer\": \"sanofi-aventis U.S. LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05e6330b-6569-436e-9caf-e86916460931\",\n                        \"FileId\": \"517c673f-db39-4b91-bd86-eb35db5bea7f\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e6330b-6569-436e-9caf-e86916460931\",\n                        \"genericNames\": \"desmopressin acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mometasone furoate monohydrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US74bb6412-7e0d-46ad-bbf6-26aa7e5d6c04\",\n                    \"NDCCode\": \"0781-6355\",\n                    \"UpdatedDate\": \"Feb 12, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MOMETASONE FUROATE MONOHYDRATE -  mometasone furoate monohydrate spray, metered Sandoz Inc.\",\n                        \"TradeName\": \"Mometasone Furoate Monohydrate\",\n                        \"Manufacturer\": \"Sandoz Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0602c22a-67b7-4708-bdbb-28a69d52d616\",\n                        \"FileId\": \"74bb6412-7e0d-46ad-bbf6-26aa7e5d6c04\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0602c22a-67b7-4708-bdbb-28a69d52d616\",\n                        \"genericNames\": \"mometasone furoate monohydrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methsuximide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USabac6b2e-bcd8-29c2-e053-2a95a90a2239\",\n                    \"NDCCode\": \"24822-525\",\n                    \"UpdatedDate\": \"Aug 04, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CELONTIN -  methsuximide capsule Farmea\",\n                        \"TradeName\": \"Celontin\",\n                        \"Manufacturer\": \"Farmea\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0613561f-1a9f-4921-89ff-ba6081e08a5f\",\n                        \"FileId\": \"abac6b2e-bcd8-29c2-e053-2a95a90a2239\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0613561f-1a9f-4921-89ff-ba6081e08a5f\",\n                        \"genericNames\": \"methsuximide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"calcitonin salmon\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99e9e62b-9796-42ec-8f69-551dabf92ec1\",\n                    \"NDCCode\": \"0781-6320\",\n                    \"UpdatedDate\": \"Jun 21, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CALCITONIN SALMON -  calcitonin salmon spray, metered Sandoz Inc\",\n                        \"TradeName\": \"calcitonin salmon\",\n                        \"Manufacturer\": \"Sandoz Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0614bf53-9644-47d2-b46e-8efbcd63afe6\",\n                        \"FileId\": \"99e9e62b-9796-42ec-8f69-551dabf92ec1\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0614bf53-9644-47d2-b46e-8efbcd63afe6\",\n                        \"genericNames\": \"calcitonin salmon\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"oxybutynin chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc8c1bf6b-8da4-439b-b4af-0b28273c5625\",\n                    \"NDCCode\": \"14539-653\",\n                    \"UpdatedDate\": \"Jun 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OXYBUTYNIN CHLORIDE -  oxybutynin chloride tablet Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Oxybutynin Chloride\",\n                        \"Manufacturer\": \"Heritage Pharma Labs, Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"06301e49-2bcf-4ff1-8f33-39ccde1a2dd0\",\n                        \"FileId\": \"c8c1bf6b-8da4-439b-b4af-0b28273c5625\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06301e49-2bcf-4ff1-8f33-39ccde1a2dd0\",\n                        \"genericNames\": \"oxybutynin chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"motixafortide acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US05f6e4ee-4ffb-d2b5-e063-6394a90af047\",\n                    \"NDCCode\": \"70383-073\",\n                    \"UpdatedDate\": \"Sep 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"APHEXDA -  motixafortide acetate injection, powder, lyophilized, for solution BioConnection B.V.\",\n                        \"TradeName\": \"Aphexda\",\n                        \"Manufacturer\": \"BioConnection B.V.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"065b582d-e5e5-eeec-e063-6394a90a5990\",\n                        \"FileId\": \"05f6e4ee-4ffb-d2b5-e063-6394a90af047\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065b582d-e5e5-eeec-e063-6394a90a5990\",\n                        \"genericNames\": \"motixafortide acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        }\n    ]\n}"}],"_postman_id":"123a24e2-fdda-4c88-9c36-8899d4b369af"},{"name":"Get label annotation details","id":"272859d6-11c4-4563-acbc-5f347cbb89f7","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]},"isInherited":false},"method":"GET","header":[],"url":"https://labelae.doctorevidence.com/discontinued/annotation/label/:labelid","description":"<ul>\n<li>Can be used to monitor a specific product label</li>\n<li>Returns label details for a single label using the label id</li>\n<li>The label id can be found as the value of the \"Id\" property for each specific label that is returned using any API endpoint.</li>\n</ul>\n<h1 id=\"response-data\">Response Data:</h1>\n<ul>\n<li><p>The <code>Id</code> property uniquely identifies the label.</p>\n<ul>\n<li><p>For <code>US</code> it is the combination of <code>Country</code> and <code>FileId</code><br />  (<code>FileId</code> uniquely identifies the label version).</p>\n</li>\n<li><p>For <code>UK</code>, <code>CA</code>, <code>EU</code> and <code>AU</code> <code>Id</code> is the combination of <code>Country</code>, <code>ProductId</code>, and <code>Version</code>.</p>\n</li>\n<li><p>e.g. UK19887-2: UK label with productid 19887 and version 2.</p>\n</li>\n</ul>\n</li>\n<li><p><code>AdverseEventTerms</code> contains the list of adverse terms, their MedDRA code and details about sections in which the term was found.</p>\n</li>\n<li><p><code>Term</code> is the preferred term found in MedDRA dictionary for the given label.</p>\n</li>\n<li><p><code>MEDDRACode</code> is a unique eight-digit number assigned to a term by MedDRA.</p>\n</li>\n<li><p><code>Overdose</code> describes whether the term found in the Overdose section or not.</p>\n</li>\n<li><p><code>Warnings</code> describes whether the term found in the Warnings section or not.</p>\n</li>\n<li><p><code>BoxedWarning</code> describes whether the term found in the Boxed Warning section or not.</p>\n</li>\n<li><p><code>AdverseReactions</code> describes whether the term found in the Adverse Reactions section or not.</p>\n</li>\n<li><p><code>Contraindications</code> describes whether the term found in the Contraindications section or not.</p>\n</li>\n<li><p><code>DrugInteractions</code> describes whether the term found in the Drug Interactions section or not.</p>\n</li>\n<li><p><code>UseInSpecificPopulations</code> contains all the sub-sections of Use In Specific Populations section and describes whether the term found in those sections or not.</p>\n</li>\n<li><p><code>AnySection</code> describes whether the term found in any of the sub-sections of Use In Specific Populations section or not.</p>\n</li>\n<li><p><code>Pregnancy</code> describes whether the term found in the Pregnancy section or not.</p>\n</li>\n<li><p><code>NursingMothers</code> describes whether the term found in the Nursing Mothers section or not.</p>\n</li>\n<li><p><code>Lactation</code> describes whether the term found in the Lactation section or not.</p>\n</li>\n<li><p><code>PediatricUse</code> describes whether the term found in the Pediatric Use section or not.</p>\n</li>\n<li><p><code>GeriatricUse</code> describes whether the term found in the Geriatric Use section or not.</p>\n</li>\n<li><p><code>Other</code> describes whether the term found in sections other than Overdose, Warnings &amp; Precautions, Boxed Warning, Adverse Drug Reactions, Contraindications, Drug Interactions and Use in specific populations or not.</p>\n</li>\n<li><p><code>Blacklisted</code> describes whether the term found is blacklisted or not.</p>\n</li>\n<li><p><code>Annotations</code> contains the list of all VerbatimTerms, Probability and SemanticContext for the given term.</p>\n<ul>\n<li><code>VerbatimTerm</code> is the raw original term (aka verbatim term).</li>\n<li><code>Probability</code> is a number between 0 and 1 that represents the confidence of the machine learning model that the term is an Adverse Event (1 being highest and 0 lowest confidence).</li>\n<li><code>SemanticContext</code> is a snippet of the context from which the verbatim term was extracted, usually the sentence.</li>\n</ul>\n</li>\n<li><p><code>IndicationTerms</code> contains the list of terms found in indication section with their MedDRA code.</p>\n</li>\n</ul>\n","urlObject":{"protocol":"https","path":["discontinued","annotation","label",":labelid"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[{"description":{"content":"<p>Label Id fetched during bulk imports (string)</p>\n","type":"text/plain"},"type":"any","value":"US5945b2c1-def7-4364-b716-bf633f6b6ce4","key":"labelid"}]}},"response":[{"id":"cc730a7f-918c-4b43-b171-9587ce53d088","name":"Get label annotation details","originalRequest":{"method":"GET","header":[],"url":{"raw":"https://labelae.doctorevidence.com/discontinued/annotation/label/:labelid","protocol":"https","host":["labelae","doctorevidence","com"],"path":["discontinued","annotation","label",":labelid"],"variable":[{"key":"labelid","value":"US5945b2c1-def7-4364-b716-bf633f6b6ce4","description":"Label Id fetched during bulk imports (string)"}]}},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Cache-Control","value":"private"},{"key":"Content-Type","name":"Content-Type","value":"application/json","description":"","type":"text"},{"key":"Vary","value":"Accept"},{"key":"Server","value":"Microsoft-IIS/8.5"},{"key":"X-StackifyID","value":"V2|07caa14a-5ec1-460b-bf24-4fd00ddc3f06|C57775|CD6"},{"key":"X-Powered-By","value":"ServiceStack/5.10 NET45 Win32NT/.NET"},{"key":"Access-Control-Allow-Methods","value":"GET, POST, PUT, DELETE, OPTIONS"},{"key":"Access-Control-Allow-Headers","value":"Content-Type, Allow, Authorization, Wait, Accept, X-Requested-With, Put-Default-Position, Put-Before, If-Match, If-None-Match, Content-Range"},{"key":"Access-Control-Allow-Credentials","value":"true"},{"key":"Access-Control-Expose-Headers","value":"Content-Range"},{"key":"X-AspNet-Version","value":"4.0.30319"},{"key":"Set-Cookie","value":"ss-id=miMyWvIwP13J2rVRIiIC; path=/; HttpOnly"},{"key":"Set-Cookie","value":"ss-pid=kwpvR6o9ZKItnA19NG88; expires=Tue, 05-May-2043 09:11:37 GMT; path=/; HttpOnly"},{"key":"Set-Cookie","value":"ss-opt=temp; expires=Tue, 05-May-2043 09:11:37 GMT; path=/; HttpOnly"},{"key":"strict-transport-security","value":"max-age=31536000; includeSubdomains"},{"key":"Date","value":"Fri, 05 May 2023 09:11:40 GMT"},{"key":"Content-Length","value":"45037"}],"cookie":[],"responseTime":null,"body":"{\n    \"Id\": \"US5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n    \"AdverseEventTerms\": [\n        {\n            \"Term\": \"abdominal discomfort\",\n            \"MEDDRACode\": \"10000059\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Gastrointestinal discomfort\",\n                    \"Probability\": \"0.98439133167266846\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                },\n                {\n                    \"VerbatimTerm\": \"Abdominal discomfort\",\n                    \"Probability\": \"0.974980890750885\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"abdominal distension\",\n            \"MEDDRACode\": \"10000060\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Abdominal bloating\",\n                    \"Probability\": \"0.9489092230796814\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"abdominal pain\",\n            \"MEDDRACode\": \"10000081\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"abdominal cramping\",\n                    \"Probability\": \"0.47223600745201111\",\n                    \"SemanticContext\": \"One patient discontinued drug because of moderate abdominal cramping and loose stools, while the other patient discontinued drug because of mild vaginal burning.\"\n                },\n                {\n                    \"VerbatimTerm\": \"abdominal cramping\",\n                    \"Probability\": \"0.96370977163314819\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"alcoholic\",\n            \"MEDDRACode\": \"10001612\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"alcoholic\",\n                    \"Probability\": \"0.032555561512708664\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"arthralgia\",\n            \"MEDDRACode\": \"10003239\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"joint pains\",\n                    \"Probability\": \"0.93116980791091919\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"asthenia\",\n            \"MEDDRACode\": \"10003549\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"weakness\",\n                    \"Probability\": \"0.99119651317596436\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"ataxia\",\n            \"MEDDRACode\": \"10003591\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"ataxia\",\n                    \"Probability\": \"0.98087126016616821\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"blindness\",\n            \"MEDDRACode\": \"10005169\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"blind\",\n                    \"Probability\": \"0.055489342659711838\",\n                    \"SemanticContext\": \"In a randomized, single-blind clinical trial of 505 non-pregnant women who received metronidazole vaginal gel USP, 0.75% once or twice a day, 2 patients one from each regimen discontinued therapy early due to drug-related adverse events.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"candida cervicitis\",\n            \"MEDDRACode\": \"10071209\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Candida cervicitis\",\n                    \"Probability\": \"0.7767188549041748\",\n                    \"SemanticContext\": \"Unless percentages are otherwise stipulated, the incidence of individual adverse reactions listed below was less than 1%: Reproductive: Vaginal discharge 12% , Symptomatic Candida cervicitis/vaginitis 10% , Vulva/vaginal irritative symptoms 9% , Pelvic discomfort 3% .\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"confusional state\",\n            \"MEDDRACode\": \"10010305\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"confusion\",\n                    \"Probability\": \"0.90557742118835449\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"constipation\",\n            \"MEDDRACode\": \"10010774\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"constipation\",\n                    \"Probability\": \"0.96444493532180786\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"coordination abnormal\",\n            \"MEDDRACode\": \"10010947\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"incoordination\",\n                    \"Probability\": \"0.98881524801254272\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"cystitis\",\n            \"MEDDRACode\": \"10011781\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"cystitis\",\n                    \"Probability\": \"0.99302268028259277\",\n                    \"SemanticContext\": \"Renal: Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"decreased appetite\",\n            \"MEDDRACode\": \"10061428\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Decreased appetite\",\n                    \"Probability\": \"0.99165135622024536\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                },\n                {\n                    \"VerbatimTerm\": \"anorexia\",\n                    \"Probability\": \"0.98660802841186523\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"depression\",\n            \"MEDDRACode\": \"10012378\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Depression\",\n                    \"Probability\": \"0.8894658088684082\",\n                    \"SemanticContext\": \"Neurologic: Headache 5% , Dizziness 2% , Depression.\"\n                },\n                {\n                    \"VerbatimTerm\": \"depression\",\n                    \"Probability\": \"0.98138165473937988\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"diarrhoea\",\n            \"MEDDRACode\": \"10012735\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"loose stools\",\n                    \"Probability\": \"0.51642906665802\",\n                    \"SemanticContext\": \"One patient discontinued drug because of moderate abdominal cramping and loose stools, while the other patient discontinued drug because of mild vaginal burning.\"\n                },\n                {\n                    \"VerbatimTerm\": \"loose stools\",\n                    \"Probability\": \"0.996992826461792\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                },\n                {\n                    \"VerbatimTerm\": \"Diarrhea\",\n                    \"Probability\": \"0.965889036655426\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                },\n                {\n                    \"VerbatimTerm\": \"diarrhea\",\n                    \"Probability\": \"0.98911333084106445\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"discomfort\",\n            \"MEDDRACode\": \"10013082\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"pressure\",\n                    \"Probability\": \"0.8618195652961731\",\n                    \"SemanticContext\": \"Renal: Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"dizziness\",\n            \"MEDDRACode\": \"10013573\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Dizziness\",\n                    \"Probability\": \"0.99599337577819824\",\n                    \"SemanticContext\": \"Neurologic: Headache 5% , Dizziness 2% , Depression.\"\n                },\n                {\n                    \"VerbatimTerm\": \"dizziness\",\n                    \"Probability\": \"0.98053139448165894\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"drug therapy\",\n            \"MEDDRACode\": \"10063370\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"drug therapy\",\n                    \"Probability\": \"0.013351773843169212\",\n                    \"SemanticContext\": \"\\n<content?styleCode=\\\"bold\\\">ADVERSE REACTIONS</content> Clinical Trials There were no deaths or serious adverse events related to drug therapy in clinical trials involving 800 non-pregnant women who received metronidazole vaginal gel USP, 0.75%.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"dry mouth\",\n            \"MEDDRACode\": \"10013781\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"dry mouth\",\n                    \"Probability\": \"0.9709746241569519\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"dysgeusia\",\n            \"MEDDRACode\": \"10013911\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"metallic taste\",\n                    \"Probability\": \"0.99039804935455322\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"dyspareunia\",\n            \"MEDDRACode\": \"10013941\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"dyspareunia\",\n                    \"Probability\": \"0.96867823600769043\",\n                    \"SemanticContext\": \"Genitourinary: Overgrowth of Candida in the vagina, dyspareunia, decreased libido, proctitis.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"dyspepsia\",\n            \"MEDDRACode\": \"10013946\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"epigastric distress\",\n                    \"Probability\": \"0.98536020517349243\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"dysuria\",\n            \"MEDDRACode\": \"10013990\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Dysuria\",\n                    \"Probability\": \"0.98540860414505\",\n                    \"SemanticContext\": \"Renal: Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"erythema\",\n            \"MEDDRACode\": \"10015150\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"skin erythema\",\n                    \"Probability\": \"0.23010265827178955\",\n                    \"SemanticContext\": \"\\n<effectiveTime?value=\\\"20191030\\\"?/>\\n<component>\\n    <section?ID=\\\"LINK_2c6fde5b-7a6b-44e2-b40b-2ed8a5818043\\\">\\n        <id?root=\\\"15d488b2-16bd-421f-91cf-d9fd90ab8b70\\\"?/>\\n        <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n        <title>\\n            <content?styleCode=\\\"bold\\\">Other Metronidazole Formulations:</content> Other effects that have been reported in association with the use of topical dermal formulations of metronidazole include skin irritation, transient skin erythema, and mild skin dryness and burning.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"fatigue\",\n            \"MEDDRACode\": \"10016256\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Fatigue\",\n                    \"Probability\": \"0.87562167644500732\",\n                    \"SemanticContext\": \"Other: Unspecified cramping 1% , Fatigue, Darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"flatulence\",\n            \"MEDDRACode\": \"10016766\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"gas\",\n                    \"Probability\": \"0.84742498397827148\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"flushing\",\n            \"MEDDRACode\": \"10016825\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"flushing\",\n                    \"Probability\": \"0.95868426561355591\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"glossitis\",\n            \"MEDDRACode\": \"10018386\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"glossitis\",\n                    \"Probability\": \"0.95117789506912231\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"headache\",\n            \"MEDDRACode\": \"10019211\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Headache\",\n                    \"Probability\": \"0.99514979124069214\",\n                    \"SemanticContext\": \"Neurologic: Headache 5% , Dizziness 2% , Depression.\"\n                },\n                {\n                    \"VerbatimTerm\": \"Headache\",\n                    \"Probability\": \"0.9742743968963623\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"hypersensitivity\",\n            \"MEDDRACode\": \"10020751\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Hypersensitivity Reactions\",\n                    \"Probability\": \"0.65931540727615356\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"incontinence\",\n            \"MEDDRACode\": \"10021639\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"incontinence\",\n                    \"Probability\": \"0.96547472476959229\",\n                    \"SemanticContext\": \"Renal: Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"insomnia\",\n            \"MEDDRACode\": \"10022437\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"insomnia\",\n                    \"Probability\": \"0.97731208801269531\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"irritability\",\n            \"MEDDRACode\": \"10022998\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"irritability\",\n                    \"Probability\": \"0.983949601650238\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"laboratory test\",\n            \"MEDDRACode\": \"10059938\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"laboratory tests\",\n                    \"Probability\": \"0.0065467748790979385\",\n                    \"SemanticContext\": \"The following adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of metronidazole: Cardiovascular: Flattening of the T-wave may be seen in electrocardiographic tracings.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"libido decreased\",\n            \"MEDDRACode\": \"10024419\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"decreased libido\",\n                    \"Probability\": \"0.98166429996490479\",\n                    \"SemanticContext\": \"Genitourinary: Overgrowth of Candida in the vagina, dyspareunia, decreased libido, proctitis.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"muscle spasms\",\n            \"MEDDRACode\": \"10028334\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"cramping\",\n                    \"Probability\": \"0.89021384716033936\",\n                    \"SemanticContext\": \"Other: Unspecified cramping 1% , Fatigue, Darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"nasal congestion\",\n            \"MEDDRACode\": \"10028735\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"nasal congestion\",\n                    \"Probability\": \"0.89350885152816772\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"nausea\",\n            \"MEDDRACode\": \"10028813\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Nausea\",\n                    \"Probability\": \"0.98479175567626953\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                },\n                {\n                    \"VerbatimTerm\": \"nausea\",\n                    \"Probability\": \"0.98766219615936279\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"nervousness\",\n            \"MEDDRACode\": \"10029216\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Nervous\",\n                    \"Probability\": \"0.10652369260787964\",\n                    \"SemanticContext\": \"Central Nervous System: See WARNINGS .\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"neuropathy peripheral\",\n            \"MEDDRACode\": \"10029331\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"peripheral neuropathy\",\n                    \"Probability\": \"0.99324774742126465\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"neutropenia\",\n            \"MEDDRACode\": \"10029354\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"neutropenia\",\n                    \"Probability\": \"0.98449534177780151\",\n                    \"SemanticContext\": \"Hematopoietic: Reversible neutropenia, reversible thrombocytopenia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"pancreatitis\",\n            \"MEDDRACode\": \"10033645\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"pancreatitis\",\n                    \"Probability\": \"0.90978372097015381\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"pelvic discomfort\",\n            \"MEDDRACode\": \"10064229\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Pelvic discomfort\",\n                    \"Probability\": \"0.949109673500061\",\n                    \"SemanticContext\": \"Unless percentages are otherwise stipulated, the incidence of individual adverse reactions listed below was less than 1%: Reproductive: Vaginal discharge 12% , Symptomatic Candida cervicitis/vaginitis 10% , Vulva/vaginal irritative symptoms 9% , Pelvic discomfort 3% .\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"polyuria\",\n            \"MEDDRACode\": \"10036142\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"polyuria\",\n                    \"Probability\": \"0.98231709003448486\",\n                    \"SemanticContext\": \"Renal: Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"pregnancy\",\n            \"MEDDRACode\": \"10036556\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"pregnant\",\n                    \"Probability\": \"0.033070750534534454\",\n                    \"SemanticContext\": \"\\n            <content?styleCode=\\\"bold\\\">ADVERSE REACTIONS</content> Clinical Trials There were no deaths or serious adverse events related to drug therapy in clinical trials involving 800 non-pregnant women who received metronidazole vaginal gel USP, 0.75%.\"\n                },\n                {\n                    \"VerbatimTerm\": \"pregnant\",\n                    \"Probability\": \"0.027843320742249489\",\n                    \"SemanticContext\": \"In a randomized, single-blind clinical trial of 505 non-pregnant women who received metronidazole vaginal gel USP, 0.75% once or twice a day, 2 patients one from each regimen discontinued therapy early due to drug-related adverse events.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"proctitis\",\n            \"MEDDRACode\": \"10036774\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"proctitis\",\n                    \"Probability\": \"0.97422462701797485\",\n                    \"SemanticContext\": \"Genitourinary: Overgrowth of Candida in the vagina, dyspareunia, decreased libido, proctitis.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"pruritus\",\n            \"MEDDRACode\": \"10037087\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Generalized itching\",\n                    \"Probability\": \"0.97711426019668579\",\n                    \"SemanticContext\": \"Dermatologic: Generalized itching or rash.\"\n                },\n                {\n                    \"VerbatimTerm\": \"pruritus\",\n                    \"Probability\": \"0.94924426078796387\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"pyrexia\",\n            \"MEDDRACode\": \"10037660\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"fever\",\n                    \"Probability\": \"0.95922249555587769\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"rash\",\n            \"MEDDRACode\": \"10037844\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"rash\",\n                    \"Probability\": \"0.98409664630889893\",\n                    \"SemanticContext\": \"Dermatologic: Generalized itching or rash.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"rash erythematous\",\n            \"MEDDRACode\": \"10037855\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"erythematous rash\",\n                    \"Probability\": \"0.97644239664077759\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"seizure\",\n            \"MEDDRACode\": \"10039906\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"convulsive seizures\",\n                    \"Probability\": \"0.98853194713592529\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"skin irritation\",\n            \"MEDDRACode\": \"10040880\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"skin irritation\",\n                    \"Probability\": \"0.251591295003891\",\n                    \"SemanticContext\": \"\\n            <effectiveTime?value=\\\"20191030\\\"?/>\\n            <component>\\n                <section?ID=\\\"LINK_2c6fde5b-7a6b-44e2-b40b-2ed8a5818043\\\">\\n                    <id?root=\\\"15d488b2-16bd-421f-91cf-d9fd90ab8b70\\\"?/>\\n                    <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n                    <title>\\n                        <content?styleCode=\\\"bold\\\">Other Metronidazole Formulations:</content> Other effects that have been reported in association with the use of topical dermal formulations of metronidazole include skin irritation, transient skin erythema, and mild skin dryness and burning.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"stomatitis\",\n            \"MEDDRACode\": \"10042128\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"stomatitis\",\n                    \"Probability\": \"0.97614628076553345\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"syncope\",\n            \"MEDDRACode\": \"10042772\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"syncope\",\n                    \"Probability\": \"0.98814409971237183\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"thermal burn\",\n            \"MEDDRACode\": \"10053615\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"burning\",\n                    \"Probability\": \"0.022564148530364037\",\n                    \"SemanticContext\": \"One patient discontinued drug because of moderate abdominal cramping and loose stools, while the other patient discontinued drug because of mild vaginal burning.\"\n                },\n                {\n                    \"VerbatimTerm\": \"burning\",\n                    \"Probability\": \"0.013475608080625534\",\n                    \"SemanticContext\": \"\\n                        <effectiveTime?value=\\\"20191030\\\"?/>\\n                        <component>\\n                            <section?ID=\\\"LINK_2c6fde5b-7a6b-44e2-b40b-2ed8a5818043\\\">\\n                                <id?root=\\\"15d488b2-16bd-421f-91cf-d9fd90ab8b70\\\"?/>\\n                                <code?code=\\\"42229-5\\\"?codeSystem=\\\"2.16.840.1.113883.6.1\\\"?displayName=\\\"SPL?UNCLASSIFIED?SECTION\\\"?/>\\n                                <title>\\n                                    <content?styleCode=\\\"bold\\\">Other Metronidazole Formulations:</content> Other effects that have been reported in association with the use of topical dermal formulations of metronidazole include skin irritation, transient skin erythema, and mild skin dryness and burning.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"thrombocytopenia\",\n            \"MEDDRACode\": \"10043554\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"thrombocytopenia\",\n                    \"Probability\": \"0.95466804504394531\",\n                    \"SemanticContext\": \"Hematopoietic: Reversible neutropenia, reversible thrombocytopenia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"urticaria\",\n            \"MEDDRACode\": \"10046735\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Urticaria\",\n                    \"Probability\": \"0.9700353741645813\",\n                    \"SemanticContext\": \"Hypersensitivity Reactions: Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"vaginal discharge\",\n            \"MEDDRACode\": \"10046901\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"Vaginal discharge\",\n                    \"Probability\": \"0.914261519908905\",\n                    \"SemanticContext\": \"Unless percentages are otherwise stipulated, the incidence of individual adverse reactions listed below was less than 1%: Reproductive: Vaginal discharge 12% , Symptomatic Candida cervicitis/vaginitis 10% , Vulva/vaginal irritative symptoms 9% , Pelvic discomfort 3% .\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"vaginal infection\",\n            \"MEDDRACode\": \"10046914\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"vaginitis\",\n                    \"Probability\": \"0.9399871826171875\",\n                    \"SemanticContext\": \"Unless percentages are otherwise stipulated, the incidence of individual adverse reactions listed below was less than 1%: Reproductive: Vaginal discharge 12% , Symptomatic Candida cervicitis/vaginitis 10% , Vulva/vaginal irritative symptoms 9% , Pelvic discomfort 3% .\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"vertigo\",\n            \"MEDDRACode\": \"10047340\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"vertigo\",\n                    \"Probability\": \"0.98460453748703\",\n                    \"SemanticContext\": \"Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"vomiting\",\n            \"MEDDRACode\": \"10047700\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"vomiting\",\n                    \"Probability\": \"0.99621176719665527\",\n                    \"SemanticContext\": \"Gastrointestinal: Gastrointestinal discomfort 7% , Nausea and/or vomiting 4% , Unusual taste 2% , Diarrhea/loose stools 1% , Decreased appetite 1% , Abdominal bloating/gas; thirsty, dry mouth.\"\n                },\n                {\n                    \"VerbatimTerm\": \"vomiting\",\n                    \"Probability\": \"0.99170601367950439\",\n                    \"SemanticContext\": \"Gastrointestinal: Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, ?furry? tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.\"\n                }\n            ]\n        },\n        {\n            \"Term\": \"white blood cell count decreased\",\n            \"MEDDRACode\": \"10047942\",\n            \"Overdose\": false,\n            \"Warnings\": false,\n            \"BoxedWarning\": false,\n            \"AdverseReactions\": true,\n            \"Contraindications\": false,\n            \"DrugInteractions\": false,\n            \"UseInSpecificPopulations\": {\n                \"AnySection\": false,\n                \"Pregnancy\": false,\n                \"NursingMothers\": false,\n                \"Lactation\": false,\n                \"PediatricUse\": false,\n                \"GeriatricUse\": false\n            },\n            \"Other\": false,\n            \"Blacklisted\": false,\n            \"Annotations\": [\n                {\n                    \"VerbatimTerm\": \"decreased white blood cell counts\",\n                    \"Probability\": \"0.84591144323349\",\n                    \"SemanticContext\": \"In previous clinical trials submitted for approved labeling of metronidazole vaginal gel USP, 0.75% the following was also reported: Laboratory: Increased/decreased white blood cell counts 1.7% .\"\n                }\n            ]\n        }\n    ],\n    \"IndicationTerms\": []\n}"}],"_postman_id":"272859d6-11c4-4563-acbc-5f347cbb89f7"},{"name":"Label metadata for given date range","id":"a4430bdd-4a65-4bc3-aca4-e2360c5d2eb0","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]},"isInherited":false},"method":"POST","header":[],"body":{"mode":"formdata","formdata":[{"key":"filtertype","value":"date","type":"text","description":"<p>Option is \"date\" (string)</p>\n"},{"key":"filtervalue","value":"20230315-20230321","type":"text","description":"<p>Option is date range as YYYYMMDD-YYYYMMDD (string)</p>\n"},{"key":"skip","value":"0","description":"<p>Value for Number of records to skip (integer). Defaults to 0</p>\n","type":"text"},{"key":"limit","value":"10","description":"<p>Value for number of records to fetch (integer). Defaults to 100</p>\n","type":"text"},{"key":"country","value":"all","description":"<p>Options are \"us\", \"uk\", \"ca\", \"eu\", \"au\", \"all\" (string). Defaults to \"us\"</p>\n","type":"text"}]},"url":"https://labelae.doctorevidence.com/discontinued/annotation/label","description":"<ul>\n<li>Returns labels metadata for all product labels that have been imported/updated between the given date range. Dates are stored in UTC and results are fetched as per UTC time. Time defaults to 00:00 and cannot be changed.</li>\n<li>This will return a maximum of 100 annotation details.</li>\n</ul>\n<p><strong>Note: All the Params should be passed as raw data in JSON format (</strong> eg. { \"skip\":0, \"limit\":10 } <strong>)</strong></p>\n","urlObject":{"protocol":"https","path":["discontinued","annotation","label"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"de6fb063-f43d-4e71-8aac-4dd904c9a28e","name":"Label metadata for given date range","originalRequest":{"method":"POST","header":[{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n    \"filtertype\": \"date\",\n    \"filtervalue\": \"20230315-20230321\",\n    \"skip\": 0,\n    \"limit\": 10,\n    \"country\": \"all\"\n}","options":{"raw":{"language":"json"}}},"url":"https://labelae.doctorevidence.com/discontinued/annotation/label"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Encoding","value":"gzip"},{"key":"Content-Type","value":"text/plain; charset=utf-8"},{"key":"Date","value":"Mon, 29 Apr 2024 08:08:53 GMT"},{"key":"Server","value":"Kestrel"},{"key":"Vary","value":"Accept-Encoding"},{"key":"Transfer-Encoding","value":"chunked"}],"cookie":[],"responseTime":null,"body":"{\n    \"totalcount\": 5018,\n    \"skip\": 0,\n    \"limit\": 100,\n    \"BaseURL\": \"https://labelae.doctorevidence.com/discontinued/annotation/label/\",\n    \"MeddraVersion\": \"26.1\",\n    \"data\": [\n        {\n            \"GenericName\": \"sodium iodide i 131\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USed6202f9-42ac-4736-b014-545f9c5c2be6\",\n                    \"NDCCode\": \"0019-9452\",\n                    \"UpdatedDate\": \"Nov 18, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"SODIUM IODIDE I 131 -  sodium iodide i - 131 capsule, gelatin coated Mallinckrodt Inc.\",\n                        \"TradeName\": \"SODIUM IODIDE I 131\",\n                        \"Manufacturer\": \"Mallinckrodt Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"000e2ca1-9a11-46f2-860c-4de0ca5be369\",\n                        \"FileId\": \"ed6202f9-42ac-4736-b014-545f9c5c2be6\",\n                        \"Version\": \"18\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000e2ca1-9a11-46f2-860c-4de0ca5be369\",\n                        \"genericNames\": \"sodium iodide i 131\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sulfacetamide sodium and sulfur\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US9b4ff6b6-2976-4054-9aae-234aa726e925\",\n                    \"NDCCode\": \"58980-330\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CERISA -  sulfacetamide sodium and sulfur lotion Stratus Pharamceuticals, Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Cerisa\",\n                        \"Manufacturer\": \"STRATUS PHARMACEUTICALS INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00278dd5-328f-4f4c-992c-a02ecde24e51\",\n                        \"FileId\": \"9b4ff6b6-2976-4054-9aae-234aa726e925\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00278dd5-328f-4f4c-992c-a02ecde24e51\",\n                        \"genericNames\": \"sulfacetamide sodium and sulfur\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US626ed157-f5a1-57e0-e053-2991aa0a500a\",\n                    \"NDCCode\": \"75854-310\",\n                    \"UpdatedDate\": \"Jan 11, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FERIVAFA -  ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium capsule, gelatin coated Avion Pharmaceuticals, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FeRivaFA\",\n                        \"Manufacturer\": \"Avion Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"002df203-be22-41aa-a52c-d14ecbc00dbe\",\n                        \"FileId\": \"626ed157-f5a1-57e0-e053-2991aa0a500a\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002df203-be22-41aa-a52c-d14ecbc00dbe\",\n                        \"genericNames\": \"ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tropicamide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6c37858c-d1d5-4cb0-af32-b63eb6d09178\",\n                    \"NDCCode\": \"0404-7192\",\n                    \"UpdatedDate\": \"Feb 09, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TROPICAMIDE -  tropicamide solution/ drops Henry Schein Inc.\",\n                        \"TradeName\": \"Tropicamide\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"002e4f96-7a74-4501-8b81-dc6f092c807a\",\n                        \"FileId\": \"6c37858c-d1d5-4cb0-af32-b63eb6d09178\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002e4f96-7a74-4501-8b81-dc6f092c807a\",\n                        \"genericNames\": \"tropicamide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"metronidazole\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n                    \"NDCCode\": \"0781-7077\",\n                    \"UpdatedDate\": \"Feb 14, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METRONIDAZOLE -  metronidazole gel Sandoz Inc.\",\n                        \"TradeName\": \"Metronidazole\",\n                        \"Manufacturer\": \"Sandoz Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0030514f-879d-416d-b422-24b67e334b36\",\n                        \"FileId\": \"5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0030514f-879d-416d-b422-24b67e334b36\",\n                        \"genericNames\": \"metronidazole\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US81779794-0dbf-454b-8179-3a985d6ba813\",\n                    \"NDCCode\": \"99207-140\",\n                    \"UpdatedDate\": \"May 29, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METRONIDAZOLE -  metronidazole gel Medicis Pharmaceutical Corp\",\n                        \"TradeName\": \"METRONIDAZOLE\",\n                        \"Manufacturer\": \"Medicis Pharmaceutical Corp\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01f0f7b8-0586-4b8e-890d-4ecf3488c617\",\n                        \"FileId\": \"81779794-0dbf-454b-8179-3a985d6ba813\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f0f7b8-0586-4b8e-890d-4ecf3488c617\",\n                        \"genericNames\": \"metronidazole\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydroquinone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd2083da3-67bd-4f36-a105-a088a50dd5e0\",\n                    \"NDCCode\": \"42851-032\",\n                    \"UpdatedDate\": \"Oct 11, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MELAMIN SKIN BLEACHING AND CORRECTING HYDROQUINONE -  hydroquinone cream ZO Skin Health, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"MELAMIN Skin Bleaching and Correcting Hydroquinone\",\n                        \"Manufacturer\": \"ZO Skin Health, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0036ad62-e92a-42cb-b0ae-61bb87049ff2\",\n                        \"FileId\": \"d2083da3-67bd-4f36-a105-a088a50dd5e0\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0036ad62-e92a-42cb-b0ae-61bb87049ff2\",\n                        \"genericNames\": \"hydroquinone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"dextrose monohydrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0038c31a-5b2d-4271-9141-04b67695996c\",\n                    \"NDCCode\": \"0338-0023\",\n                    \"UpdatedDate\": \"Sep 27, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DEXTROSE -  dextrose hydrous injection, solution Baxter Healthcare Corporation\",\n                        \"TradeName\": \"DEXTROSE\",\n                        \"Manufacturer\": \"Baxter Healthcare Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"FileId\": \"0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"genericNames\": \"dextrose monohydrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"iodoquinol 1% - hydrocortisone acetate 2% - aloe polysaccharides 1%\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScce6a8e9-53c5-4298-9a3b-3dacc7add9be\",\n                    \"NDCCode\": \"13925-174\",\n                    \"UpdatedDate\": \"May 05, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"IODOQUINOL 1%  -  HYDROCORTISONE ACETATE 2%  -  ALOE POLYSACCHARIDES 1% -  iodoquinol, hydrocortisone acetate and aloe vera leaf polysaccharides gel Seton Pharmaceuticals      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Iodoquinol 1% - Hydrocortisone Acetate 2% - Aloe Polysaccharides 1%\",\n                        \"Manufacturer\": \"Seton Pharmaceuticals\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"005c57c2-a323-4ab6-b994-0a63bf9b915f\",\n                        \"FileId\": \"cce6a8e9-53c5-4298-9a3b-3dacc7add9be\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=005c57c2-a323-4ab6-b994-0a63bf9b915f\",\n                        \"genericNames\": \"iodoquinol 1% - hydrocortisone acetate 2% - aloe polysaccharides 1%\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"chlorzoxazone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US31777bf1-9074-4232-b32f-3e675a68f51d\",\n                    \"NDCCode\": \"68462-724\",\n                    \"UpdatedDate\": \"Jun 28, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CHLORZOXAZONE -  chlorzoxazone tablet Glenmark Pharmaceuticals Inc., USA\",\n                        \"TradeName\": \"chlorzoxazone\",\n                        \"Manufacturer\": \"Glenmark Pharmaceuticals Inc., USA\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00663cd9-5405-4a1d-8038-23ec0874dc28\",\n                        \"FileId\": \"31777bf1-9074-4232-b32f-3e675a68f51d\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00663cd9-5405-4a1d-8038-23ec0874dc28\",\n                        \"genericNames\": \"chlorzoxazone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ketorolac tromethamine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US1c79d44d-8f10-4a8f-a0b5-21c2ba258777\",\n                    \"NDCCode\": \"65862-770\",\n                    \"UpdatedDate\": \"Dec 29, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"KETOROLAC TROMETHAMINE  -  ketorolac tromethamine solution/ drops Aurobindo Pharma Limited\",\n                        \"TradeName\": \"Ketorolac Tromethamine\",\n                        \"Manufacturer\": \"Aurobindo Pharma Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"007a4da5-d794-416c-94b3-6ee9e7842c52\",\n                        \"FileId\": \"1c79d44d-8f10-4a8f-a0b5-21c2ba258777\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a4da5-d794-416c-94b3-6ee9e7842c52\",\n                        \"genericNames\": \"ketorolac tromethamine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tapentadol hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US926544cc-122c-4f9f-9434-a886827b0871\",\n                    \"NDCCode\": \"50458-830\",\n                    \"UpdatedDate\": \"Nov 01, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NUCYNTA -  tapentadol hydrochloride tablet, film coated Janssen Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"NUCYNTA\",\n                        \"Manufacturer\": \"Janssen Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00a8921e-46a6-4df1-a744-9e532b6fb06f\",\n                        \"FileId\": \"926544cc-122c-4f9f-9434-a886827b0871\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a8921e-46a6-4df1-a744-9e532b6fb06f\",\n                        \"genericNames\": \"tapentadol hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"donepezil hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8c8f4e5f-acf1-443f-a890-6665c7cc9aa4\",\n                    \"NDCCode\": \"68382-347\",\n                    \"UpdatedDate\": \"Nov 12, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DONEPEZIL HYDROCHLORIDE  -  donepezil hydrochloride tablet, orally disintegrating Zydus Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"donepezil hydrochloride\",\n                        \"Manufacturer\": \"Zydus Pharmaceuticals (USA) Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00a9d965-4c27-419b-a23a-b109864e47fa\",\n                        \"FileId\": \"8c8f4e5f-acf1-443f-a890-6665c7cc9aa4\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a9d965-4c27-419b-a23a-b109864e47fa\",\n                        \"genericNames\": \"donepezil hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"amoxicillin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe8bb6e15-4912-4ab8-a5d5-4ccede21853d\",\n                    \"NDCCode\": \"0143-9820\",\n                    \"UpdatedDate\": \"Aug 03, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"AMOXICILLIN -  amoxicillin tablet, chewable Hikma Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"Amoxicillin\",\n                        \"Manufacturer\": \"Hikma Pharmaceuticals USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00c35e29-0b05-4232-a4d6-38a230102ef5\",\n                        \"FileId\": \"e8bb6e15-4912-4ab8-a5d5-4ccede21853d\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c35e29-0b05-4232-a4d6-38a230102ef5\",\n                        \"genericNames\": \"amoxicillin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sodium fluoride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0a04a9d3-c869-4a4a-b96f-4f56c91553e6\",\n                    \"NDCCode\": \"48878-3160\",\n                    \"UpdatedDate\": \"Jun 03, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUORIDE TREATMENT -  sodium fluoride solution 3M ESPE Dental Products      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Fluoride Treatment\",\n                        \"Manufacturer\": \"3M ESPE Dental Products\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00c68fa6-ae49-4b73-bb71-5e960dc98368\",\n                        \"FileId\": \"0a04a9d3-c869-4a4a-b96f-4f56c91553e6\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c68fa6-ae49-4b73-bb71-5e960dc98368\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US61eee3de-2569-40e0-bab8-33e9e1994dcd\",\n                    \"NDCCode\": \"69962-014\",\n                    \"UpdatedDate\": \"Jul 17, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FIDELIS APF -  sodium fluoride gel Webco Dental &amp; Medical Supplies, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FIDELIS APF\",\n                        \"Manufacturer\": \"Webco Dental & Medical Supplies, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"011ba0c9-7b31-4cac-8c2a-9bcd4d5b8ef9\",\n                        \"FileId\": \"61eee3de-2569-40e0-bab8-33e9e1994dcd\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=011ba0c9-7b31-4cac-8c2a-9bcd4d5b8ef9\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"USa530e5e7-f391-4af7-9137-f673fc454378\",\n                    \"NDCCode\": \"69509-076\",\n                    \"UpdatedDate\": \"Feb 21, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PRIMO APF -  sodium fluoride aerosol, foam Tri State Dental Supply      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Primo APF\",\n                        \"Manufacturer\": \"Tri State Dental Supply\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0202ab96-5f39-4fd5-8d5f-b828e81c1ab4\",\n                        \"FileId\": \"a530e5e7-f391-4af7-9137-f673fc454378\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0202ab96-5f39-4fd5-8d5f-b828e81c1ab4\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US7e9203d2-c833-76f0-e053-2a91aa0a305a\",\n                    \"NDCCode\": \"64778-0378\",\n                    \"UpdatedDate\": \"Jan 05, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DENTI - CARE DENTI - FOAM TOPICAL SODIUM FLUORIDE RASPBERRY -  sodium fluoride aerosol, foam AMD Medicom Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Denti-Care Denti-Foam\",\n                        \"Manufacturer\": \"AMD Medicom Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02486b16-b1a4-4a1d-b7ca-ed77d97e97e4\",\n                        \"FileId\": \"7e9203d2-c833-76f0-e053-2a91aa0a305a\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02486b16-b1a4-4a1d-b7ca-ed77d97e97e4\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US30c61365-3693-4c64-9eec-a38bba83bdaa\",\n                    \"NDCCode\": \"69962-020\",\n                    \"UpdatedDate\": \"Jul 17, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FIDELIS APF -  sodium fluoride aerosol, foam Webco Dental &amp; Medical Supplies, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FIDELIS APF\",\n                        \"Manufacturer\": \"Webco Dental & Medical Supplies, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02a9ae8d-2910-4986-8493-d378d09ab4b1\",\n                        \"FileId\": \"30c61365-3693-4c64-9eec-a38bba83bdaa\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a9ae8d-2910-4986-8493-d378d09ab4b1\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US7e40fae9-b3eb-49c9-e053-2991aa0a21b3\",\n                    \"NDCCode\": \"64778-0214\",\n                    \"UpdatedDate\": \"Jan 01, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DENTI - CARE DENTI - PRO TOPICAL SODIUM FLUORIDE 60 SECOND -  sodium fluoride gel AMD Medicom Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Denti-Care Denti-Pro\",\n                        \"Manufacturer\": \"AR Medicom Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05af0929-6a37-4b76-b3f9-94ccd8a3a17b\",\n                        \"FileId\": \"7e40fae9-b3eb-49c9-e053-2991aa0a21b3\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05af0929-6a37-4b76-b3f9-94ccd8a3a17b\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"USb60be188-1df3-c64e-e053-2a95a90a2cdc\",\n                    \"NDCCode\": \"66467-3790\",\n                    \"UpdatedDate\": \"Dec 11, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DARBY TOPICAL SODIUM FLUORIDE STRAWBERRY -  sodium fluoride aerosol, foam Darby Dental Supply, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Darby\",\n                        \"Manufacturer\": \"Darby Dental Supply, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05daaae5-57c5-47e9-834a-e453c7526782\",\n                        \"FileId\": \"b60be188-1df3-c64e-e053-2a95a90a2cdc\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05daaae5-57c5-47e9-834a-e453c7526782\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fluoride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US28d952e7-7caa-492f-a1f5-7a39098da55e\",\n                    \"NDCCode\": \"51862-172\",\n                    \"UpdatedDate\": \"Aug 02, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUORIDE  -  sodium fluoride tablet, chewable Mayne Pharma Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Fluoride\",\n                        \"Manufacturer\": \"Mayne Pharma Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00e1f644-1538-4054-b112-227e7254317e\",\n                        \"FileId\": \"28d952e7-7caa-492f-a1f5-7a39098da55e\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00e1f644-1538-4054-b112-227e7254317e\",\n                        \"genericNames\": \"fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mirtazapine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US325197a6-1a5f-4c6f-bb05-c8b3f64ce3ad\",\n                    \"NDCCode\": \"0052-0110\",\n                    \"UpdatedDate\": \"Oct 15, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REMERON -  mirtazapine tablet, film coated REMERONSOLTAB -  mirtazapine tablet, orally disintegrating Organon USA Inc.\",\n                        \"TradeName\": \"REMERONSOLTAB\",\n                        \"Manufacturer\": \"Organon USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"010f9162-9f7f-4b6d-a6e4-4f832f26f38e\",\n                        \"FileId\": \"325197a6-1a5f-4c6f-bb05-c8b3f64ce3ad\",\n                        \"Version\": \"32\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010f9162-9f7f-4b6d-a6e4-4f832f26f38e\",\n                        \"genericNames\": \"mirtazapine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"zileuton\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USf1429302-86df-1568-e053-2995a90a9b93\",\n                    \"NDCCode\": \"69339-130\",\n                    \"UpdatedDate\": \"Jan 04, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ZILEUTON -  zileuton tablet, multilayer, extended release DASH Pharmaceutical LLC\",\n                        \"TradeName\": \"Zileuton\",\n                        \"Manufacturer\": \"DASH Pharmaceutical LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01249483-f82f-4b09-b116-b50f1c7ebdf3\",\n                        \"FileId\": \"f1429302-86df-1568-e053-2995a90a9b93\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01249483-f82f-4b09-b116-b50f1c7ebdf3\",\n                        \"genericNames\": \"zileuton\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"dextrose monohydrate, sodium chloride and potassium chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa5043890-7a8f-4718-bfc3-d20792d4bd61\",\n                    \"NDCCode\": \"0338-6335\",\n                    \"UpdatedDate\": \"Jul 28, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE -  dextrose monohydrate, sodium chloride and potassium chloride injection, solution Baxter Healthcare Corporation\",\n                        \"TradeName\": \"Potassium Chloride in Dextrose and Sodium Chloride\",\n                        \"Manufacturer\": \"Baxter Healthcare Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01321de3-bf0b-4460-9aee-511406ee101e\",\n                        \"FileId\": \"a5043890-7a8f-4718-bfc3-d20792d4bd61\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01321de3-bf0b-4460-9aee-511406ee101e\",\n                        \"genericNames\": \"dextrose monohydrate, sodium chloride and potassium chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fenofibrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                    \"NDCCode\": \"70199-027\",\n                    \"UpdatedDate\": \"Nov 15, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FENOFIBRATE  -  fenofibrate tablet Casper Pharma LLC\",\n                        \"TradeName\": \"FENOFIBRATE\",\n                        \"Manufacturer\": \"Casper Pharma LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"FileId\": \"0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"genericNames\": \"fenofibrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"etonogestrel and ethinyl estradiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USeb39f2fd-0ee1-4cee-ad04-e5371706310a\",\n                    \"NDCCode\": \"0052-0273\",\n                    \"UpdatedDate\": \"Feb 05, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NUVARING -  etonogestrel and ethinyl estradiol insert, extended release Organon USA Inc.\",\n                        \"TradeName\": \"NuvaRing\",\n                        \"Manufacturer\": \"Organon USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"017343fb-86c4-45ab-9c47-52cc5b9f3a02\",\n                        \"FileId\": \"eb39f2fd-0ee1-4cee-ad04-e5371706310a\",\n                        \"Version\": \"27\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017343fb-86c4-45ab-9c47-52cc5b9f3a02\",\n                        \"genericNames\": \"etonogestrel and ethinyl estradiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"trimipramine maleate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USff72526a-1529-4354-a265-c23f5704a65e\",\n                    \"NDCCode\": \"51285-554\",\n                    \"UpdatedDate\": \"Aug 06, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"SURMONTIL -  trimipramine maleate capsule Teva Women's Health, Inc.\",\n                        \"TradeName\": \"Surmontil\",\n                        \"Manufacturer\": \"Teva Women's Health, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0177d783-773c-41bf-9db9-eb7e5c64474a\",\n                        \"FileId\": \"ff72526a-1529-4354-a265-c23f5704a65e\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0177d783-773c-41bf-9db9-eb7e5c64474a\",\n                        \"genericNames\": \"trimipramine maleate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydroxypropyl cellulose\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US587d995e-963a-4990-9077-747490bfface\",\n                    \"NDCCode\": \"25010-805\",\n                    \"UpdatedDate\": \"Oct 08, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LACRISERT -  hydroxypropyl cellulose (type h) pellet Aton Pharma, Inc.\",\n                        \"TradeName\": \"Lacrisert\",\n                        \"Manufacturer\": \"ATON PHARMA INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"017980de-48b6-4b28-aec0-315411149a7e\",\n                        \"FileId\": \"587d995e-963a-4990-9077-747490bfface\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017980de-48b6-4b28-aec0-315411149a7e\",\n                        \"genericNames\": \"hydroxypropyl cellulose\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tobramycin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe59394a3-3474-4186-9986-5c589cd851ed\",\n                    \"NDCCode\": \"0404-7196\",\n                    \"UpdatedDate\": \"Feb 09, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TOBRAMYCIN -  tobramycin solution/ drops Henry Schein Inc.\",\n                        \"TradeName\": \"Tobramycin\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"019172e3-bf24-4b76-9253-f58765d7b4f3\",\n                        \"FileId\": \"e59394a3-3474-4186-9986-5c589cd851ed\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=019172e3-bf24-4b76-9253-f58765d7b4f3\",\n                        \"genericNames\": \"tobramycin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cimetidine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0337689b-c5d5-d881-e063-6394a90aaec9\",\n                    \"NDCCode\": \"62135-631\",\n                    \"UpdatedDate\": \"Aug 22, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CIMETIDINE -  cimetidine tablet, film coated Chartwell RX, LLC\",\n                        \"TradeName\": \"CIMETIDINE\",\n                        \"Manufacturer\": \"Chartwell RX, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01997826-7ca1-473e-bfc9-075b14b58a35\",\n                        \"FileId\": \"0337689b-c5d5-d881-e063-6394a90aaec9\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01997826-7ca1-473e-bfc9-075b14b58a35\",\n                        \"genericNames\": \"cimetidine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cat pelt, standardized\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc7ac1890-9d51-4036-9022-d4f406b9dc88\",\n                    \"NDCCode\": \"0268-2002\",\n                    \"UpdatedDate\": \"May 23, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CAT PELT, STANDARDIZED -  felis catus skin injection, solution CAT PELT, STANDARDIZED -  felis catus skin solution ALK - Abello, Inc.\",\n                        \"TradeName\": \"Cat Pelt, Standardized\",\n                        \"Manufacturer\": \"ALK-Abello, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01a914b7-51b5-4aab-952f-2eae56d25e9c\",\n                        \"FileId\": \"c7ac1890-9d51-4036-9022-d4f406b9dc88\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a914b7-51b5-4aab-952f-2eae56d25e9c\",\n                        \"genericNames\": \"cat pelt, standardized\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"clopidogrel bisulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USfdbc18a6-b364-4f85-9fd1-71d04b3a7ab1\",\n                    \"NDCCode\": \"63653-1171\",\n                    \"UpdatedDate\": \"Mar 11, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PLAVIX -  clopidogrel bisulfate tablet, film coated Bristol - Myers Squibb/Sanofi Pharmaceuticals Partnership\",\n                        \"TradeName\": \"Plavix\",\n                        \"Manufacturer\": \"Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01b14603-8f29-4fa3-8d7e-9d523f802e0b\",\n                        \"FileId\": \"fdbc18a6-b364-4f85-9fd1-71d04b3a7ab1\",\n                        \"Version\": \"34\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b\",\n                        \"genericNames\": \"clopidogrel||clopidogrel bisulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"torsemide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US5da4dfd2-88e9-4270-a408-c0bbd566acf4\",\n                    \"NDCCode\": \"0037-5010\",\n                    \"UpdatedDate\": \"Jan 13, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DEMADEX -  torsemide tablet Meda Pharmaceuticals\",\n                        \"TradeName\": \"Demadex\",\n                        \"Manufacturer\": \"Meda Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01b388a0-7dfb-11de-bc4e-0002a5d5c51b\",\n                        \"FileId\": \"5da4dfd2-88e9-4270-a408-c0bbd566acf4\",\n                        \"Version\": \"13\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b388a0-7dfb-11de-bc4e-0002a5d5c51b\",\n                        \"genericNames\": \"torsemide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"vincristine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USaaacd521-3f4e-450d-a8cc-f5229e7fb65c\",\n                    \"NDCCode\": \"0703-4412\",\n                    \"UpdatedDate\": \"Jun 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VINCASAR PFS -  vincristine sulfate injection, solution Teva Parenteral Medicines, Inc.\",\n                        \"TradeName\": \"Vincasar PFS\",\n                        \"Manufacturer\": \"Teva Parenteral Medicines, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01cee93f-3ab9-44fa-8c9a-dd5958fd2db9\",\n                        \"FileId\": \"aaacd521-3f4e-450d-a8cc-f5229e7fb65c\",\n                        \"Version\": \"18\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cee93f-3ab9-44fa-8c9a-dd5958fd2db9\",\n                        \"genericNames\": \"vincristine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"thyroid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US7c47ad19-42de-592f-e053-2991aa0a3c35\",\n                    \"NDCCode\": \"43063-819\",\n                    \"UpdatedDate\": \"Dec 06, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NATURE - THROID -  thyroid, porcine tablet PD - Rx Pharmaceuticals, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Nature-Throid\",\n                        \"Manufacturer\": \"PD-Rx Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01cf8d6f-5ec1-4bd4-94f0-e9edf116cf2f\",\n                        \"FileId\": \"7c47ad19-42de-592f-e053-2991aa0a3c35\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cf8d6f-5ec1-4bd4-94f0-e9edf116cf2f\",\n                        \"genericNames\": \"thyroid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ondansetron hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USffbc2301-05e0-5f75-e053-6394a90ab415\",\n                    \"NDCCode\": \"82449-200\",\n                    \"UpdatedDate\": \"Oct 03, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ONDANSETRON HYDROCHLORIDE -  ondansetron hydrochloride injection Steriscience Specialties Private Limited\",\n                        \"TradeName\": \"ondansetron hydrochloride\",\n                        \"Manufacturer\": \"Steriscience Specialties Private Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01d69f4d-eddf-4fc8-820b-832f11f2e3c0\",\n                        \"FileId\": \"ffbc2301-05e0-5f75-e053-6394a90ab415\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01d69f4d-eddf-4fc8-820b-832f11f2e3c0\",\n                        \"genericNames\": \"ondansetron hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"albumin (human)\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USeddd4478-99a9-4827-ba0b-17e04ba67454\",\n                    \"NDCCode\": \"76125-785\",\n                    \"UpdatedDate\": \"Dec 22, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ALBUKED  -  albumin human solution KEDRION BIOPHARMA, INC.\",\n                        \"TradeName\": \"Albuked\",\n                        \"Manufacturer\": \"KEDRION BIOPHARMA INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01d78cc3-765c-89a9-7a60-b578e5723cbb\",\n                        \"FileId\": \"eddd4478-99a9-4827-ba0b-17e04ba67454\",\n                        \"Version\": \"12\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01d78cc3-765c-89a9-7a60-b578e5723cbb\",\n                        \"genericNames\": \"albumin (human)\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cholera vaccine, live, oral\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USaa67e293-7e9e-4b1d-9637-17ce3a0161a4\",\n                    \"NDCCode\": \"70460-001\",\n                    \"UpdatedDate\": \"Oct 26, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VAXCHORA -  cholera vaccine, live, oral \\t\\t\\t Paxvax, Inc.\",\n                        \"TradeName\": \"Vaxchora\",\n                        \"Manufacturer\": \"Paxvax, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01dae2ac-8332-4e23-b971-67dc36c3ee16\",\n                        \"FileId\": \"aa67e293-7e9e-4b1d-9637-17ce3a0161a4\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01dae2ac-8332-4e23-b971-67dc36c3ee16\",\n                        \"genericNames\": \"cholera vaccine, live, oral\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"medroxyprogesterone acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US10fdc3f5-de88-4bbb-9f3f-c0a0630d0222\",\n                    \"NDCCode\": \"62756-091\",\n                    \"UpdatedDate\": \"Dec 20, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEDROXYPROGESTERONE ACETATE  -  medroxyprogesterone acetate injection, suspension Sun Pharmaceutical Industries, Inc.\",\n                        \"TradeName\": \"MEDROXYPROGESTERONE ACETATE\",\n                        \"Manufacturer\": \"Sun Pharmaceutical Industries, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01e28bef-9758-40cf-a4ff-86ae9f4f5105\",\n                        \"FileId\": \"10fdc3f5-de88-4bbb-9f3f-c0a0630d0222\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e28bef-9758-40cf-a4ff-86ae9f4f5105\",\n                        \"genericNames\": \"medroxyprogesterone acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US4e917729-3eac-400c-bbaf-8b30a04a380c\",\n                    \"NDCCode\": \"24201-150\",\n                    \"UpdatedDate\": \"May 04, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION -  medroxyprogesterone acetate injection, suspension Hikma Pharmaceuticals USA inc.\",\n                        \"TradeName\": \"Medroxyprogesterone Acetate Injectable Suspension\",\n                        \"Manufacturer\": \"Hikma Pharmaceuticals USA inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0476eac5-d96c-4910-aa86-1ddeeefefe50\",\n                        \"FileId\": \"4e917729-3eac-400c-bbaf-8b30a04a380c\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0476eac5-d96c-4910-aa86-1ddeeefefe50\",\n                        \"genericNames\": \"medroxyprogesterone acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"benzoyl peroxide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US19004b02-2e4b-4d66-aa84-7a19ad8c3c69\",\n                    \"NDCCode\": \"45802-910\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PERRIGO BENZOYL PEROXIDE AQUEOUS BASE -  benzoyl peroxide gel Perrigo New York Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Perrigo Benzoyl Peroxide\",\n                        \"Manufacturer\": \"PERRIGO NEW YORK INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01e8bf1e-db02-4dd0-a448-645f0f367401\",\n                        \"FileId\": \"19004b02-2e4b-4d66-aa84-7a19ad8c3c69\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e8bf1e-db02-4dd0-a448-645f0f367401\",\n                        \"genericNames\": \"benzoyl peroxide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"progesterone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6339e30d-a5d3-09b0-852a-84ef2e8c2a83\",\n                    \"NDCCode\": \"0032-1708\",\n                    \"UpdatedDate\": \"Aug 26, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PROMETRIUM -  progesterone capsule AbbVie Inc.\",\n                        \"TradeName\": \"Prometrium\",\n                        \"Manufacturer\": \"AbbVie Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0224b5a6-25a3-44c9-b94f-90e2e064c164\",\n                        \"FileId\": \"6339e30d-a5d3-09b0-852a-84ef2e8c2a83\",\n                        \"Version\": \"23\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224b5a6-25a3-44c9-b94f-90e2e064c164\",\n                        \"genericNames\": \"progesterone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"desvenlafaxine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USbf7c38d6-3cba-42dd-a439-ed28c34789c3\",\n                    \"NDCCode\": \"49884-375\",\n                    \"UpdatedDate\": \"Dec 20, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"KHEDEZLA EXTENDED - RELEASE -  desvenlafaxine tablet, extended release Par Pharmaceutical Inc.\",\n                        \"TradeName\": \"KHEDEZLA\",\n                        \"Manufacturer\": \"Par Pharmaceutical Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0224e77b-7f6f-4191-ad3b-06847d5930e2\",\n                        \"FileId\": \"bf7c38d6-3cba-42dd-a439-ed28c34789c3\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224e77b-7f6f-4191-ad3b-06847d5930e2\",\n                        \"genericNames\": \"desvenlafaxine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"luvira\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99d7525d-b62e-7f8e-e053-2a95a90a2080\",\n                    \"NDCCode\": \"69336-351\",\n                    \"UpdatedDate\": \"Dec 18, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LUVIRA -  omega - 3 - acid ethyl esters, 12 - hydroxyeicosapentaenoic acid, (12r) -  and 4,7,10,13,16,19 - docosahexaenoic acid, (4e,7e,10e,13e,16e,19e) -  capsule Sterling - Knight Pharmaceuticals, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Luvira\",\n                        \"Manufacturer\": \"Sterling-Knight Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"025679cf-dfb2-4988-9e18-2f55ef9b306f\",\n                        \"FileId\": \"99d7525d-b62e-7f8e-e053-2a95a90a2080\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=025679cf-dfb2-4988-9e18-2f55ef9b306f\",\n                        \"genericNames\": \"luvira\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine, and glycine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USdad76e26-0274-4501-abaf-216a4165a2ae\",\n                    \"NDCCode\": \"0409-4191\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"AMINOSYN -  isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine and glycine injection, solution Hospira, Inc.\",\n                        \"TradeName\": \"Aminosyn\",\n                        \"Manufacturer\": \"Hospira, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02597da7-70bc-44f5-50a5-d67934125b7f\",\n                        \"FileId\": \"dad76e26-0274-4501-abaf-216a4165a2ae\",\n                        \"Version\": \"13\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02597da7-70bc-44f5-50a5-d67934125b7f\",\n                        \"genericNames\": \"isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine, and glycine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fenortho\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US91b0ac5b-994c-468f-9331-542b8f92f9a8\",\n                    \"NDCCode\": \"54288-130\",\n                    \"UpdatedDate\": \"Jun 16, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FENORTHO -  fenoprofen calcium capsule BPI Labs LLC\",\n                        \"TradeName\": \"FENORTHO\",\n                        \"Manufacturer\": \"BPI Labs LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02a23e48-f371-448b-92b2-e2d010be1886\",\n                        \"FileId\": \"91b0ac5b-994c-468f-9331-542b8f92f9a8\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a23e48-f371-448b-92b2-e2d010be1886\",\n                        \"genericNames\": \"fenortho\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"neomycin sulfate, polymyxin b sulfate and bacitracin zinc\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd6ca470d-dd66-45d4-b2b5-23090c9223b6\",\n                    \"NDCCode\": \"0404-7194\",\n                    \"UpdatedDate\": \"Feb 05, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NEOMYCIN AND POLYMYXIN B SULFATES, AND BACITRACIN ZINC -  neomycin sulfate, polymyxin b sulfate and bacitracin zinc ointment Henry Schein Inc.\",\n                        \"TradeName\": \"Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02af2a5f-32fb-460b-b29f-7b18cb95204c\",\n                        \"FileId\": \"d6ca470d-dd66-45d4-b2b5-23090c9223b6\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c\",\n                        \"genericNames\": \"neomycin sulfate, polymyxin b sulfate and bacitracin zinc\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"betamethasone valerate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6094e3c6-ba85-4774-a61d-233f92b92c6c\",\n                    \"NDCCode\": \"0145-0021\",\n                    \"UpdatedDate\": \"Jul 01, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LUXIQ -  betamethasone valerate aerosol, foam Stiefel Laboratories Inc\",\n                        \"TradeName\": \"LUXIQ\",\n                        \"Manufacturer\": \"Stiefel Laboratories Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55\",\n                        \"FileId\": \"6094e3c6-ba85-4774-a61d-233f92b92c6c\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55\",\n                        \"genericNames\": \"betamethasone valerate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methenamine hippurate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6b264a9e-f32b-4d56-8738-70b8d36c95b2\",\n                    \"NDCCode\": \"30698-277\",\n                    \"UpdatedDate\": \"Jan 26, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HIPREX -  methenamine hippurate tablet Validus Pharmaceuticals LLC\",\n                        \"TradeName\": \"HIPREX\",\n                        \"Manufacturer\": \"Validus Pharmaceuticals LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02c70c23-b644-430c-b524-29af3360436d\",\n                        \"FileId\": \"6b264a9e-f32b-4d56-8738-70b8d36c95b2\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c70c23-b644-430c-b524-29af3360436d\",\n                        \"genericNames\": \"methenamine hippurate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tranexamic acid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa2b02c92-a449-4624-9936-423a9c0993e2\",\n                    \"NDCCode\": \"66993-121\",\n                    \"UpdatedDate\": \"Dec 07, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TRANEXAMIC ACID -  tranexamic acid tablet Prasco Laboratories\",\n                        \"TradeName\": \"Tranexamic Acid\",\n                        \"Manufacturer\": \"Prasco Laboratories\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03003067-1bbc-4f5b-85ec-c21a955fbc06\",\n                        \"FileId\": \"a2b02c92-a449-4624-9936-423a9c0993e2\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03003067-1bbc-4f5b-85ec-c21a955fbc06\",\n                        \"genericNames\": \"tranexamic acid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (mdck cell derived, propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated)\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe2f91bc2-f0dc-462c-87bf-847d95aad516\",\n                    \"NDCCode\": \"63851-612\",\n                    \"UpdatedDate\": \"Aug 21, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUCELVAX -  influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated),  influenza a virus a/texas/50/2012 x - 223a (h3n2) antigen (mdck cell derived, propiolactone inactivated) and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated) injection, suspension Novartis Vaccines and Diagnostics GmbH\",\n                        \"TradeName\": \"Flucelvax\",\n                        \"Manufacturer\": \"Novartis Vaccines and Diagnostics GmbH\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"030dfb30-589d-4335-85fe-d609644088e0\",\n                        \"FileId\": \"e2f91bc2-f0dc-462c-87bf-847d95aad516\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=030dfb30-589d-4335-85fe-d609644088e0\",\n                        \"genericNames\": \"influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (mdck cell derived, propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated)\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"doxepin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8989ba3a-9624-40f6-92d4-7ec21d75e54d\",\n                    \"NDCCode\": \"40085-716\",\n                    \"UpdatedDate\": \"Jan 26, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DOXEPIN HYDROCHLORIDE -  doxepin hydrochloride cream Renaissance Pharma, Inc.\",\n                        \"TradeName\": \"Doxepin Hydrochloride\",\n                        \"Manufacturer\": \"Renaissance Pharma, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03107529-561a-4408-b319-94b245b3117b\",\n                        \"FileId\": \"8989ba3a-9624-40f6-92d4-7ec21d75e54d\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03107529-561a-4408-b319-94b245b3117b\",\n                        \"genericNames\": \"doxepin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"halobetasol propionate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScd9a3fc1-f9e4-4ab7-9c75-50ab9c65e270\",\n                    \"NDCCode\": \"10631-102\",\n                    \"UpdatedDate\": \"Jan 30, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ULTRAVATE -  halobetasol propionate cream ULTRAVATE -  halobetasol propionate ointment Ranbaxy Laboratories Inc.\",\n                        \"TradeName\": \"Ultravate\",\n                        \"Manufacturer\": \"Ranbaxy Laboratories Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"031f1120-7da1-4ea6-a0be-d368018e2c1f\",\n                        \"FileId\": \"cd9a3fc1-f9e4-4ab7-9c75-50ab9c65e270\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=031f1120-7da1-4ea6-a0be-d368018e2c1f\",\n                        \"genericNames\": \"halobetasol propionate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"abciximab\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US36b7d963-49cb-4192-ab24-ea8f6e81d2d6\",\n                    \"NDCCode\": \"0002-7140\",\n                    \"UpdatedDate\": \"Sep 27, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REOPRO -  abciximab injection, solution Eli Lilly and Company\",\n                        \"TradeName\": \"REOPRO\",\n                        \"Manufacturer\": \"Eli Lilly and Company\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"033d4c3b-4630-4256-b8f7-9ed5f15de9a3\",\n                        \"FileId\": \"36b7d963-49cb-4192-ab24-ea8f6e81d2d6\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3\",\n                        \"genericNames\": \"abciximab\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"leuprolide acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US24a44295-5073-434e-af06-a405a6f3ba55\",\n                    \"NDCCode\": \"62935-302\",\n                    \"UpdatedDate\": \"Apr 26, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ELIGARD  -  leuprolide acetate \\t\\t\\t TOLMAR Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"ELIGARD\",\n                        \"Manufacturer\": \"TOLMAR PHARMACEUTICALS INC.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0342f4a9-1037-4d41-b791-e5b0dbaeffeb\",\n                        \"FileId\": \"24a44295-5073-434e-af06-a405a6f3ba55\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0342f4a9-1037-4d41-b791-e5b0dbaeffeb\",\n                        \"genericNames\": \"leuprolide acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cyanocobalamin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USed0ce38e-b59a-9e8f-e053-2995a90a2341\",\n                    \"NDCCode\": \"68001-509\",\n                    \"UpdatedDate\": \"Nov 11, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CYANOCOBALAMIN -  cyanocobalamin injection, solution BluePoint Laboratories\",\n                        \"TradeName\": \"Cyanocobalamin\",\n                        \"Manufacturer\": \"BluePoint Laboratories\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"034615bb-9f98-4034-b3a2-b1cc22a00a46\",\n                        \"FileId\": \"ed0ce38e-b59a-9e8f-e053-2995a90a2341\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=034615bb-9f98-4034-b3a2-b1cc22a00a46\",\n                        \"genericNames\": \"cyanocobalamin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methylphenidate hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US663ba889-95b5-45c2-af06-c90459d30d6d\",\n                    \"NDCCode\": \"0093-5346\",\n                    \"UpdatedDate\": \"Nov 20, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METHYLPHENIDATE HYDROCHLORIDE (LA) -  methylphenidate hydrochloride capsule, extended release Teva Pharmaceuticals USA, Inc.\",\n                        \"TradeName\": \"Methylphenidate Hydrochloride\",\n                        \"Manufacturer\": \"Teva Pharmaceuticals USA, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"034fb7cd-e183-475e-8beb-64fd88facc8f\",\n                        \"FileId\": \"663ba889-95b5-45c2-af06-c90459d30d6d\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=034fb7cd-e183-475e-8beb-64fd88facc8f\",\n                        \"genericNames\": \"methylphenidate hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US6b2dcacd-6280-421e-8ac2-ac00db79a5d5\",\n                    \"NDCCode\": \"0591-2716\",\n                    \"UpdatedDate\": \"Jul 16, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METHYLPHENIDATE HYDROCHLORIDE -  methylphenidate hydrochloride tablet Actavis Pharma, Inc.\",\n                        \"TradeName\": \"methylphenidate hydrochloride\",\n                        \"Manufacturer\": \"Actavis Pharma, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"038ae416-4bd5-411b-bd28-d4f0af5c2ab7\",\n                        \"FileId\": \"6b2dcacd-6280-421e-8ac2-ac00db79a5d5\",\n                        \"Version\": \"14\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038ae416-4bd5-411b-bd28-d4f0af5c2ab7\",\n                        \"genericNames\": \"methylphenidate hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"bicalutamide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USdbfb2d98-13ad-4815-83d6-b0e10e184881\",\n                    \"NDCCode\": \"0310-0705\",\n                    \"UpdatedDate\": \"Nov 15, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CASODEX -  bicalutamide tablet AstraZeneca Pharmaceuticals LP\",\n                        \"TradeName\": \"CASODEX\",\n                        \"Manufacturer\": \"AstraZeneca Pharmaceuticals LP\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03607c0d-b772-435f-c985-ecce8ea8cafd\",\n                        \"FileId\": \"dbfb2d98-13ad-4815-83d6-b0e10e184881\",\n                        \"Version\": \"20\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03607c0d-b772-435f-c985-ecce8ea8cafd\",\n                        \"genericNames\": \"bicalutamide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"trypan blue\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd0d5872f-d428-189b-e053-2995a90a7f32\",\n                    \"NDCCode\": \"68803-672\",\n                    \"UpdatedDate\": \"Nov 17, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEMBRANEBLUE -  trypan blue injection, solution Dutch Ophthalmic Research Center (International) B.V.\",\n                        \"TradeName\": \"MEMBRANEBLUE\",\n                        \"Manufacturer\": \"Dutch Ophthalmic Research Center (International) B.V.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0364aceb-dd3f-4bac-b468-25379a07ccfc\",\n                        \"FileId\": \"d0d5872f-d428-189b-e053-2995a90a7f32\",\n                        \"Version\": \"16\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0364aceb-dd3f-4bac-b468-25379a07ccfc\",\n                        \"genericNames\": \"trypan blue\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"diclofenac sodium, capsaicin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US039c9724-fa4e-1b84-e063-6394a90ac491\",\n                    \"NDCCode\": \"59088-798\",\n                    \"UpdatedDate\": \"Aug 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEXTOL -  diclofenac sodium, capsaicin \\t\\t\\t PureTek Corporation      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Lextol\",\n                        \"Manufacturer\": \"PureTek Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"039ca738-c2c4-41c8-e063-6394a90ab4c4\",\n                        \"FileId\": \"039c9724-fa4e-1b84-e063-6394a90ac491\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=039ca738-c2c4-41c8-e063-6394a90ab4c4\",\n                        \"genericNames\": \"diclofenac sodium, capsaicin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tramadol hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US96bec1b6-7ff2-4e89-be58-d5c359fb51f4\",\n                    \"NDCCode\": \"50458-655\",\n                    \"UpdatedDate\": \"Sep 12, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ULTRAM ER -  tramadol hydrochloride tablet, extended release Janssen Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"Ultram ER\",\n                        \"Manufacturer\": \"Janssen Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"039f9e7c-97f5-4062-8656-6f355c82008e\",\n                        \"FileId\": \"96bec1b6-7ff2-4e89-be58-d5c359fb51f4\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=039f9e7c-97f5-4062-8656-6f355c82008e\",\n                        \"genericNames\": \"tramadol hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mesalamine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3712f360-d3ac-407d-85bf-48e0d7f298cf\",\n                    \"NDCCode\": \"0430-0783\",\n                    \"UpdatedDate\": \"Dec 01, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ASACOL HD -  mesalamine tablet, delayed release Allergan, Inc.\",\n                        \"TradeName\": \"ASACOL HD\",\n                        \"Manufacturer\": \"Warner Chilcott (US), LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03a3bff5-e652-4771-9bf7-3b6850423cc5\",\n                        \"FileId\": \"3712f360-d3ac-407d-85bf-48e0d7f298cf\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5\",\n                        \"genericNames\": \"mesalamine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"diclofenac sodium and benzalkonium chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US12dd097b-f199-4a63-bbba-3d52ac54fa3c\",\n                    \"NDCCode\": \"15455-9565\",\n                    \"UpdatedDate\": \"Apr 21, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DST PLUS PAK -  diclofenac sodium and benzalkonium chloride \\t\\t\\t Alvix Laboratories, LLC\",\n                        \"TradeName\": \"DST Plus Pak\",\n                        \"Manufacturer\": \"Alvix Laboratories, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03ac5de0-68da-40a9-8f2d-feba05c799c1\",\n                        \"FileId\": \"12dd097b-f199-4a63-bbba-3d52ac54fa3c\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ac5de0-68da-40a9-8f2d-feba05c799c1\",\n                        \"genericNames\": \"diclofenac sodium and benzalkonium chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"folic acid, cholecalciferol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US52531723-606a-1dda-e054-00144ff88e88\",\n                    \"NDCCode\": \"70033-113\",\n                    \"UpdatedDate\": \"Jun 20, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ZOLATE -  folic acid and cholecalciferol capsule Axiom Pharma      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Zolate\",\n                        \"Manufacturer\": \"Axiom Pharma\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03b4af81-152e-40d4-84d7-e213b0ee31fc\",\n                        \"FileId\": \"52531723-606a-1dda-e054-00144ff88e88\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b4af81-152e-40d4-84d7-e213b0ee31fc\",\n                        \"genericNames\": \"folic acid, cholecalciferol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"capecitabine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa38e2215-77d1-4671-8093-746efa1c5344\",\n                    \"NDCCode\": \"0378-2511\",\n                    \"UpdatedDate\": \"Dec 07, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CAPECITABINE -  capecitabine tablet, film coated Mylan Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Capecitabine\",\n                        \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03dd3301-e9ce-40af-84e1-7b70fc6557b0\",\n                        \"FileId\": \"a38e2215-77d1-4671-8093-746efa1c5344\",\n                        \"Version\": \"14\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dd3301-e9ce-40af-84e1-7b70fc6557b0\",\n                        \"genericNames\": \"capecitabine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"esomeprazole magnesium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US26990f16-e3d3-4491-a99d-1cc5411f2e86\",\n                    \"NDCCode\": \"16714-736\",\n                    \"UpdatedDate\": \"Nov 30, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ESOMEPRAZOLE MAGNESIUM  -  esomeprazole magnesium dihydrate capsule, delayed release NorthStar Rx LLC\",\n                        \"TradeName\": \"Esomeprazole Magnesium\",\n                        \"Manufacturer\": \"NorthStar Rx LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03ddda6d-2ac0-42d3-a329-7e8f05ee9b22\",\n                        \"FileId\": \"26990f16-e3d3-4491-a99d-1cc5411f2e86\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ddda6d-2ac0-42d3-a329-7e8f05ee9b22\",\n                        \"genericNames\": \"esomeprazole magnesium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"bortezomib\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US81e8728c-5928-4029-8aa0-0e7f761af75a\",\n                    \"NDCCode\": \"63323-721\",\n                    \"UpdatedDate\": \"Apr 29, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"BORTEZOMIB -  bortezomib injection, powder, lyophilized, for solution Fresenius Kabi USA, LLC\",\n                        \"TradeName\": \"Bortezomib\",\n                        \"Manufacturer\": \"Fresenius Kabi USA, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"042329d6-8077-4af2-816f-cd0a2bbcbbd3\",\n                        \"FileId\": \"81e8728c-5928-4029-8aa0-0e7f761af75a\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=042329d6-8077-4af2-816f-cd0a2bbcbbd3\",\n                        \"genericNames\": \"bortezomib\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sargramostim\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USac281296-b49b-4f33-a16c-a83e60964713\",\n                    \"NDCCode\": \"0024-5844\",\n                    \"UpdatedDate\": \"Jun 14, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEUKINE -  sargramostim liquid LEUKINE -  sargramostim injection, powder, for solution sanofi - aventis U.S. LLC\",\n                        \"TradeName\": \"Leukine\",\n                        \"Manufacturer\": \"sanofi-aventis U.S. LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04765fbf-f005-43aa-a628-5cc3d80f91e7\",\n                        \"FileId\": \"ac281296-b49b-4f33-a16c-a83e60964713\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04765fbf-f005-43aa-a628-5cc3d80f91e7\",\n                        \"genericNames\": \"sargramostim\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"moderna covid-19 vaccine, bivalent\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc1811012-39af-4116-a873-4a5b93bf6468\",\n                    \"NDCCode\": \"80777-283\",\n                    \"UpdatedDate\": \"Dec 20, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MODERNA COVID - 19 VACCINE, BIVALENT -  elasomeran and cx - 034476 omicron (ba.4/ba.5) injection, suspension Moderna US, Inc.\",\n                        \"TradeName\": \"Moderna COVID-19 Vaccine, Bivalent\",\n                        \"Manufacturer\": \"Moderna US, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04c2d0f3-6209-4ae8-823c-842d0881b61b\",\n                        \"FileId\": \"c1811012-39af-4116-a873-4a5b93bf6468\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04c2d0f3-6209-4ae8-823c-842d0881b61b\",\n                        \"genericNames\": \"moderna covid-19 vaccine, bivalent\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"indomethacin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8a792cbe-8874-4655-a1e7-ca9007eee950\",\n                    \"NDCCode\": \"42211-202\",\n                    \"UpdatedDate\": \"Feb 22, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TIVORBEX -  indomethacin capsule Iroko Pharmaceuticals, LLC\",\n                        \"TradeName\": \"Tivorbex\",\n                        \"Manufacturer\": \"Iroko Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04ca474c-798e-43dd-be7a-1b36720e6a3d\",\n                        \"FileId\": \"8a792cbe-8874-4655-a1e7-ca9007eee950\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d\",\n                        \"genericNames\": \"indomethacin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ribavirin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3380c831-db90-4ac0-9c2f-398a00137e58\",\n                    \"NDCCode\": \"0085-1385\",\n                    \"UpdatedDate\": \"Apr 01, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REBETOL -  ribavirin capsule REBETOL -  ribavirin liquid Merck Sharp &amp; Dohme Corp.\",\n                        \"TradeName\": \"REBETOL\",\n                        \"Manufacturer\": \"Merck Sharp & Dohme Corp.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04d2b6f4-bd9b-4871-9527-92c81aa2d4d0\",\n                        \"FileId\": \"3380c831-db90-4ac0-9c2f-398a00137e58\",\n                        \"Version\": \"33\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0\",\n                        \"genericNames\": \"ribavirin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"risedronate sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3cbf30c0-30dd-4022-88b6-86a84697379c\",\n                    \"NDCCode\": \"68382-075\",\n                    \"UpdatedDate\": \"Nov 16, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"RISEDRONATE SODIUM  -  risedronate sodium anhydrous tablet, delayed release Zydus Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"Risedronate Sodium\",\n                        \"Manufacturer\": \"Zydus Pharmaceuticals USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04e4baa7-62a5-45d0-8f8d-a4daea68c5aa\",\n                        \"FileId\": \"3cbf30c0-30dd-4022-88b6-86a84697379c\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04e4baa7-62a5-45d0-8f8d-a4daea68c5aa\",\n                        \"genericNames\": \"risedronate sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"levonorgestrel\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US054f9706-94d2-4ea3-8e32-7185457f5c63\",\n                    \"NDCCode\": \"73302-911\",\n                    \"UpdatedDate\": \"Dec 02, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEVONORGESTREL -  levonorgestrel tablet HRA Pharma America, Inc.\",\n                        \"TradeName\": \"Levonorgestrel\",\n                        \"Manufacturer\": \"HRA Pharma America, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0518a86b-af59-455e-b834-04fa8b20a637\",\n                        \"FileId\": \"054f9706-94d2-4ea3-8e32-7185457f5c63\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0518a86b-af59-455e-b834-04fa8b20a637\",\n                        \"genericNames\": \"levonorgestrel\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ursodiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd126d870-95f5-bb75-e053-2995a90ad67d\",\n                    \"NDCCode\": \"51079-383\",\n                    \"UpdatedDate\": \"Nov 23, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"URSODIOL -  ursodiol capsule Mylan Institutional Inc.\",\n                        \"TradeName\": \"Ursodiol\",\n                        \"Manufacturer\": \"Mylan Institutional Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05243d8f-9057-46a9-ae50-6e16ba6cd7dc\",\n                        \"FileId\": \"d126d870-95f5-bb75-e053-2995a90ad67d\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05243d8f-9057-46a9-ae50-6e16ba6cd7dc\",\n                        \"genericNames\": \"ursodiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"moxifloxacin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USba96c083-00b4-4b6f-8aa0-327e9e918461\",\n                    \"NDCCode\": \"0065-0006\",\n                    \"UpdatedDate\": \"Aug 21, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MOXEZA  -  moxifloxacin hydrochloride solution Alcon Laboratories, Inc.\",\n                        \"TradeName\": \"MOXEZA\",\n                        \"Manufacturer\": \"Alcon Laboratories, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05248b68-16a9-488d-a39f-5137d2410471\",\n                        \"FileId\": \"ba96c083-00b4-4b6f-8aa0-327e9e918461\",\n                        \"Version\": \"20\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05248b68-16a9-488d-a39f-5137d2410471\",\n                        \"genericNames\": \"moxifloxacin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ulipristal acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd6ca82aa-9488-4aa7-a5f1-69873ecb8d0e\",\n                    \"NDCCode\": \"50102-911\",\n                    \"UpdatedDate\": \"Jan 30, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ELLA -  ulipristal acetate tablet Afaxys Pharma LLC\",\n                        \"TradeName\": \"Ella\",\n                        \"Manufacturer\": \"Afaxys Pharma LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"052bfe45-c485-49e5-8fc4-51990b2efba4\",\n                        \"FileId\": \"d6ca82aa-9488-4aa7-a5f1-69873ecb8d0e\",\n                        \"Version\": \"12\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4\",\n                        \"genericNames\": \"ulipristal acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha-tocopherol succinate, d-, riboflavin, niacinamide,\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc697dfae-210c-43a6-b893-f3054e74901c\",\n                    \"NDCCode\": \"68220-089\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PREFERA OB PLUS DHA -  folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha - tocopherol succinate, d - , riboflavin, niacinamide, pyridoxine hydrochloride, cyanocobalamin, biotin and calcium pantothenate tablet Alaven Pharmaceutical LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Prefera OB plus DHA\",\n                        \"Manufacturer\": \"ALAVEN PHARMACEUTICAL LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0539ec9c-b625-4c4e-a321-e7073041c8e0\",\n                        \"FileId\": \"c697dfae-210c-43a6-b893-f3054e74901c\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0539ec9c-b625-4c4e-a321-e7073041c8e0\",\n                        \"genericNames\": \"folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha-tocopherol succinate, d-, riboflavin, niacinamide,\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydromorphone hcl\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScc127289-395c-46bc-b705-d08529e9fce5\",\n                    \"NDCCode\": \"52533-002\",\n                    \"UpdatedDate\": \"Mar 26, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HYDROMORPHONE HCL  -  hydromorphone hydrochloride injection, solution Cantrell Drug Company      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Hydromorphone HCl\",\n                        \"Manufacturer\": \"Cantrell Drug Company\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"053a62b8-92c2-47e8-bbdd-ff2ec4d75dc7\",\n                        \"FileId\": \"cc127289-395c-46bc-b705-d08529e9fce5\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053a62b8-92c2-47e8-bbdd-ff2ec4d75dc7\",\n                        \"genericNames\": \"hydromorphone hcl\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"morphine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USffd2a1bb-d072-8af8-e053-6394a90a48ed\",\n                    \"NDCCode\": \"51862-188\",\n                    \"UpdatedDate\": \"Jul 08, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MORPHINE SULFATE -  morphine sulfate tablet, film coated, extended release Mayne Pharma Commercial LLC\",\n                        \"TradeName\": \"Morphine Sulfate\",\n                        \"Manufacturer\": \"Mayne Pharma Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"053e3fd9-25fc-4b55-b683-63fb9d190dae\",\n                        \"FileId\": \"ffd2a1bb-d072-8af8-e053-6394a90a48ed\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053e3fd9-25fc-4b55-b683-63fb9d190dae\",\n                        \"genericNames\": \"morphine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"gabapentin enacarbil\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6330994e-5391-42ac-ac85-7eda5c6c875f\",\n                    \"NDCCode\": \"0173-0832\",\n                    \"UpdatedDate\": \"Apr 01, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HORIZANT- gabapentin enacarbil tablet, extended release GlaxoSmithKline LLC\",\n                        \"TradeName\": \"HORIZANT\",\n                        \"Manufacturer\": \"GlaxoSmithKline LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05506250-1641-4b64-ac0c-69f96c46a773\",\n                        \"FileId\": \"6330994e-5391-42ac-ac85-7eda5c6c875f\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05506250-1641-4b64-ac0c-69f96c46a773\",\n                        \"genericNames\": \"gabapentin enacarbil\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"oxycodone hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US056f088d-cff1-4b46-8539-ff85880586bf\",\n                    \"NDCCode\": \"63304-684\",\n                    \"UpdatedDate\": \"Jan 14, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OXYCODONE HCL -  oxycodone hydrochloride tablet, film coated, extended release Ranbaxy Pharmaceuticals Inc.\",\n                        \"TradeName\": \"OXYCODONE HCl\",\n                        \"Manufacturer\": \"Ranbaxy Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"FileId\": \"056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"genericNames\": \"oxycodone hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"benzhydrocodone and acetaminophen\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US4e76bae1-6ed1-4624-af64-2151218705b4\",\n                    \"NDCCode\": \"70040-0189\",\n                    \"UpdatedDate\": \"Jul 02, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"APADAZ -  benzhydrocodone hydrochloride and acetaminophen tablet KemPharm, Inc.\",\n                        \"TradeName\": \"APADAZ\",\n                        \"Manufacturer\": \"KemPharm, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0590d4e5-7107-4015-a6a8-deac14265aa2\",\n                        \"FileId\": \"4e76bae1-6ed1-4624-af64-2151218705b4\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0590d4e5-7107-4015-a6a8-deac14265aa2\",\n                        \"genericNames\": \"benzhydrocodone and acetaminophen\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"erythromycin and benzoyl peroxide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                    \"NDCCode\": \"45802-083\",\n                    \"UpdatedDate\": \"Jul 23, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ERYTHROMYCIN - BENZOYL PEROXIDE -  erythromycin and benzoyl peroxide \\t\\t\\t Perrigo New York Inc\",\n                        \"TradeName\": \"Erythromycin-Benzoyl Peroxide\",\n                        \"Manufacturer\": \"PERRIGO NEW YORK INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"FileId\": \"059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"genericNames\": \"erythromycin and benzoyl peroxide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"olmesartan medoxomil\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USf29310d1-7b00-4057-9dd1-d9a69f542d5e\",\n                    \"NDCCode\": \"49252-066\",\n                    \"UpdatedDate\": \"Sep 20, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OLMESARTAN MEDOXOMIL -  olmesartan medoxomil tablet, coated Inventia Healthcare Limited\",\n                        \"TradeName\": \"OLMESARTAN MEDOXOMIL\",\n                        \"Manufacturer\": \"Inventia Healthcare Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05a807bf-5175-43a2-a676-215bba2645a8\",\n                        \"FileId\": \"f29310d1-7b00-4057-9dd1-d9a69f542d5e\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05a807bf-5175-43a2-a676-215bba2645a8\",\n                        \"genericNames\": \"olmesartan medoxomil\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"drospirenone and estradiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USC8074480-B1ED-4468-78AE-C2BCAC4D8079\",\n                    \"NDCCode\": \"50419-483\",\n                    \"UpdatedDate\": \"Sep 27, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ANGELIQ -  estradiol and drospirenone tablet, film coated Berlex\",\n                        \"TradeName\": \"Angeliq\",\n                        \"Manufacturer\": \"BAYER HEALTHCARE PHARMACEUTICA\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05B46F6A-9C52-4246-B500-D359B25A45DC\",\n                        \"FileId\": \"C8074480-B1ED-4468-78AE-C2BCAC4D8079\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05B46F6A-9C52-4246-B500-D359B25A45DC\",\n                        \"genericNames\": \"drospirenone and estradiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fulvestrant\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US45b2245b-9f11-4b58-a275-b664b5b89e7d\",\n                    \"NDCCode\": \"0310-7720\",\n                    \"UpdatedDate\": \"Jun 08, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FULVESTRANT -  fulvestrant injection AstraZeneca Pharmaceuticals LP\",\n                        \"TradeName\": \"Fulvestrant\",\n                        \"Manufacturer\": \"AstraZeneca Pharmaceuticals LP\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05b6bd57-36aa-47c3-bcf6-2470ba42feb5\",\n                        \"FileId\": \"45b2245b-9f11-4b58-a275-b664b5b89e7d\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05b6bd57-36aa-47c3-bcf6-2470ba42feb5\",\n                        \"genericNames\": \"fulvestrant\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fondaparinux sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US26db3097-342b-48cb-a91d-8f39d64c46ca\",\n                    \"NDCCode\": \"0007-3232\",\n                    \"UpdatedDate\": \"Sep 17, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ARIXTRA -  fondaparinux sodium injection, solution GlaxoSmithKline LLC\",\n                        \"TradeName\": \"ARIXTRA\",\n                        \"Manufacturer\": \"GlaxoSmithKline LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f\",\n                        \"FileId\": \"26db3097-342b-48cb-a91d-8f39d64c46ca\",\n                        \"Version\": \"16\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f\",\n                        \"genericNames\": \"fondaparinux sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USee12ad5a-2004-4a59-8173-20bb9eefa655\",\n                    \"NDCCode\": \"35573-300\",\n                    \"UpdatedDate\": \"Apr 30, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"URAMIT MB -  methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule Burel Pharmaceuticals, Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"URAMIT MB\",\n                        \"Manufacturer\": \"Burel Pharmaceuticals, Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05bc6057-7dec-4e35-b8ec-3dffa655520c\",\n                        \"FileId\": \"ee12ad5a-2004-4a59-8173-20bb9eefa655\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05bc6057-7dec-4e35-b8ec-3dffa655520c\",\n                        \"genericNames\": \"methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"influenza vaccine, adjuvanted\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US97c3669d-ac04-4c97-b2ab-2ce4d0bf6e12\",\n                    \"NDCCode\": \"70461-019\",\n                    \"UpdatedDate\": \"Jul 16, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUAD -  influenza a virus a/brisbane/02/2018 ivr - 190 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/kansas/14/2017 x - 327 (h3n2) antigen (formaldehyde inactivated) and influenza b virus b/maryland/15/2016 antigen (formaldehyde inactivated) injection, suspension Seqirus, Inc.\",\n                        \"TradeName\": \"FLUAD\",\n                        \"Manufacturer\": \"Seqirus, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05be1932-bb7a-4e3a-9200-4ccdc5565edc\",\n                        \"FileId\": \"97c3669d-ac04-4c97-b2ab-2ce4d0bf6e12\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05be1932-bb7a-4e3a-9200-4ccdc5565edc\",\n                        \"genericNames\": \"influenza vaccine, adjuvanted\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"clobetasol propionate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99d8672a-7e92-4a25-9a7b-849efaafb525\",\n                    \"NDCCode\": \"0378-8055\",\n                    \"UpdatedDate\": \"Apr 22, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CLOBETASOL PROPIONATE -  clobetasol propionate aerosol, foam Mylan Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Clobetasol Propionate\",\n                        \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05cff296-2daf-408c-8e63-883737cbfb22\",\n                        \"FileId\": \"99d8672a-7e92-4a25-9a7b-849efaafb525\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05cff296-2daf-408c-8e63-883737cbfb22\",\n                        \"genericNames\": \"clobetasol propionate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"metformin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8ed86d67-8a49-4334-82c4-1dbf6a489d3b\",\n                    \"NDCCode\": \"10631-206\",\n                    \"UpdatedDate\": \"Dec 12, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"RIOMET -  metformin hydrochloride solution Sun Pharmaceutical Industries, Inc.\",\n                        \"TradeName\": \"Riomet\",\n                        \"Manufacturer\": \"Ranbaxy Laboratories Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05d4df4b-dfe8-4828-b423-a3d4f2c4114a\",\n                        \"FileId\": \"8ed86d67-8a49-4334-82c4-1dbf6a489d3b\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05d4df4b-dfe8-4828-b423-a3d4f2c4114a\",\n                        \"genericNames\": \"metformin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"valproic acid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USfb8bf963-9299-45f0-926a-18da554412ff\",\n                    \"NDCCode\": \"68094-193\",\n                    \"UpdatedDate\": \"Dec 03, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VALPROIC ACID -  valproic acid solution Precision Dose Inc.\",\n                        \"TradeName\": \"Valproic Acid\",\n                        \"Manufacturer\": \"Precision Dose Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05e16c10-ff0a-4238-8181-f3e84379ed6a\",\n                        \"FileId\": \"fb8bf963-9299-45f0-926a-18da554412ff\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e16c10-ff0a-4238-8181-f3e84379ed6a\",\n                        \"genericNames\": \"valproic acid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"desmopressin acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US517c673f-db39-4b91-bd86-eb35db5bea7f\",\n                    \"NDCCode\": \"0075-2452\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DDAVP -  desmopressin acetate solution sanofi - aventis U.S. LLC\",\n                        \"TradeName\": \"DDAVP\",\n                        \"Manufacturer\": \"sanofi-aventis U.S. LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05e6330b-6569-436e-9caf-e86916460931\",\n                        \"FileId\": \"517c673f-db39-4b91-bd86-eb35db5bea7f\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e6330b-6569-436e-9caf-e86916460931\",\n                        \"genericNames\": \"desmopressin acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mometasone furoate monohydrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US74bb6412-7e0d-46ad-bbf6-26aa7e5d6c04\",\n                    \"NDCCode\": \"0781-6355\",\n                    \"UpdatedDate\": \"Feb 12, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MOMETASONE FUROATE MONOHYDRATE -  mometasone furoate monohydrate spray, metered Sandoz Inc.\",\n                        \"TradeName\": \"Mometasone Furoate Monohydrate\",\n                        \"Manufacturer\": \"Sandoz Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0602c22a-67b7-4708-bdbb-28a69d52d616\",\n                        \"FileId\": \"74bb6412-7e0d-46ad-bbf6-26aa7e5d6c04\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0602c22a-67b7-4708-bdbb-28a69d52d616\",\n                        \"genericNames\": \"mometasone furoate monohydrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methsuximide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USabac6b2e-bcd8-29c2-e053-2a95a90a2239\",\n                    \"NDCCode\": \"24822-525\",\n                    \"UpdatedDate\": \"Aug 04, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CELONTIN -  methsuximide capsule Farmea\",\n                        \"TradeName\": \"Celontin\",\n                        \"Manufacturer\": \"Farmea\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0613561f-1a9f-4921-89ff-ba6081e08a5f\",\n                        \"FileId\": \"abac6b2e-bcd8-29c2-e053-2a95a90a2239\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0613561f-1a9f-4921-89ff-ba6081e08a5f\",\n                        \"genericNames\": \"methsuximide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"calcitonin salmon\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99e9e62b-9796-42ec-8f69-551dabf92ec1\",\n                    \"NDCCode\": \"0781-6320\",\n                    \"UpdatedDate\": \"Jun 21, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CALCITONIN SALMON -  calcitonin salmon spray, metered Sandoz Inc\",\n                        \"TradeName\": \"calcitonin salmon\",\n                        \"Manufacturer\": \"Sandoz Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0614bf53-9644-47d2-b46e-8efbcd63afe6\",\n                        \"FileId\": \"99e9e62b-9796-42ec-8f69-551dabf92ec1\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0614bf53-9644-47d2-b46e-8efbcd63afe6\",\n                        \"genericNames\": \"calcitonin salmon\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"oxybutynin chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc8c1bf6b-8da4-439b-b4af-0b28273c5625\",\n                    \"NDCCode\": \"14539-653\",\n                    \"UpdatedDate\": \"Jun 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OXYBUTYNIN CHLORIDE -  oxybutynin chloride tablet Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Oxybutynin Chloride\",\n                        \"Manufacturer\": \"Heritage Pharma Labs, Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"06301e49-2bcf-4ff1-8f33-39ccde1a2dd0\",\n                        \"FileId\": \"c8c1bf6b-8da4-439b-b4af-0b28273c5625\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06301e49-2bcf-4ff1-8f33-39ccde1a2dd0\",\n                        \"genericNames\": \"oxybutynin chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"motixafortide acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US05f6e4ee-4ffb-d2b5-e063-6394a90af047\",\n                    \"NDCCode\": \"70383-073\",\n                    \"UpdatedDate\": \"Sep 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"APHEXDA -  motixafortide acetate injection, powder, lyophilized, for solution BioConnection B.V.\",\n                        \"TradeName\": \"Aphexda\",\n                        \"Manufacturer\": \"BioConnection B.V.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"065b582d-e5e5-eeec-e063-6394a90a5990\",\n                        \"FileId\": \"05f6e4ee-4ffb-d2b5-e063-6394a90af047\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065b582d-e5e5-eeec-e063-6394a90a5990\",\n                        \"genericNames\": \"motixafortide acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        }\n    ]\n}"}],"_postman_id":"a4430bdd-4a65-4bc3-aca4-e2360c5d2eb0"},{"name":"Label metadata for given generic names","id":"6f58cebd-eeb4-4a18-8140-522f0e8662b8","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]},"isInherited":false},"method":"POST","header":[],"body":{"mode":"formdata","formdata":[{"key":"filtertype","value":"genericname","type":"text","description":"<p>Option is \"genericname\" (string)</p>\n"},{"key":"filtervalue","value":"Allopurinol sodium;aflibercept;Alfuzosin\nHCl;AMANTADINE HYDROCHLORIDE;anagrelide;andexanet alfa;Albuterol Sulfate;Amiodarone Hydrochloride","type":"text","description":"<p>Option is semi-colon separated genericnames (string)</p>\n"},{"key":"skip","value":"0","type":"text","description":"<p>Value for Number of records to skip (integer). Defaults to 0</p>\n"},{"key":"limit","value":"10","type":"text","description":"<p>Value for number of records to fetch (integer). Defaults to 100</p>\n"},{"key":"country","value":"all","description":"<p>Options are \"us\", \"uk\", \"ca\", \"eu\", \"au\", \"all\" (string). Defaults to \"us\"</p>\n","type":"text"}]},"url":"https://labelae.doctorevidence.com/discontinued/annotation/label","description":"<ul>\n<li>Returns label metadata matching a given set of generic names.</li>\n<li>User can pass generic names retrieved from endpoint \"<a href=\"#650bd5aa-57c3-4301-91fc-3b50621b259a\">annotation/genericnames</a>\", as up to a 100 semi-colon separated values .</li>\n<li>Multiple generic names are treated as \"OR\" queries.</li>\n<li>This will return a maximum of 100 annotation details.</li>\n</ul>\n<p><strong>Note: All the Params should be passed as raw data in JSON format (</strong> eg. { \"skip\":0, \"limit\":10 } <strong>)</strong></p>\n","urlObject":{"protocol":"https","path":["discontinued","annotation","label"],"host":["labelae","doctorevidence","com"],"query":[],"variable":[]}},"response":[{"id":"4ace0d74-be33-4e50-b3c0-46b8d9e8116f","name":"Label metadata for given generic names","originalRequest":{"method":"POST","header":[{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n    \"filtertype\": \"genericname\",\n    \"filtervalue\": \"Allopurinol sodium;aflibercept;Alfuzosin HCl;AMANTADINE HYDROCHLORIDE;anagrelide;andexanet alfa;Albuterol Sulfate;Amiodarone Hydrochloride\",\n    \"skip\": 0,\n    \"limit\": 10,\n    \"country\": \"all\"\n}","options":{"raw":{"language":"json"}}},"url":"https://labelae.doctorevidence.com/discontinued/annotation/label"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Encoding","value":"gzip"},{"key":"Content-Type","value":"text/plain; charset=utf-8"},{"key":"Date","value":"Mon, 29 Apr 2024 08:10:26 GMT"},{"key":"Server","value":"Kestrel"},{"key":"Vary","value":"Accept-Encoding"},{"key":"Transfer-Encoding","value":"chunked"}],"cookie":[],"responseTime":null,"body":"{\n    \"totalcount\": 5018,\n    \"skip\": 0,\n    \"limit\": 100,\n    \"BaseURL\": \"https://labelae.doctorevidence.com/discontinued/annotation/label/\",\n    \"MeddraVersion\": \"26.1\",\n    \"data\": [\n        {\n            \"GenericName\": \"sodium iodide i 131\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USed6202f9-42ac-4736-b014-545f9c5c2be6\",\n                    \"NDCCode\": \"0019-9452\",\n                    \"UpdatedDate\": \"Nov 18, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"SODIUM IODIDE I 131 -  sodium iodide i - 131 capsule, gelatin coated Mallinckrodt Inc.\",\n                        \"TradeName\": \"SODIUM IODIDE I 131\",\n                        \"Manufacturer\": \"Mallinckrodt Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"000e2ca1-9a11-46f2-860c-4de0ca5be369\",\n                        \"FileId\": \"ed6202f9-42ac-4736-b014-545f9c5c2be6\",\n                        \"Version\": \"18\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000e2ca1-9a11-46f2-860c-4de0ca5be369\",\n                        \"genericNames\": \"sodium iodide i 131\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sulfacetamide sodium and sulfur\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US9b4ff6b6-2976-4054-9aae-234aa726e925\",\n                    \"NDCCode\": \"58980-330\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CERISA -  sulfacetamide sodium and sulfur lotion Stratus Pharamceuticals, Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Cerisa\",\n                        \"Manufacturer\": \"STRATUS PHARMACEUTICALS INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00278dd5-328f-4f4c-992c-a02ecde24e51\",\n                        \"FileId\": \"9b4ff6b6-2976-4054-9aae-234aa726e925\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00278dd5-328f-4f4c-992c-a02ecde24e51\",\n                        \"genericNames\": \"sulfacetamide sodium and sulfur\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US626ed157-f5a1-57e0-e053-2991aa0a500a\",\n                    \"NDCCode\": \"75854-310\",\n                    \"UpdatedDate\": \"Jan 11, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FERIVAFA -  ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium capsule, gelatin coated Avion Pharmaceuticals, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FeRivaFA\",\n                        \"Manufacturer\": \"Avion Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"002df203-be22-41aa-a52c-d14ecbc00dbe\",\n                        \"FileId\": \"626ed157-f5a1-57e0-e053-2991aa0a500a\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002df203-be22-41aa-a52c-d14ecbc00dbe\",\n                        \"genericNames\": \"ferrous bisglycinate, ascorbic acid, folic acid, cyanocobalamin, biotin, cupric oxide and docusate sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tropicamide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6c37858c-d1d5-4cb0-af32-b63eb6d09178\",\n                    \"NDCCode\": \"0404-7192\",\n                    \"UpdatedDate\": \"Feb 09, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TROPICAMIDE -  tropicamide solution/ drops Henry Schein Inc.\",\n                        \"TradeName\": \"Tropicamide\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"002e4f96-7a74-4501-8b81-dc6f092c807a\",\n                        \"FileId\": \"6c37858c-d1d5-4cb0-af32-b63eb6d09178\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=002e4f96-7a74-4501-8b81-dc6f092c807a\",\n                        \"genericNames\": \"tropicamide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"metronidazole\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n                    \"NDCCode\": \"0781-7077\",\n                    \"UpdatedDate\": \"Feb 14, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METRONIDAZOLE -  metronidazole gel Sandoz Inc.\",\n                        \"TradeName\": \"Metronidazole\",\n                        \"Manufacturer\": \"Sandoz Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0030514f-879d-416d-b422-24b67e334b36\",\n                        \"FileId\": \"5945b2c1-def7-4364-b716-bf633f6b6ce4\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0030514f-879d-416d-b422-24b67e334b36\",\n                        \"genericNames\": \"metronidazole\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US81779794-0dbf-454b-8179-3a985d6ba813\",\n                    \"NDCCode\": \"99207-140\",\n                    \"UpdatedDate\": \"May 29, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METRONIDAZOLE -  metronidazole gel Medicis Pharmaceutical Corp\",\n                        \"TradeName\": \"METRONIDAZOLE\",\n                        \"Manufacturer\": \"Medicis Pharmaceutical Corp\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01f0f7b8-0586-4b8e-890d-4ecf3488c617\",\n                        \"FileId\": \"81779794-0dbf-454b-8179-3a985d6ba813\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f0f7b8-0586-4b8e-890d-4ecf3488c617\",\n                        \"genericNames\": \"metronidazole\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydroquinone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd2083da3-67bd-4f36-a105-a088a50dd5e0\",\n                    \"NDCCode\": \"42851-032\",\n                    \"UpdatedDate\": \"Oct 11, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MELAMIN SKIN BLEACHING AND CORRECTING HYDROQUINONE -  hydroquinone cream ZO Skin Health, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"MELAMIN Skin Bleaching and Correcting Hydroquinone\",\n                        \"Manufacturer\": \"ZO Skin Health, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0036ad62-e92a-42cb-b0ae-61bb87049ff2\",\n                        \"FileId\": \"d2083da3-67bd-4f36-a105-a088a50dd5e0\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0036ad62-e92a-42cb-b0ae-61bb87049ff2\",\n                        \"genericNames\": \"hydroquinone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"dextrose monohydrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0038c31a-5b2d-4271-9141-04b67695996c\",\n                    \"NDCCode\": \"0338-0023\",\n                    \"UpdatedDate\": \"Sep 27, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DEXTROSE -  dextrose hydrous injection, solution Baxter Healthcare Corporation\",\n                        \"TradeName\": \"DEXTROSE\",\n                        \"Manufacturer\": \"Baxter Healthcare Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"FileId\": \"0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038c31a-5b2d-4271-9141-04b67695996c\",\n                        \"genericNames\": \"dextrose monohydrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"iodoquinol 1% - hydrocortisone acetate 2% - aloe polysaccharides 1%\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScce6a8e9-53c5-4298-9a3b-3dacc7add9be\",\n                    \"NDCCode\": \"13925-174\",\n                    \"UpdatedDate\": \"May 05, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"IODOQUINOL 1%  -  HYDROCORTISONE ACETATE 2%  -  ALOE POLYSACCHARIDES 1% -  iodoquinol, hydrocortisone acetate and aloe vera leaf polysaccharides gel Seton Pharmaceuticals      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Iodoquinol 1% - Hydrocortisone Acetate 2% - Aloe Polysaccharides 1%\",\n                        \"Manufacturer\": \"Seton Pharmaceuticals\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"005c57c2-a323-4ab6-b994-0a63bf9b915f\",\n                        \"FileId\": \"cce6a8e9-53c5-4298-9a3b-3dacc7add9be\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=005c57c2-a323-4ab6-b994-0a63bf9b915f\",\n                        \"genericNames\": \"iodoquinol 1% - hydrocortisone acetate 2% - aloe polysaccharides 1%\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"chlorzoxazone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US31777bf1-9074-4232-b32f-3e675a68f51d\",\n                    \"NDCCode\": \"68462-724\",\n                    \"UpdatedDate\": \"Jun 28, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CHLORZOXAZONE -  chlorzoxazone tablet Glenmark Pharmaceuticals Inc., USA\",\n                        \"TradeName\": \"chlorzoxazone\",\n                        \"Manufacturer\": \"Glenmark Pharmaceuticals Inc., USA\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00663cd9-5405-4a1d-8038-23ec0874dc28\",\n                        \"FileId\": \"31777bf1-9074-4232-b32f-3e675a68f51d\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00663cd9-5405-4a1d-8038-23ec0874dc28\",\n                        \"genericNames\": \"chlorzoxazone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ketorolac tromethamine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US1c79d44d-8f10-4a8f-a0b5-21c2ba258777\",\n                    \"NDCCode\": \"65862-770\",\n                    \"UpdatedDate\": \"Dec 29, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"KETOROLAC TROMETHAMINE  -  ketorolac tromethamine solution/ drops Aurobindo Pharma Limited\",\n                        \"TradeName\": \"Ketorolac Tromethamine\",\n                        \"Manufacturer\": \"Aurobindo Pharma Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"007a4da5-d794-416c-94b3-6ee9e7842c52\",\n                        \"FileId\": \"1c79d44d-8f10-4a8f-a0b5-21c2ba258777\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a4da5-d794-416c-94b3-6ee9e7842c52\",\n                        \"genericNames\": \"ketorolac tromethamine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tapentadol hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US926544cc-122c-4f9f-9434-a886827b0871\",\n                    \"NDCCode\": \"50458-830\",\n                    \"UpdatedDate\": \"Nov 01, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NUCYNTA -  tapentadol hydrochloride tablet, film coated Janssen Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"NUCYNTA\",\n                        \"Manufacturer\": \"Janssen Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00a8921e-46a6-4df1-a744-9e532b6fb06f\",\n                        \"FileId\": \"926544cc-122c-4f9f-9434-a886827b0871\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a8921e-46a6-4df1-a744-9e532b6fb06f\",\n                        \"genericNames\": \"tapentadol hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"donepezil hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8c8f4e5f-acf1-443f-a890-6665c7cc9aa4\",\n                    \"NDCCode\": \"68382-347\",\n                    \"UpdatedDate\": \"Nov 12, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DONEPEZIL HYDROCHLORIDE  -  donepezil hydrochloride tablet, orally disintegrating Zydus Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"donepezil hydrochloride\",\n                        \"Manufacturer\": \"Zydus Pharmaceuticals (USA) Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00a9d965-4c27-419b-a23a-b109864e47fa\",\n                        \"FileId\": \"8c8f4e5f-acf1-443f-a890-6665c7cc9aa4\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a9d965-4c27-419b-a23a-b109864e47fa\",\n                        \"genericNames\": \"donepezil hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"amoxicillin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe8bb6e15-4912-4ab8-a5d5-4ccede21853d\",\n                    \"NDCCode\": \"0143-9820\",\n                    \"UpdatedDate\": \"Aug 03, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"AMOXICILLIN -  amoxicillin tablet, chewable Hikma Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"Amoxicillin\",\n                        \"Manufacturer\": \"Hikma Pharmaceuticals USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00c35e29-0b05-4232-a4d6-38a230102ef5\",\n                        \"FileId\": \"e8bb6e15-4912-4ab8-a5d5-4ccede21853d\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c35e29-0b05-4232-a4d6-38a230102ef5\",\n                        \"genericNames\": \"amoxicillin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sodium fluoride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0a04a9d3-c869-4a4a-b96f-4f56c91553e6\",\n                    \"NDCCode\": \"48878-3160\",\n                    \"UpdatedDate\": \"Jun 03, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUORIDE TREATMENT -  sodium fluoride solution 3M ESPE Dental Products      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Fluoride Treatment\",\n                        \"Manufacturer\": \"3M ESPE Dental Products\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00c68fa6-ae49-4b73-bb71-5e960dc98368\",\n                        \"FileId\": \"0a04a9d3-c869-4a4a-b96f-4f56c91553e6\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c68fa6-ae49-4b73-bb71-5e960dc98368\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US61eee3de-2569-40e0-bab8-33e9e1994dcd\",\n                    \"NDCCode\": \"69962-014\",\n                    \"UpdatedDate\": \"Jul 17, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FIDELIS APF -  sodium fluoride gel Webco Dental &amp; Medical Supplies, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FIDELIS APF\",\n                        \"Manufacturer\": \"Webco Dental & Medical Supplies, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"011ba0c9-7b31-4cac-8c2a-9bcd4d5b8ef9\",\n                        \"FileId\": \"61eee3de-2569-40e0-bab8-33e9e1994dcd\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=011ba0c9-7b31-4cac-8c2a-9bcd4d5b8ef9\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"USa530e5e7-f391-4af7-9137-f673fc454378\",\n                    \"NDCCode\": \"69509-076\",\n                    \"UpdatedDate\": \"Feb 21, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PRIMO APF -  sodium fluoride aerosol, foam Tri State Dental Supply      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Primo APF\",\n                        \"Manufacturer\": \"Tri State Dental Supply\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0202ab96-5f39-4fd5-8d5f-b828e81c1ab4\",\n                        \"FileId\": \"a530e5e7-f391-4af7-9137-f673fc454378\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0202ab96-5f39-4fd5-8d5f-b828e81c1ab4\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US7e9203d2-c833-76f0-e053-2a91aa0a305a\",\n                    \"NDCCode\": \"64778-0378\",\n                    \"UpdatedDate\": \"Jan 05, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DENTI - CARE DENTI - FOAM TOPICAL SODIUM FLUORIDE RASPBERRY -  sodium fluoride aerosol, foam AMD Medicom Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Denti-Care Denti-Foam\",\n                        \"Manufacturer\": \"AMD Medicom Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02486b16-b1a4-4a1d-b7ca-ed77d97e97e4\",\n                        \"FileId\": \"7e9203d2-c833-76f0-e053-2a91aa0a305a\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02486b16-b1a4-4a1d-b7ca-ed77d97e97e4\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US30c61365-3693-4c64-9eec-a38bba83bdaa\",\n                    \"NDCCode\": \"69962-020\",\n                    \"UpdatedDate\": \"Jul 17, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FIDELIS APF -  sodium fluoride aerosol, foam Webco Dental &amp; Medical Supplies, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"FIDELIS APF\",\n                        \"Manufacturer\": \"Webco Dental & Medical Supplies, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02a9ae8d-2910-4986-8493-d378d09ab4b1\",\n                        \"FileId\": \"30c61365-3693-4c64-9eec-a38bba83bdaa\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a9ae8d-2910-4986-8493-d378d09ab4b1\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US7e40fae9-b3eb-49c9-e053-2991aa0a21b3\",\n                    \"NDCCode\": \"64778-0214\",\n                    \"UpdatedDate\": \"Jan 01, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DENTI - CARE DENTI - PRO TOPICAL SODIUM FLUORIDE 60 SECOND -  sodium fluoride gel AMD Medicom Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Denti-Care Denti-Pro\",\n                        \"Manufacturer\": \"AR Medicom Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05af0929-6a37-4b76-b3f9-94ccd8a3a17b\",\n                        \"FileId\": \"7e40fae9-b3eb-49c9-e053-2991aa0a21b3\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05af0929-6a37-4b76-b3f9-94ccd8a3a17b\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"USb60be188-1df3-c64e-e053-2a95a90a2cdc\",\n                    \"NDCCode\": \"66467-3790\",\n                    \"UpdatedDate\": \"Dec 11, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DARBY TOPICAL SODIUM FLUORIDE STRAWBERRY -  sodium fluoride aerosol, foam Darby Dental Supply, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Darby\",\n                        \"Manufacturer\": \"Darby Dental Supply, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05daaae5-57c5-47e9-834a-e453c7526782\",\n                        \"FileId\": \"b60be188-1df3-c64e-e053-2a95a90a2cdc\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05daaae5-57c5-47e9-834a-e453c7526782\",\n                        \"genericNames\": \"sodium fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fluoride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US28d952e7-7caa-492f-a1f5-7a39098da55e\",\n                    \"NDCCode\": \"51862-172\",\n                    \"UpdatedDate\": \"Aug 02, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUORIDE  -  sodium fluoride tablet, chewable Mayne Pharma Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Fluoride\",\n                        \"Manufacturer\": \"Mayne Pharma Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"00e1f644-1538-4054-b112-227e7254317e\",\n                        \"FileId\": \"28d952e7-7caa-492f-a1f5-7a39098da55e\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00e1f644-1538-4054-b112-227e7254317e\",\n                        \"genericNames\": \"fluoride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mirtazapine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US325197a6-1a5f-4c6f-bb05-c8b3f64ce3ad\",\n                    \"NDCCode\": \"0052-0110\",\n                    \"UpdatedDate\": \"Oct 15, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REMERON -  mirtazapine tablet, film coated REMERONSOLTAB -  mirtazapine tablet, orally disintegrating Organon USA Inc.\",\n                        \"TradeName\": \"REMERONSOLTAB\",\n                        \"Manufacturer\": \"Organon USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"010f9162-9f7f-4b6d-a6e4-4f832f26f38e\",\n                        \"FileId\": \"325197a6-1a5f-4c6f-bb05-c8b3f64ce3ad\",\n                        \"Version\": \"32\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010f9162-9f7f-4b6d-a6e4-4f832f26f38e\",\n                        \"genericNames\": \"mirtazapine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"zileuton\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USf1429302-86df-1568-e053-2995a90a9b93\",\n                    \"NDCCode\": \"69339-130\",\n                    \"UpdatedDate\": \"Jan 04, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ZILEUTON -  zileuton tablet, multilayer, extended release DASH Pharmaceutical LLC\",\n                        \"TradeName\": \"Zileuton\",\n                        \"Manufacturer\": \"DASH Pharmaceutical LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01249483-f82f-4b09-b116-b50f1c7ebdf3\",\n                        \"FileId\": \"f1429302-86df-1568-e053-2995a90a9b93\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01249483-f82f-4b09-b116-b50f1c7ebdf3\",\n                        \"genericNames\": \"zileuton\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"dextrose monohydrate, sodium chloride and potassium chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa5043890-7a8f-4718-bfc3-d20792d4bd61\",\n                    \"NDCCode\": \"0338-6335\",\n                    \"UpdatedDate\": \"Jul 28, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"POTASSIUM CHLORIDE IN DEXTROSE AND SODIUM CHLORIDE -  dextrose monohydrate, sodium chloride and potassium chloride injection, solution Baxter Healthcare Corporation\",\n                        \"TradeName\": \"Potassium Chloride in Dextrose and Sodium Chloride\",\n                        \"Manufacturer\": \"Baxter Healthcare Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01321de3-bf0b-4460-9aee-511406ee101e\",\n                        \"FileId\": \"a5043890-7a8f-4718-bfc3-d20792d4bd61\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01321de3-bf0b-4460-9aee-511406ee101e\",\n                        \"genericNames\": \"dextrose monohydrate, sodium chloride and potassium chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fenofibrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                    \"NDCCode\": \"70199-027\",\n                    \"UpdatedDate\": \"Nov 15, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FENOFIBRATE  -  fenofibrate tablet Casper Pharma LLC\",\n                        \"TradeName\": \"FENOFIBRATE\",\n                        \"Manufacturer\": \"Casper Pharma LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"FileId\": \"0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0149c1a1-0386-4e80-a669-ab7ba177ca56\",\n                        \"genericNames\": \"fenofibrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"etonogestrel and ethinyl estradiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USeb39f2fd-0ee1-4cee-ad04-e5371706310a\",\n                    \"NDCCode\": \"0052-0273\",\n                    \"UpdatedDate\": \"Feb 05, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NUVARING -  etonogestrel and ethinyl estradiol insert, extended release Organon USA Inc.\",\n                        \"TradeName\": \"NuvaRing\",\n                        \"Manufacturer\": \"Organon USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"017343fb-86c4-45ab-9c47-52cc5b9f3a02\",\n                        \"FileId\": \"eb39f2fd-0ee1-4cee-ad04-e5371706310a\",\n                        \"Version\": \"27\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017343fb-86c4-45ab-9c47-52cc5b9f3a02\",\n                        \"genericNames\": \"etonogestrel and ethinyl estradiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"trimipramine maleate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USff72526a-1529-4354-a265-c23f5704a65e\",\n                    \"NDCCode\": \"51285-554\",\n                    \"UpdatedDate\": \"Aug 06, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"SURMONTIL -  trimipramine maleate capsule Teva Women's Health, Inc.\",\n                        \"TradeName\": \"Surmontil\",\n                        \"Manufacturer\": \"Teva Women's Health, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0177d783-773c-41bf-9db9-eb7e5c64474a\",\n                        \"FileId\": \"ff72526a-1529-4354-a265-c23f5704a65e\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0177d783-773c-41bf-9db9-eb7e5c64474a\",\n                        \"genericNames\": \"trimipramine maleate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydroxypropyl cellulose\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US587d995e-963a-4990-9077-747490bfface\",\n                    \"NDCCode\": \"25010-805\",\n                    \"UpdatedDate\": \"Oct 08, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LACRISERT -  hydroxypropyl cellulose (type h) pellet Aton Pharma, Inc.\",\n                        \"TradeName\": \"Lacrisert\",\n                        \"Manufacturer\": \"ATON PHARMA INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"017980de-48b6-4b28-aec0-315411149a7e\",\n                        \"FileId\": \"587d995e-963a-4990-9077-747490bfface\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=017980de-48b6-4b28-aec0-315411149a7e\",\n                        \"genericNames\": \"hydroxypropyl cellulose\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tobramycin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe59394a3-3474-4186-9986-5c589cd851ed\",\n                    \"NDCCode\": \"0404-7196\",\n                    \"UpdatedDate\": \"Feb 09, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TOBRAMYCIN -  tobramycin solution/ drops Henry Schein Inc.\",\n                        \"TradeName\": \"Tobramycin\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"019172e3-bf24-4b76-9253-f58765d7b4f3\",\n                        \"FileId\": \"e59394a3-3474-4186-9986-5c589cd851ed\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=019172e3-bf24-4b76-9253-f58765d7b4f3\",\n                        \"genericNames\": \"tobramycin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cimetidine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US0337689b-c5d5-d881-e063-6394a90aaec9\",\n                    \"NDCCode\": \"62135-631\",\n                    \"UpdatedDate\": \"Aug 22, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CIMETIDINE -  cimetidine tablet, film coated Chartwell RX, LLC\",\n                        \"TradeName\": \"CIMETIDINE\",\n                        \"Manufacturer\": \"Chartwell RX, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01997826-7ca1-473e-bfc9-075b14b58a35\",\n                        \"FileId\": \"0337689b-c5d5-d881-e063-6394a90aaec9\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01997826-7ca1-473e-bfc9-075b14b58a35\",\n                        \"genericNames\": \"cimetidine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cat pelt, standardized\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc7ac1890-9d51-4036-9022-d4f406b9dc88\",\n                    \"NDCCode\": \"0268-2002\",\n                    \"UpdatedDate\": \"May 23, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CAT PELT, STANDARDIZED -  felis catus skin injection, solution CAT PELT, STANDARDIZED -  felis catus skin solution ALK - Abello, Inc.\",\n                        \"TradeName\": \"Cat Pelt, Standardized\",\n                        \"Manufacturer\": \"ALK-Abello, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01a914b7-51b5-4aab-952f-2eae56d25e9c\",\n                        \"FileId\": \"c7ac1890-9d51-4036-9022-d4f406b9dc88\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01a914b7-51b5-4aab-952f-2eae56d25e9c\",\n                        \"genericNames\": \"cat pelt, standardized\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"clopidogrel bisulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USfdbc18a6-b364-4f85-9fd1-71d04b3a7ab1\",\n                    \"NDCCode\": \"63653-1171\",\n                    \"UpdatedDate\": \"Mar 11, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PLAVIX -  clopidogrel bisulfate tablet, film coated Bristol - Myers Squibb/Sanofi Pharmaceuticals Partnership\",\n                        \"TradeName\": \"Plavix\",\n                        \"Manufacturer\": \"Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01b14603-8f29-4fa3-8d7e-9d523f802e0b\",\n                        \"FileId\": \"fdbc18a6-b364-4f85-9fd1-71d04b3a7ab1\",\n                        \"Version\": \"34\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b\",\n                        \"genericNames\": \"clopidogrel||clopidogrel bisulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"torsemide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US5da4dfd2-88e9-4270-a408-c0bbd566acf4\",\n                    \"NDCCode\": \"0037-5010\",\n                    \"UpdatedDate\": \"Jan 13, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DEMADEX -  torsemide tablet Meda Pharmaceuticals\",\n                        \"TradeName\": \"Demadex\",\n                        \"Manufacturer\": \"Meda Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01b388a0-7dfb-11de-bc4e-0002a5d5c51b\",\n                        \"FileId\": \"5da4dfd2-88e9-4270-a408-c0bbd566acf4\",\n                        \"Version\": \"13\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01b388a0-7dfb-11de-bc4e-0002a5d5c51b\",\n                        \"genericNames\": \"torsemide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"vincristine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USaaacd521-3f4e-450d-a8cc-f5229e7fb65c\",\n                    \"NDCCode\": \"0703-4412\",\n                    \"UpdatedDate\": \"Jun 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VINCASAR PFS -  vincristine sulfate injection, solution Teva Parenteral Medicines, Inc.\",\n                        \"TradeName\": \"Vincasar PFS\",\n                        \"Manufacturer\": \"Teva Parenteral Medicines, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01cee93f-3ab9-44fa-8c9a-dd5958fd2db9\",\n                        \"FileId\": \"aaacd521-3f4e-450d-a8cc-f5229e7fb65c\",\n                        \"Version\": \"18\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cee93f-3ab9-44fa-8c9a-dd5958fd2db9\",\n                        \"genericNames\": \"vincristine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"thyroid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US7c47ad19-42de-592f-e053-2991aa0a3c35\",\n                    \"NDCCode\": \"43063-819\",\n                    \"UpdatedDate\": \"Dec 06, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NATURE - THROID -  thyroid, porcine tablet PD - Rx Pharmaceuticals, Inc.      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Nature-Throid\",\n                        \"Manufacturer\": \"PD-Rx Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01cf8d6f-5ec1-4bd4-94f0-e9edf116cf2f\",\n                        \"FileId\": \"7c47ad19-42de-592f-e053-2991aa0a3c35\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01cf8d6f-5ec1-4bd4-94f0-e9edf116cf2f\",\n                        \"genericNames\": \"thyroid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ondansetron hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USffbc2301-05e0-5f75-e053-6394a90ab415\",\n                    \"NDCCode\": \"82449-200\",\n                    \"UpdatedDate\": \"Oct 03, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ONDANSETRON HYDROCHLORIDE -  ondansetron hydrochloride injection Steriscience Specialties Private Limited\",\n                        \"TradeName\": \"ondansetron hydrochloride\",\n                        \"Manufacturer\": \"Steriscience Specialties Private Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01d69f4d-eddf-4fc8-820b-832f11f2e3c0\",\n                        \"FileId\": \"ffbc2301-05e0-5f75-e053-6394a90ab415\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01d69f4d-eddf-4fc8-820b-832f11f2e3c0\",\n                        \"genericNames\": \"ondansetron hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"albumin (human)\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USeddd4478-99a9-4827-ba0b-17e04ba67454\",\n                    \"NDCCode\": \"76125-785\",\n                    \"UpdatedDate\": \"Dec 22, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ALBUKED  -  albumin human solution KEDRION BIOPHARMA, INC.\",\n                        \"TradeName\": \"Albuked\",\n                        \"Manufacturer\": \"KEDRION BIOPHARMA INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01d78cc3-765c-89a9-7a60-b578e5723cbb\",\n                        \"FileId\": \"eddd4478-99a9-4827-ba0b-17e04ba67454\",\n                        \"Version\": \"12\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01d78cc3-765c-89a9-7a60-b578e5723cbb\",\n                        \"genericNames\": \"albumin (human)\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cholera vaccine, live, oral\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USaa67e293-7e9e-4b1d-9637-17ce3a0161a4\",\n                    \"NDCCode\": \"70460-001\",\n                    \"UpdatedDate\": \"Oct 26, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VAXCHORA -  cholera vaccine, live, oral \\t\\t\\t Paxvax, Inc.\",\n                        \"TradeName\": \"Vaxchora\",\n                        \"Manufacturer\": \"Paxvax, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01dae2ac-8332-4e23-b971-67dc36c3ee16\",\n                        \"FileId\": \"aa67e293-7e9e-4b1d-9637-17ce3a0161a4\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01dae2ac-8332-4e23-b971-67dc36c3ee16\",\n                        \"genericNames\": \"cholera vaccine, live, oral\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"medroxyprogesterone acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US10fdc3f5-de88-4bbb-9f3f-c0a0630d0222\",\n                    \"NDCCode\": \"62756-091\",\n                    \"UpdatedDate\": \"Dec 20, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEDROXYPROGESTERONE ACETATE  -  medroxyprogesterone acetate injection, suspension Sun Pharmaceutical Industries, Inc.\",\n                        \"TradeName\": \"MEDROXYPROGESTERONE ACETATE\",\n                        \"Manufacturer\": \"Sun Pharmaceutical Industries, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01e28bef-9758-40cf-a4ff-86ae9f4f5105\",\n                        \"FileId\": \"10fdc3f5-de88-4bbb-9f3f-c0a0630d0222\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e28bef-9758-40cf-a4ff-86ae9f4f5105\",\n                        \"genericNames\": \"medroxyprogesterone acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US4e917729-3eac-400c-bbaf-8b30a04a380c\",\n                    \"NDCCode\": \"24201-150\",\n                    \"UpdatedDate\": \"May 04, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION -  medroxyprogesterone acetate injection, suspension Hikma Pharmaceuticals USA inc.\",\n                        \"TradeName\": \"Medroxyprogesterone Acetate Injectable Suspension\",\n                        \"Manufacturer\": \"Hikma Pharmaceuticals USA inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0476eac5-d96c-4910-aa86-1ddeeefefe50\",\n                        \"FileId\": \"4e917729-3eac-400c-bbaf-8b30a04a380c\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0476eac5-d96c-4910-aa86-1ddeeefefe50\",\n                        \"genericNames\": \"medroxyprogesterone acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"benzoyl peroxide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US19004b02-2e4b-4d66-aa84-7a19ad8c3c69\",\n                    \"NDCCode\": \"45802-910\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PERRIGO BENZOYL PEROXIDE AQUEOUS BASE -  benzoyl peroxide gel Perrigo New York Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Perrigo Benzoyl Peroxide\",\n                        \"Manufacturer\": \"PERRIGO NEW YORK INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"01e8bf1e-db02-4dd0-a448-645f0f367401\",\n                        \"FileId\": \"19004b02-2e4b-4d66-aa84-7a19ad8c3c69\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e8bf1e-db02-4dd0-a448-645f0f367401\",\n                        \"genericNames\": \"benzoyl peroxide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"progesterone\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6339e30d-a5d3-09b0-852a-84ef2e8c2a83\",\n                    \"NDCCode\": \"0032-1708\",\n                    \"UpdatedDate\": \"Aug 26, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PROMETRIUM -  progesterone capsule AbbVie Inc.\",\n                        \"TradeName\": \"Prometrium\",\n                        \"Manufacturer\": \"AbbVie Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0224b5a6-25a3-44c9-b94f-90e2e064c164\",\n                        \"FileId\": \"6339e30d-a5d3-09b0-852a-84ef2e8c2a83\",\n                        \"Version\": \"23\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224b5a6-25a3-44c9-b94f-90e2e064c164\",\n                        \"genericNames\": \"progesterone\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"desvenlafaxine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USbf7c38d6-3cba-42dd-a439-ed28c34789c3\",\n                    \"NDCCode\": \"49884-375\",\n                    \"UpdatedDate\": \"Dec 20, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"KHEDEZLA EXTENDED - RELEASE -  desvenlafaxine tablet, extended release Par Pharmaceutical Inc.\",\n                        \"TradeName\": \"KHEDEZLA\",\n                        \"Manufacturer\": \"Par Pharmaceutical Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0224e77b-7f6f-4191-ad3b-06847d5930e2\",\n                        \"FileId\": \"bf7c38d6-3cba-42dd-a439-ed28c34789c3\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0224e77b-7f6f-4191-ad3b-06847d5930e2\",\n                        \"genericNames\": \"desvenlafaxine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"luvira\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99d7525d-b62e-7f8e-e053-2a95a90a2080\",\n                    \"NDCCode\": \"69336-351\",\n                    \"UpdatedDate\": \"Dec 18, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LUVIRA -  omega - 3 - acid ethyl esters, 12 - hydroxyeicosapentaenoic acid, (12r) -  and 4,7,10,13,16,19 - docosahexaenoic acid, (4e,7e,10e,13e,16e,19e) -  capsule Sterling - Knight Pharmaceuticals, LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Luvira\",\n                        \"Manufacturer\": \"Sterling-Knight Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"025679cf-dfb2-4988-9e18-2f55ef9b306f\",\n                        \"FileId\": \"99d7525d-b62e-7f8e-e053-2a95a90a2080\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=025679cf-dfb2-4988-9e18-2f55ef9b306f\",\n                        \"genericNames\": \"luvira\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine, and glycine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USdad76e26-0274-4501-abaf-216a4165a2ae\",\n                    \"NDCCode\": \"0409-4191\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"AMINOSYN -  isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine and glycine injection, solution Hospira, Inc.\",\n                        \"TradeName\": \"Aminosyn\",\n                        \"Manufacturer\": \"Hospira, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02597da7-70bc-44f5-50a5-d67934125b7f\",\n                        \"FileId\": \"dad76e26-0274-4501-abaf-216a4165a2ae\",\n                        \"Version\": \"13\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02597da7-70bc-44f5-50a5-d67934125b7f\",\n                        \"genericNames\": \"isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, tyrosine, and glycine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fenortho\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US91b0ac5b-994c-468f-9331-542b8f92f9a8\",\n                    \"NDCCode\": \"54288-130\",\n                    \"UpdatedDate\": \"Jun 16, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FENORTHO -  fenoprofen calcium capsule BPI Labs LLC\",\n                        \"TradeName\": \"FENORTHO\",\n                        \"Manufacturer\": \"BPI Labs LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02a23e48-f371-448b-92b2-e2d010be1886\",\n                        \"FileId\": \"91b0ac5b-994c-468f-9331-542b8f92f9a8\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02a23e48-f371-448b-92b2-e2d010be1886\",\n                        \"genericNames\": \"fenortho\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"neomycin sulfate, polymyxin b sulfate and bacitracin zinc\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd6ca470d-dd66-45d4-b2b5-23090c9223b6\",\n                    \"NDCCode\": \"0404-7194\",\n                    \"UpdatedDate\": \"Feb 05, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"NEOMYCIN AND POLYMYXIN B SULFATES, AND BACITRACIN ZINC -  neomycin sulfate, polymyxin b sulfate and bacitracin zinc ointment Henry Schein Inc.\",\n                        \"TradeName\": \"Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc\",\n                        \"Manufacturer\": \"Henry Schein Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02af2a5f-32fb-460b-b29f-7b18cb95204c\",\n                        \"FileId\": \"d6ca470d-dd66-45d4-b2b5-23090c9223b6\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02af2a5f-32fb-460b-b29f-7b18cb95204c\",\n                        \"genericNames\": \"neomycin sulfate, polymyxin b sulfate and bacitracin zinc\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"betamethasone valerate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6094e3c6-ba85-4774-a61d-233f92b92c6c\",\n                    \"NDCCode\": \"0145-0021\",\n                    \"UpdatedDate\": \"Jul 01, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LUXIQ -  betamethasone valerate aerosol, foam Stiefel Laboratories Inc\",\n                        \"TradeName\": \"LUXIQ\",\n                        \"Manufacturer\": \"Stiefel Laboratories Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55\",\n                        \"FileId\": \"6094e3c6-ba85-4774-a61d-233f92b92c6c\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02b6cc3c-3aec-47dc-8936-fdc7ce8bdb55\",\n                        \"genericNames\": \"betamethasone valerate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methenamine hippurate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6b264a9e-f32b-4d56-8738-70b8d36c95b2\",\n                    \"NDCCode\": \"30698-277\",\n                    \"UpdatedDate\": \"Jan 26, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HIPREX -  methenamine hippurate tablet Validus Pharmaceuticals LLC\",\n                        \"TradeName\": \"HIPREX\",\n                        \"Manufacturer\": \"Validus Pharmaceuticals LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"02c70c23-b644-430c-b524-29af3360436d\",\n                        \"FileId\": \"6b264a9e-f32b-4d56-8738-70b8d36c95b2\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02c70c23-b644-430c-b524-29af3360436d\",\n                        \"genericNames\": \"methenamine hippurate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tranexamic acid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa2b02c92-a449-4624-9936-423a9c0993e2\",\n                    \"NDCCode\": \"66993-121\",\n                    \"UpdatedDate\": \"Dec 07, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TRANEXAMIC ACID -  tranexamic acid tablet Prasco Laboratories\",\n                        \"TradeName\": \"Tranexamic Acid\",\n                        \"Manufacturer\": \"Prasco Laboratories\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03003067-1bbc-4f5b-85ec-c21a955fbc06\",\n                        \"FileId\": \"a2b02c92-a449-4624-9936-423a9c0993e2\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03003067-1bbc-4f5b-85ec-c21a955fbc06\",\n                        \"genericNames\": \"tranexamic acid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (mdck cell derived, propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated)\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USe2f91bc2-f0dc-462c-87bf-847d95aad516\",\n                    \"NDCCode\": \"63851-612\",\n                    \"UpdatedDate\": \"Aug 21, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUCELVAX -  influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated),  influenza a virus a/texas/50/2012 x - 223a (h3n2) antigen (mdck cell derived, propiolactone inactivated) and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated) injection, suspension Novartis Vaccines and Diagnostics GmbH\",\n                        \"TradeName\": \"Flucelvax\",\n                        \"Manufacturer\": \"Novartis Vaccines and Diagnostics GmbH\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"030dfb30-589d-4335-85fe-d609644088e0\",\n                        \"FileId\": \"e2f91bc2-f0dc-462c-87bf-847d95aad516\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=030dfb30-589d-4335-85fe-d609644088e0\",\n                        \"genericNames\": \"influenza a virus a/brisbane/10/2010 (h1n1) antigen (mdck cell derived, propiolactone inactivated), influenza a virus a/texas/50/2012 x-223a (h3n2) antigen (mdck cell derived, propiolactone inactivated), and influenza b virus b/massachusetts/2/2012 antigen (mdck cell derived, propiolactone inactivated)\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"doxepin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8989ba3a-9624-40f6-92d4-7ec21d75e54d\",\n                    \"NDCCode\": \"40085-716\",\n                    \"UpdatedDate\": \"Jan 26, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DOXEPIN HYDROCHLORIDE -  doxepin hydrochloride cream Renaissance Pharma, Inc.\",\n                        \"TradeName\": \"Doxepin Hydrochloride\",\n                        \"Manufacturer\": \"Renaissance Pharma, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03107529-561a-4408-b319-94b245b3117b\",\n                        \"FileId\": \"8989ba3a-9624-40f6-92d4-7ec21d75e54d\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03107529-561a-4408-b319-94b245b3117b\",\n                        \"genericNames\": \"doxepin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"halobetasol propionate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScd9a3fc1-f9e4-4ab7-9c75-50ab9c65e270\",\n                    \"NDCCode\": \"10631-102\",\n                    \"UpdatedDate\": \"Jan 30, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ULTRAVATE -  halobetasol propionate cream ULTRAVATE -  halobetasol propionate ointment Ranbaxy Laboratories Inc.\",\n                        \"TradeName\": \"Ultravate\",\n                        \"Manufacturer\": \"Ranbaxy Laboratories Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"031f1120-7da1-4ea6-a0be-d368018e2c1f\",\n                        \"FileId\": \"cd9a3fc1-f9e4-4ab7-9c75-50ab9c65e270\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=031f1120-7da1-4ea6-a0be-d368018e2c1f\",\n                        \"genericNames\": \"halobetasol propionate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"abciximab\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US36b7d963-49cb-4192-ab24-ea8f6e81d2d6\",\n                    \"NDCCode\": \"0002-7140\",\n                    \"UpdatedDate\": \"Sep 27, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REOPRO -  abciximab injection, solution Eli Lilly and Company\",\n                        \"TradeName\": \"REOPRO\",\n                        \"Manufacturer\": \"Eli Lilly and Company\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"033d4c3b-4630-4256-b8f7-9ed5f15de9a3\",\n                        \"FileId\": \"36b7d963-49cb-4192-ab24-ea8f6e81d2d6\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3\",\n                        \"genericNames\": \"abciximab\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"leuprolide acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US24a44295-5073-434e-af06-a405a6f3ba55\",\n                    \"NDCCode\": \"62935-302\",\n                    \"UpdatedDate\": \"Apr 26, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ELIGARD  -  leuprolide acetate \\t\\t\\t TOLMAR Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"ELIGARD\",\n                        \"Manufacturer\": \"TOLMAR PHARMACEUTICALS INC.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0342f4a9-1037-4d41-b791-e5b0dbaeffeb\",\n                        \"FileId\": \"24a44295-5073-434e-af06-a405a6f3ba55\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0342f4a9-1037-4d41-b791-e5b0dbaeffeb\",\n                        \"genericNames\": \"leuprolide acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"cyanocobalamin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USed0ce38e-b59a-9e8f-e053-2995a90a2341\",\n                    \"NDCCode\": \"68001-509\",\n                    \"UpdatedDate\": \"Nov 11, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CYANOCOBALAMIN -  cyanocobalamin injection, solution BluePoint Laboratories\",\n                        \"TradeName\": \"Cyanocobalamin\",\n                        \"Manufacturer\": \"BluePoint Laboratories\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"034615bb-9f98-4034-b3a2-b1cc22a00a46\",\n                        \"FileId\": \"ed0ce38e-b59a-9e8f-e053-2995a90a2341\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=034615bb-9f98-4034-b3a2-b1cc22a00a46\",\n                        \"genericNames\": \"cyanocobalamin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methylphenidate hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US663ba889-95b5-45c2-af06-c90459d30d6d\",\n                    \"NDCCode\": \"0093-5346\",\n                    \"UpdatedDate\": \"Nov 20, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METHYLPHENIDATE HYDROCHLORIDE (LA) -  methylphenidate hydrochloride capsule, extended release Teva Pharmaceuticals USA, Inc.\",\n                        \"TradeName\": \"Methylphenidate Hydrochloride\",\n                        \"Manufacturer\": \"Teva Pharmaceuticals USA, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"034fb7cd-e183-475e-8beb-64fd88facc8f\",\n                        \"FileId\": \"663ba889-95b5-45c2-af06-c90459d30d6d\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=034fb7cd-e183-475e-8beb-64fd88facc8f\",\n                        \"genericNames\": \"methylphenidate hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                },\n                {\n                    \"Id\": \"US6b2dcacd-6280-421e-8ac2-ac00db79a5d5\",\n                    \"NDCCode\": \"0591-2716\",\n                    \"UpdatedDate\": \"Jul 16, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"METHYLPHENIDATE HYDROCHLORIDE -  methylphenidate hydrochloride tablet Actavis Pharma, Inc.\",\n                        \"TradeName\": \"methylphenidate hydrochloride\",\n                        \"Manufacturer\": \"Actavis Pharma, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"038ae416-4bd5-411b-bd28-d4f0af5c2ab7\",\n                        \"FileId\": \"6b2dcacd-6280-421e-8ac2-ac00db79a5d5\",\n                        \"Version\": \"14\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038ae416-4bd5-411b-bd28-d4f0af5c2ab7\",\n                        \"genericNames\": \"methylphenidate hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"bicalutamide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USdbfb2d98-13ad-4815-83d6-b0e10e184881\",\n                    \"NDCCode\": \"0310-0705\",\n                    \"UpdatedDate\": \"Nov 15, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CASODEX -  bicalutamide tablet AstraZeneca Pharmaceuticals LP\",\n                        \"TradeName\": \"CASODEX\",\n                        \"Manufacturer\": \"AstraZeneca Pharmaceuticals LP\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03607c0d-b772-435f-c985-ecce8ea8cafd\",\n                        \"FileId\": \"dbfb2d98-13ad-4815-83d6-b0e10e184881\",\n                        \"Version\": \"20\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03607c0d-b772-435f-c985-ecce8ea8cafd\",\n                        \"genericNames\": \"bicalutamide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"trypan blue\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd0d5872f-d428-189b-e053-2995a90a7f32\",\n                    \"NDCCode\": \"68803-672\",\n                    \"UpdatedDate\": \"Nov 17, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MEMBRANEBLUE -  trypan blue injection, solution Dutch Ophthalmic Research Center (International) B.V.\",\n                        \"TradeName\": \"MEMBRANEBLUE\",\n                        \"Manufacturer\": \"Dutch Ophthalmic Research Center (International) B.V.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0364aceb-dd3f-4bac-b468-25379a07ccfc\",\n                        \"FileId\": \"d0d5872f-d428-189b-e053-2995a90a7f32\",\n                        \"Version\": \"16\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0364aceb-dd3f-4bac-b468-25379a07ccfc\",\n                        \"genericNames\": \"trypan blue\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"diclofenac sodium, capsaicin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US039c9724-fa4e-1b84-e063-6394a90ac491\",\n                    \"NDCCode\": \"59088-798\",\n                    \"UpdatedDate\": \"Aug 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEXTOL -  diclofenac sodium, capsaicin \\t\\t\\t PureTek Corporation      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Lextol\",\n                        \"Manufacturer\": \"PureTek Corporation\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"039ca738-c2c4-41c8-e063-6394a90ab4c4\",\n                        \"FileId\": \"039c9724-fa4e-1b84-e063-6394a90ac491\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=039ca738-c2c4-41c8-e063-6394a90ab4c4\",\n                        \"genericNames\": \"diclofenac sodium, capsaicin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"tramadol hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US96bec1b6-7ff2-4e89-be58-d5c359fb51f4\",\n                    \"NDCCode\": \"50458-655\",\n                    \"UpdatedDate\": \"Sep 12, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ULTRAM ER -  tramadol hydrochloride tablet, extended release Janssen Pharmaceuticals, Inc.\",\n                        \"TradeName\": \"Ultram ER\",\n                        \"Manufacturer\": \"Janssen Pharmaceuticals, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"039f9e7c-97f5-4062-8656-6f355c82008e\",\n                        \"FileId\": \"96bec1b6-7ff2-4e89-be58-d5c359fb51f4\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=039f9e7c-97f5-4062-8656-6f355c82008e\",\n                        \"genericNames\": \"tramadol hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mesalamine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3712f360-d3ac-407d-85bf-48e0d7f298cf\",\n                    \"NDCCode\": \"0430-0783\",\n                    \"UpdatedDate\": \"Dec 01, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ASACOL HD -  mesalamine tablet, delayed release Allergan, Inc.\",\n                        \"TradeName\": \"ASACOL HD\",\n                        \"Manufacturer\": \"Warner Chilcott (US), LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03a3bff5-e652-4771-9bf7-3b6850423cc5\",\n                        \"FileId\": \"3712f360-d3ac-407d-85bf-48e0d7f298cf\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a3bff5-e652-4771-9bf7-3b6850423cc5\",\n                        \"genericNames\": \"mesalamine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"diclofenac sodium and benzalkonium chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US12dd097b-f199-4a63-bbba-3d52ac54fa3c\",\n                    \"NDCCode\": \"15455-9565\",\n                    \"UpdatedDate\": \"Apr 21, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DST PLUS PAK -  diclofenac sodium and benzalkonium chloride \\t\\t\\t Alvix Laboratories, LLC\",\n                        \"TradeName\": \"DST Plus Pak\",\n                        \"Manufacturer\": \"Alvix Laboratories, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03ac5de0-68da-40a9-8f2d-feba05c799c1\",\n                        \"FileId\": \"12dd097b-f199-4a63-bbba-3d52ac54fa3c\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ac5de0-68da-40a9-8f2d-feba05c799c1\",\n                        \"genericNames\": \"diclofenac sodium and benzalkonium chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"folic acid, cholecalciferol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US52531723-606a-1dda-e054-00144ff88e88\",\n                    \"NDCCode\": \"70033-113\",\n                    \"UpdatedDate\": \"Jun 20, 2017\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ZOLATE -  folic acid and cholecalciferol capsule Axiom Pharma      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Zolate\",\n                        \"Manufacturer\": \"Axiom Pharma\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03b4af81-152e-40d4-84d7-e213b0ee31fc\",\n                        \"FileId\": \"52531723-606a-1dda-e054-00144ff88e88\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b4af81-152e-40d4-84d7-e213b0ee31fc\",\n                        \"genericNames\": \"folic acid, cholecalciferol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"capecitabine\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USa38e2215-77d1-4671-8093-746efa1c5344\",\n                    \"NDCCode\": \"0378-2511\",\n                    \"UpdatedDate\": \"Dec 07, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CAPECITABINE -  capecitabine tablet, film coated Mylan Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Capecitabine\",\n                        \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03dd3301-e9ce-40af-84e1-7b70fc6557b0\",\n                        \"FileId\": \"a38e2215-77d1-4671-8093-746efa1c5344\",\n                        \"Version\": \"14\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dd3301-e9ce-40af-84e1-7b70fc6557b0\",\n                        \"genericNames\": \"capecitabine\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"esomeprazole magnesium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US26990f16-e3d3-4491-a99d-1cc5411f2e86\",\n                    \"NDCCode\": \"16714-736\",\n                    \"UpdatedDate\": \"Nov 30, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ESOMEPRAZOLE MAGNESIUM  -  esomeprazole magnesium dihydrate capsule, delayed release NorthStar Rx LLC\",\n                        \"TradeName\": \"Esomeprazole Magnesium\",\n                        \"Manufacturer\": \"NorthStar Rx LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"03ddda6d-2ac0-42d3-a329-7e8f05ee9b22\",\n                        \"FileId\": \"26990f16-e3d3-4491-a99d-1cc5411f2e86\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ddda6d-2ac0-42d3-a329-7e8f05ee9b22\",\n                        \"genericNames\": \"esomeprazole magnesium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"bortezomib\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US81e8728c-5928-4029-8aa0-0e7f761af75a\",\n                    \"NDCCode\": \"63323-721\",\n                    \"UpdatedDate\": \"Apr 29, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"BORTEZOMIB -  bortezomib injection, powder, lyophilized, for solution Fresenius Kabi USA, LLC\",\n                        \"TradeName\": \"Bortezomib\",\n                        \"Manufacturer\": \"Fresenius Kabi USA, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"042329d6-8077-4af2-816f-cd0a2bbcbbd3\",\n                        \"FileId\": \"81e8728c-5928-4029-8aa0-0e7f761af75a\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=042329d6-8077-4af2-816f-cd0a2bbcbbd3\",\n                        \"genericNames\": \"bortezomib\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"sargramostim\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USac281296-b49b-4f33-a16c-a83e60964713\",\n                    \"NDCCode\": \"0024-5844\",\n                    \"UpdatedDate\": \"Jun 14, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEUKINE -  sargramostim liquid LEUKINE -  sargramostim injection, powder, for solution sanofi - aventis U.S. LLC\",\n                        \"TradeName\": \"Leukine\",\n                        \"Manufacturer\": \"sanofi-aventis U.S. LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04765fbf-f005-43aa-a628-5cc3d80f91e7\",\n                        \"FileId\": \"ac281296-b49b-4f33-a16c-a83e60964713\",\n                        \"Version\": \"10\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04765fbf-f005-43aa-a628-5cc3d80f91e7\",\n                        \"genericNames\": \"sargramostim\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"moderna covid-19 vaccine, bivalent\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc1811012-39af-4116-a873-4a5b93bf6468\",\n                    \"NDCCode\": \"80777-283\",\n                    \"UpdatedDate\": \"Dec 20, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MODERNA COVID - 19 VACCINE, BIVALENT -  elasomeran and cx - 034476 omicron (ba.4/ba.5) injection, suspension Moderna US, Inc.\",\n                        \"TradeName\": \"Moderna COVID-19 Vaccine, Bivalent\",\n                        \"Manufacturer\": \"Moderna US, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04c2d0f3-6209-4ae8-823c-842d0881b61b\",\n                        \"FileId\": \"c1811012-39af-4116-a873-4a5b93bf6468\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04c2d0f3-6209-4ae8-823c-842d0881b61b\",\n                        \"genericNames\": \"moderna covid-19 vaccine, bivalent\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"indomethacin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8a792cbe-8874-4655-a1e7-ca9007eee950\",\n                    \"NDCCode\": \"42211-202\",\n                    \"UpdatedDate\": \"Feb 22, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"TIVORBEX -  indomethacin capsule Iroko Pharmaceuticals, LLC\",\n                        \"TradeName\": \"Tivorbex\",\n                        \"Manufacturer\": \"Iroko Pharmaceuticals, LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04ca474c-798e-43dd-be7a-1b36720e6a3d\",\n                        \"FileId\": \"8a792cbe-8874-4655-a1e7-ca9007eee950\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04ca474c-798e-43dd-be7a-1b36720e6a3d\",\n                        \"genericNames\": \"indomethacin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ribavirin\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3380c831-db90-4ac0-9c2f-398a00137e58\",\n                    \"NDCCode\": \"0085-1385\",\n                    \"UpdatedDate\": \"Apr 01, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"REBETOL -  ribavirin capsule REBETOL -  ribavirin liquid Merck Sharp &amp; Dohme Corp.\",\n                        \"TradeName\": \"REBETOL\",\n                        \"Manufacturer\": \"Merck Sharp & Dohme Corp.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04d2b6f4-bd9b-4871-9527-92c81aa2d4d0\",\n                        \"FileId\": \"3380c831-db90-4ac0-9c2f-398a00137e58\",\n                        \"Version\": \"33\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0\",\n                        \"genericNames\": \"ribavirin\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"risedronate sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US3cbf30c0-30dd-4022-88b6-86a84697379c\",\n                    \"NDCCode\": \"68382-075\",\n                    \"UpdatedDate\": \"Nov 16, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"RISEDRONATE SODIUM  -  risedronate sodium anhydrous tablet, delayed release Zydus Pharmaceuticals USA Inc.\",\n                        \"TradeName\": \"Risedronate Sodium\",\n                        \"Manufacturer\": \"Zydus Pharmaceuticals USA Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"04e4baa7-62a5-45d0-8f8d-a4daea68c5aa\",\n                        \"FileId\": \"3cbf30c0-30dd-4022-88b6-86a84697379c\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04e4baa7-62a5-45d0-8f8d-a4daea68c5aa\",\n                        \"genericNames\": \"risedronate sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"levonorgestrel\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US054f9706-94d2-4ea3-8e32-7185457f5c63\",\n                    \"NDCCode\": \"73302-911\",\n                    \"UpdatedDate\": \"Dec 02, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"LEVONORGESTREL -  levonorgestrel tablet HRA Pharma America, Inc.\",\n                        \"TradeName\": \"Levonorgestrel\",\n                        \"Manufacturer\": \"HRA Pharma America, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0518a86b-af59-455e-b834-04fa8b20a637\",\n                        \"FileId\": \"054f9706-94d2-4ea3-8e32-7185457f5c63\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0518a86b-af59-455e-b834-04fa8b20a637\",\n                        \"genericNames\": \"levonorgestrel\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ursodiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd126d870-95f5-bb75-e053-2995a90ad67d\",\n                    \"NDCCode\": \"51079-383\",\n                    \"UpdatedDate\": \"Nov 23, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"URSODIOL -  ursodiol capsule Mylan Institutional Inc.\",\n                        \"TradeName\": \"Ursodiol\",\n                        \"Manufacturer\": \"Mylan Institutional Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05243d8f-9057-46a9-ae50-6e16ba6cd7dc\",\n                        \"FileId\": \"d126d870-95f5-bb75-e053-2995a90ad67d\",\n                        \"Version\": \"6\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05243d8f-9057-46a9-ae50-6e16ba6cd7dc\",\n                        \"genericNames\": \"ursodiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"moxifloxacin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USba96c083-00b4-4b6f-8aa0-327e9e918461\",\n                    \"NDCCode\": \"0065-0006\",\n                    \"UpdatedDate\": \"Aug 21, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MOXEZA  -  moxifloxacin hydrochloride solution Alcon Laboratories, Inc.\",\n                        \"TradeName\": \"MOXEZA\",\n                        \"Manufacturer\": \"Alcon Laboratories, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05248b68-16a9-488d-a39f-5137d2410471\",\n                        \"FileId\": \"ba96c083-00b4-4b6f-8aa0-327e9e918461\",\n                        \"Version\": \"20\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05248b68-16a9-488d-a39f-5137d2410471\",\n                        \"genericNames\": \"moxifloxacin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"ulipristal acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USd6ca82aa-9488-4aa7-a5f1-69873ecb8d0e\",\n                    \"NDCCode\": \"50102-911\",\n                    \"UpdatedDate\": \"Jan 30, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ELLA -  ulipristal acetate tablet Afaxys Pharma LLC\",\n                        \"TradeName\": \"Ella\",\n                        \"Manufacturer\": \"Afaxys Pharma LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"052bfe45-c485-49e5-8fc4-51990b2efba4\",\n                        \"FileId\": \"d6ca82aa-9488-4aa7-a5f1-69873ecb8d0e\",\n                        \"Version\": \"12\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4\",\n                        \"genericNames\": \"ulipristal acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha-tocopherol succinate, d-, riboflavin, niacinamide,\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc697dfae-210c-43a6-b893-f3054e74901c\",\n                    \"NDCCode\": \"68220-089\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"PREFERA OB PLUS DHA -  folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha - tocopherol succinate, d - , riboflavin, niacinamide, pyridoxine hydrochloride, cyanocobalamin, biotin and calcium pantothenate tablet Alaven Pharmaceutical LLC      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Prefera OB plus DHA\",\n                        \"Manufacturer\": \"ALAVEN PHARMACEUTICAL LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0539ec9c-b625-4c4e-a321-e7073041c8e0\",\n                        \"FileId\": \"c697dfae-210c-43a6-b893-f3054e74901c\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0539ec9c-b625-4c4e-a321-e7073041c8e0\",\n                        \"genericNames\": \"folic acid, heme iron polypeptide, iron dextran, potassium iodide, zinc oxide, selenium, cupric sulfate, cholecalciferol, thiamine mononitrate, alpha-tocopherol succinate, d-, riboflavin, niacinamide,\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"hydromorphone hcl\",\n            \"Labels\": [\n                {\n                    \"Id\": \"UScc127289-395c-46bc-b705-d08529e9fce5\",\n                    \"NDCCode\": \"52533-002\",\n                    \"UpdatedDate\": \"Mar 26, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HYDROMORPHONE HCL  -  hydromorphone hydrochloride injection, solution Cantrell Drug Company      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"Hydromorphone HCl\",\n                        \"Manufacturer\": \"Cantrell Drug Company\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"053a62b8-92c2-47e8-bbdd-ff2ec4d75dc7\",\n                        \"FileId\": \"cc127289-395c-46bc-b705-d08529e9fce5\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053a62b8-92c2-47e8-bbdd-ff2ec4d75dc7\",\n                        \"genericNames\": \"hydromorphone hcl\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"morphine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USffd2a1bb-d072-8af8-e053-6394a90a48ed\",\n                    \"NDCCode\": \"51862-188\",\n                    \"UpdatedDate\": \"Jul 08, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MORPHINE SULFATE -  morphine sulfate tablet, film coated, extended release Mayne Pharma Commercial LLC\",\n                        \"TradeName\": \"Morphine Sulfate\",\n                        \"Manufacturer\": \"Mayne Pharma Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"053e3fd9-25fc-4b55-b683-63fb9d190dae\",\n                        \"FileId\": \"ffd2a1bb-d072-8af8-e053-6394a90a48ed\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053e3fd9-25fc-4b55-b683-63fb9d190dae\",\n                        \"genericNames\": \"morphine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"gabapentin enacarbil\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US6330994e-5391-42ac-ac85-7eda5c6c875f\",\n                    \"NDCCode\": \"0173-0832\",\n                    \"UpdatedDate\": \"Apr 01, 2013\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"HORIZANT- gabapentin enacarbil tablet, extended release GlaxoSmithKline LLC\",\n                        \"TradeName\": \"HORIZANT\",\n                        \"Manufacturer\": \"GlaxoSmithKline LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05506250-1641-4b64-ac0c-69f96c46a773\",\n                        \"FileId\": \"6330994e-5391-42ac-ac85-7eda5c6c875f\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05506250-1641-4b64-ac0c-69f96c46a773\",\n                        \"genericNames\": \"gabapentin enacarbil\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"oxycodone hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US056f088d-cff1-4b46-8539-ff85880586bf\",\n                    \"NDCCode\": \"63304-684\",\n                    \"UpdatedDate\": \"Jan 14, 2015\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OXYCODONE HCL -  oxycodone hydrochloride tablet, film coated, extended release Ranbaxy Pharmaceuticals Inc.\",\n                        \"TradeName\": \"OXYCODONE HCl\",\n                        \"Manufacturer\": \"Ranbaxy Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"FileId\": \"056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=056f088d-cff1-4b46-8539-ff85880586bf\",\n                        \"genericNames\": \"oxycodone hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"benzhydrocodone and acetaminophen\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US4e76bae1-6ed1-4624-af64-2151218705b4\",\n                    \"NDCCode\": \"70040-0189\",\n                    \"UpdatedDate\": \"Jul 02, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"APADAZ -  benzhydrocodone hydrochloride and acetaminophen tablet KemPharm, Inc.\",\n                        \"TradeName\": \"APADAZ\",\n                        \"Manufacturer\": \"KemPharm, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0590d4e5-7107-4015-a6a8-deac14265aa2\",\n                        \"FileId\": \"4e76bae1-6ed1-4624-af64-2151218705b4\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0590d4e5-7107-4015-a6a8-deac14265aa2\",\n                        \"genericNames\": \"benzhydrocodone and acetaminophen\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"erythromycin and benzoyl peroxide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                    \"NDCCode\": \"45802-083\",\n                    \"UpdatedDate\": \"Jul 23, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ERYTHROMYCIN - BENZOYL PEROXIDE -  erythromycin and benzoyl peroxide \\t\\t\\t Perrigo New York Inc\",\n                        \"TradeName\": \"Erythromycin-Benzoyl Peroxide\",\n                        \"Manufacturer\": \"PERRIGO NEW YORK INC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"FileId\": \"059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=059323b0-1034-4cc3-96b8-31af3c0c6d22\",\n                        \"genericNames\": \"erythromycin and benzoyl peroxide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"olmesartan medoxomil\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USf29310d1-7b00-4057-9dd1-d9a69f542d5e\",\n                    \"NDCCode\": \"49252-066\",\n                    \"UpdatedDate\": \"Sep 20, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OLMESARTAN MEDOXOMIL -  olmesartan medoxomil tablet, coated Inventia Healthcare Limited\",\n                        \"TradeName\": \"OLMESARTAN MEDOXOMIL\",\n                        \"Manufacturer\": \"Inventia Healthcare Limited\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05a807bf-5175-43a2-a676-215bba2645a8\",\n                        \"FileId\": \"f29310d1-7b00-4057-9dd1-d9a69f542d5e\",\n                        \"Version\": \"3\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05a807bf-5175-43a2-a676-215bba2645a8\",\n                        \"genericNames\": \"olmesartan medoxomil\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"drospirenone and estradiol\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USC8074480-B1ED-4468-78AE-C2BCAC4D8079\",\n                    \"NDCCode\": \"50419-483\",\n                    \"UpdatedDate\": \"Sep 27, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ANGELIQ -  estradiol and drospirenone tablet, film coated Berlex\",\n                        \"TradeName\": \"Angeliq\",\n                        \"Manufacturer\": \"BAYER HEALTHCARE PHARMACEUTICA\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05B46F6A-9C52-4246-B500-D359B25A45DC\",\n                        \"FileId\": \"C8074480-B1ED-4468-78AE-C2BCAC4D8079\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05B46F6A-9C52-4246-B500-D359B25A45DC\",\n                        \"genericNames\": \"drospirenone and estradiol\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fulvestrant\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US45b2245b-9f11-4b58-a275-b664b5b89e7d\",\n                    \"NDCCode\": \"0310-7720\",\n                    \"UpdatedDate\": \"Jun 08, 2022\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FULVESTRANT -  fulvestrant injection AstraZeneca Pharmaceuticals LP\",\n                        \"TradeName\": \"Fulvestrant\",\n                        \"Manufacturer\": \"AstraZeneca Pharmaceuticals LP\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05b6bd57-36aa-47c3-bcf6-2470ba42feb5\",\n                        \"FileId\": \"45b2245b-9f11-4b58-a275-b664b5b89e7d\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05b6bd57-36aa-47c3-bcf6-2470ba42feb5\",\n                        \"genericNames\": \"fulvestrant\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"fondaparinux sodium\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US26db3097-342b-48cb-a91d-8f39d64c46ca\",\n                    \"NDCCode\": \"0007-3232\",\n                    \"UpdatedDate\": \"Sep 17, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"ARIXTRA -  fondaparinux sodium injection, solution GlaxoSmithKline LLC\",\n                        \"TradeName\": \"ARIXTRA\",\n                        \"Manufacturer\": \"GlaxoSmithKline LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f\",\n                        \"FileId\": \"26db3097-342b-48cb-a91d-8f39d64c46ca\",\n                        \"Version\": \"16\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f\",\n                        \"genericNames\": \"fondaparinux sodium\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USee12ad5a-2004-4a59-8173-20bb9eefa655\",\n                    \"NDCCode\": \"35573-300\",\n                    \"UpdatedDate\": \"Apr 30, 2016\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"URAMIT MB -  methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue and hyoscyamine sulfate capsule Burel Pharmaceuticals, Inc      Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.\",\n                        \"TradeName\": \"URAMIT MB\",\n                        \"Manufacturer\": \"Burel Pharmaceuticals, Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05bc6057-7dec-4e35-b8ec-3dffa655520c\",\n                        \"FileId\": \"ee12ad5a-2004-4a59-8173-20bb9eefa655\",\n                        \"Version\": \"2\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05bc6057-7dec-4e35-b8ec-3dffa655520c\",\n                        \"genericNames\": \"methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"influenza vaccine, adjuvanted\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US97c3669d-ac04-4c97-b2ab-2ce4d0bf6e12\",\n                    \"NDCCode\": \"70461-019\",\n                    \"UpdatedDate\": \"Jul 16, 2019\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"FLUAD -  influenza a virus a/brisbane/02/2018 ivr - 190 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/kansas/14/2017 x - 327 (h3n2) antigen (formaldehyde inactivated) and influenza b virus b/maryland/15/2016 antigen (formaldehyde inactivated) injection, suspension Seqirus, Inc.\",\n                        \"TradeName\": \"FLUAD\",\n                        \"Manufacturer\": \"Seqirus, Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05be1932-bb7a-4e3a-9200-4ccdc5565edc\",\n                        \"FileId\": \"97c3669d-ac04-4c97-b2ab-2ce4d0bf6e12\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05be1932-bb7a-4e3a-9200-4ccdc5565edc\",\n                        \"genericNames\": \"influenza vaccine, adjuvanted\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"clobetasol propionate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99d8672a-7e92-4a25-9a7b-849efaafb525\",\n                    \"NDCCode\": \"0378-8055\",\n                    \"UpdatedDate\": \"Apr 22, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CLOBETASOL PROPIONATE -  clobetasol propionate aerosol, foam Mylan Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Clobetasol Propionate\",\n                        \"Manufacturer\": \"Mylan Pharmaceuticals Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05cff296-2daf-408c-8e63-883737cbfb22\",\n                        \"FileId\": \"99d8672a-7e92-4a25-9a7b-849efaafb525\",\n                        \"Version\": \"4\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05cff296-2daf-408c-8e63-883737cbfb22\",\n                        \"genericNames\": \"clobetasol propionate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"metformin hydrochloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US8ed86d67-8a49-4334-82c4-1dbf6a489d3b\",\n                    \"NDCCode\": \"10631-206\",\n                    \"UpdatedDate\": \"Dec 12, 2018\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"RIOMET -  metformin hydrochloride solution Sun Pharmaceutical Industries, Inc.\",\n                        \"TradeName\": \"Riomet\",\n                        \"Manufacturer\": \"Ranbaxy Laboratories Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05d4df4b-dfe8-4828-b423-a3d4f2c4114a\",\n                        \"FileId\": \"8ed86d67-8a49-4334-82c4-1dbf6a489d3b\",\n                        \"Version\": \"11\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05d4df4b-dfe8-4828-b423-a3d4f2c4114a\",\n                        \"genericNames\": \"metformin hydrochloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"valproic acid\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USfb8bf963-9299-45f0-926a-18da554412ff\",\n                    \"NDCCode\": \"68094-193\",\n                    \"UpdatedDate\": \"Dec 03, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"VALPROIC ACID -  valproic acid solution Precision Dose Inc.\",\n                        \"TradeName\": \"Valproic Acid\",\n                        \"Manufacturer\": \"Precision Dose Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05e16c10-ff0a-4238-8181-f3e84379ed6a\",\n                        \"FileId\": \"fb8bf963-9299-45f0-926a-18da554412ff\",\n                        \"Version\": \"8\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e16c10-ff0a-4238-8181-f3e84379ed6a\",\n                        \"genericNames\": \"valproic acid\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"desmopressin acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US517c673f-db39-4b91-bd86-eb35db5bea7f\",\n                    \"NDCCode\": \"0075-2452\",\n                    \"UpdatedDate\": \"Jun 18, 2012\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"DDAVP -  desmopressin acetate solution sanofi - aventis U.S. LLC\",\n                        \"TradeName\": \"DDAVP\",\n                        \"Manufacturer\": \"sanofi-aventis U.S. LLC\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"05e6330b-6569-436e-9caf-e86916460931\",\n                        \"FileId\": \"517c673f-db39-4b91-bd86-eb35db5bea7f\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e6330b-6569-436e-9caf-e86916460931\",\n                        \"genericNames\": \"desmopressin acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"mometasone furoate monohydrate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US74bb6412-7e0d-46ad-bbf6-26aa7e5d6c04\",\n                    \"NDCCode\": \"0781-6355\",\n                    \"UpdatedDate\": \"Feb 12, 2021\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"MOMETASONE FUROATE MONOHYDRATE -  mometasone furoate monohydrate spray, metered Sandoz Inc.\",\n                        \"TradeName\": \"Mometasone Furoate Monohydrate\",\n                        \"Manufacturer\": \"Sandoz Inc.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0602c22a-67b7-4708-bdbb-28a69d52d616\",\n                        \"FileId\": \"74bb6412-7e0d-46ad-bbf6-26aa7e5d6c04\",\n                        \"Version\": \"7\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0602c22a-67b7-4708-bdbb-28a69d52d616\",\n                        \"genericNames\": \"mometasone furoate monohydrate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"methsuximide\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USabac6b2e-bcd8-29c2-e053-2a95a90a2239\",\n                    \"NDCCode\": \"24822-525\",\n                    \"UpdatedDate\": \"Aug 04, 2020\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CELONTIN -  methsuximide capsule Farmea\",\n                        \"TradeName\": \"Celontin\",\n                        \"Manufacturer\": \"Farmea\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0613561f-1a9f-4921-89ff-ba6081e08a5f\",\n                        \"FileId\": \"abac6b2e-bcd8-29c2-e053-2a95a90a2239\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0613561f-1a9f-4921-89ff-ba6081e08a5f\",\n                        \"genericNames\": \"methsuximide\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"calcitonin salmon\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US99e9e62b-9796-42ec-8f69-551dabf92ec1\",\n                    \"NDCCode\": \"0781-6320\",\n                    \"UpdatedDate\": \"Jun 21, 2014\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"CALCITONIN SALMON -  calcitonin salmon spray, metered Sandoz Inc\",\n                        \"TradeName\": \"calcitonin salmon\",\n                        \"Manufacturer\": \"Sandoz Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"0614bf53-9644-47d2-b46e-8efbcd63afe6\",\n                        \"FileId\": \"99e9e62b-9796-42ec-8f69-551dabf92ec1\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0614bf53-9644-47d2-b46e-8efbcd63afe6\",\n                        \"genericNames\": \"calcitonin salmon\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"oxybutynin chloride\",\n            \"Labels\": [\n                {\n                    \"Id\": \"USc8c1bf6b-8da4-439b-b4af-0b28273c5625\",\n                    \"NDCCode\": \"14539-653\",\n                    \"UpdatedDate\": \"Jun 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"OXYBUTYNIN CHLORIDE -  oxybutynin chloride tablet Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.\",\n                        \"TradeName\": \"Oxybutynin Chloride\",\n                        \"Manufacturer\": \"Heritage Pharma Labs, Inc\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"06301e49-2bcf-4ff1-8f33-39ccde1a2dd0\",\n                        \"FileId\": \"c8c1bf6b-8da4-439b-b4af-0b28273c5625\",\n                        \"Version\": \"5\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06301e49-2bcf-4ff1-8f33-39ccde1a2dd0\",\n                        \"genericNames\": \"oxybutynin chloride\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        },\n        {\n            \"GenericName\": \"motixafortide acetate\",\n            \"Labels\": [\n                {\n                    \"Id\": \"US05f6e4ee-4ffb-d2b5-e063-6394a90af047\",\n                    \"NDCCode\": \"70383-073\",\n                    \"UpdatedDate\": \"Sep 29, 2023\",\n                    \"LabelSource\": {\n                        \"LabelTitle\": \"APHEXDA -  motixafortide acetate injection, powder, lyophilized, for solution BioConnection B.V.\",\n                        \"TradeName\": \"Aphexda\",\n                        \"Manufacturer\": \"BioConnection B.V.\",\n                        \"Country\": \"us\",\n                        \"ProductId\": \"065b582d-e5e5-eeec-e063-6394a90a5990\",\n                        \"FileId\": \"05f6e4ee-4ffb-d2b5-e063-6394a90af047\",\n                        \"Version\": \"1\",\n                        \"LabelURL\": \"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065b582d-e5e5-eeec-e063-6394a90a5990\",\n                        \"genericNames\": \"motixafortide acetate\"\n                    },\n                    \"AdverseEventTerms\": null,\n                    \"IndicationTerms\": null\n                }\n            ]\n        }\n    ]\n}"}],"_postman_id":"6f58cebd-eeb4-4a18-8140-522f0e8662b8"}],"auth":{"type":"basic","basic":{"basicConfig":[{"key":"username","value":"<username>"},{"key":"password","value":"<password>"}]}},"event":[{"listen":"prerequest","script":{"id":"864fe197-4f8c-4686-b767-16059bdb88dc","type":"text/javascript","exec":[""]}},{"listen":"test","script":{"id":"a8445ed3-872e-40aa-ad3f-ec26a349bf28","type":"text/javascript","exec":[""]}}],"variable":[{"key":"uniquelabelid","value":"US3f5d8caf-a587-4c9f-85a7-f74935acc991"}]}